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Abstract 
 
Sulphadoxine pyrimethamine resistance (SPR) emerged soon after SP was introduced as 
first line therapy for malaria in Africa during the 1990s. This thesis presents the first 
attempt to describe the spatio-temporal distribution of SPR in sub-Saharan Africa. 
Molecular and in vivo SPR data were gathered from primarily published sources onto a 
handwritten and digital template, recording the precise geo-location of every data point. 
The most commonly used methods were the World Health Organisation 1973 and 1996 
protocols to measure in vivo efficacy and PCR-RFLP for molecular studies. Consistent 
data gaps with both SPR measures were found in Botswana, Burundi, Cape Verde, 
Eritrea, Somalia, Togo and Mauritius (chapter two). Three broad categories of molecular 
resistance emerged, reflecting the distribution patterns of dhfr and dhps point mutation 
prevalence: (1) scarce partially resistant mutations namely dhps 436A and 613S which are 
not increasing significantly over time, (2) emerging resistance mutations such as dhfr 164L 
and dhps 581G which are rare but increasing within distinct geographical foci and (3) 
major resistance mutations namely dhps 437G and 540E, which are widespread with 
significantly increased prevalence over time and regional differences (chapter three). 
Statistical analysis showed that the sensitive dhfr allelic haplotype frequencies decreased 
over time in all regions whilst the triple mutant increased. The models developed for dhps 
haplotypes showed a clear East-West divide with the double mutant dominating East 
Africa and the single mutant occurring mainly in West Africa (chapter four). Standardised 
in vivo efficacy data were matched with dhfr and dhps haplotypes using the nearest 
geographic location and study year and then modelled. These analyses showed for the 
first time, a clear effect of the frequency of dhps allelic haplotypes on SP efficacy (chapter 
five). These findings are important in the context of continued use of SP in sub-Saharan 
Africa for intermittent preventive treatment and support the use of molecular surveillance to 
inform policy on SP use. 
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Chapter 1 Introduction and scope of thesis 
 
This introductory chapter summarises the current malaria situation in sub-Saharan Africa 
and presents a chronology of antimalarial drug use and its relationship to resistance. It 
describes the background and spatial context of antimalarial resistance and reviews the 
factors thought to be important to the emergence of resistance and its geographical 
distribution in Africa. The chapter concludes with an overview of current resistance 
surveillance practice and an outline of the research covered in this thesis.  
 
The current malaria situation in sub-Saharan Africa  
 
Malaria occurs in 47 sub-Saharan countries with diverse epidemiological settings and 30 
of these carry the highest malaria risk and mortality rates attributed to Plasmodium 
falciparum based on national surveillance reports (WHO, 2008; WHO, 2011a; WHO, 
2012). Renewed efforts to control malaria have resulted in many of those countries (which 
have sufficiently good surveillance systems) recording a reduction in confirmed malaria 
cases and mortality rates (WHO, 2011a). However global and Africa-wide malaria burden 
estimates reveal the extent of malaria risk. Approximately 1.2 billion people live in areas 
classified as high risk of malaria (>1 case per 1000 population) and 47% of these reside in 
Africa. In 2009 there were approximately 225 million malaria cases globally with 78% of 
these being from Africa (WHO, 2010a) and in 2010 the number of malaria cases worldwide 
dropped to 219 million with 81% of these presenting in Africa  (WHO, 2011a, WHO, 2012). 
In 2009 there were approximately 781,000 malaria related deaths globally and 91% of 
these occurred in Africa (WHO, 2010a) whilst later in 2010 the number of malaria deaths 
worldwide was 660,000 and again the majority (91%) occurred in Africa (WHO, 2011a). 
Children under five years of age account for the largest proportion of the malaria mortality 
rates (WHO, 2011a).  
 
The World Health Organisation (WHO) categorised the malarious countries within Africa 
into five subregions, grouping countries which share similar epidemiological settings, 
malaria control strategies and malaria incidence patterns (WHO, 2011a, WHO, 2012). The 
five subregions illustrated in Figure 1.1 are `Central Africa’, `West Africa’, `East Africa’ (this 
category includes high transmission countries in Southern Africa and Madagascar), 
`Southern Africa’ (the low transmission countries of Southern Africa) and finally the 
`Eastern Mediterranean’ subregion which includes North Sudan, South Sudan, Somalia 
and Djibouti (WHO, 2011a, WHO, 2012).  
16 
 
The Central Africa group representing nine Central African countries includes Angola, 
Burundi, Cameroon, Central African Republic, Chad, Democratic Republic of Congo 
(DRC), Equatorial Guinea, Gabon and Republic of Congo. The West African group 
consists of 17 countries namely Benin, Burkina Faso, Cape Verde, Gambia, Ghana, 
Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Sao 
Tome/Principe, Senegal, Sierra Leone and Togo. The East African subregion also includes 
high transmission countries in Southern Africa and consists of 11 countries namely 
Comoros, Eritrea, Ethiopia, Kenya, Madagascar, Malawi, Mozambique, Rwanda, 
Tanzania, Uganda and Zambia. The low transmission Southern African countries make up 
the fourth group consisting of five countries namely Botswana, Namibia, South Africa, 
Swaziland and Zimbabwe. The fifth group termed the Eastern Mediterranean area consists 
of four countries namely North Sudan, South Sudan, Somalia and Djibouti. Each group is 
described briefly below. 
 
All nine Central African countries are classified as being at high risk of P. falciparum 
malaria where the numbers of reported cases are ≥ 1 per 1000 per year (WHO, 2011a). 
Malaria cases increased in the DRC and Republic of Congo whilst it remained stable in all 
other countries (WHO, 2011a). High malaria transmission occurs in Angola, Central 
African Republic, Equatorial Guinea, Gabon and Republic of Congo (WHO, 2011a). Both 
high and low transmission occurs in Burundi, Cameroon, Chad and DRC (WHO, 2011a). 
Low malaria transmission is characterised as having zero to one case per 1000 people 
(WHO, 2012). 
 
In West Africa there are marked variations in the malaria burden among the 17 countries in 
this group (Figure 1.1). Predominately high malaria transmission occurs in Benin, Burkina 
Faso, Ivory Coast, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Nigeria, Sao 
Tome/Principe, Sierra Leone and Togo (WHO, 2011a, WHO, 2012). Notably over 40% of 
the malaria mortality rates mentioned previously occurs in the DRC and Nigeria alone 
(WHO, 2012). Both high and low malaria transmission occurs in Mali, Niger, Senegal, 
Mauritania and Cape Verde, although there have been reductions in malaria cases in the 
Cape Verde and Sao Tome/Principe islands (WHO, 2011a). Sao Tome/Principe has 
successfully reduced malaria incidence by ≥ 75% during 2010-2011 (WHO, 2012, Snow et 
al., 2012). 
 
The East and some Southern African countries are grouped together making up the third 
group of 11 countries. Within this region Malawi, Mozambique, Rwanda, Uganda and 
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Zambia are characterised by high malaria transmission whilst Comoros, Eritrea, Ethiopia, 
Kenya, Madagascar and Tanzania have a mixture of both high and low transmission foci 
(WHO, 2012). This group excludes the low transmission countries in Southern Africa, 
which make up the fourth subgroup. 
 
With the exception of Zimbabwe in this fourth group, the other four countries have reported 
declining malaria incidence of ≥75% since 2000 (WHO, 2012) and efforts are underway to 
reduce malaria transmission to zero cases and thus eliminate malaria (Global Health 
Group, 2009). Eight countries in Southern Africa have embarked on the goal to eliminate 
malaria by 2020 (Malaria Elimination 8 Ministerial Meeting, 2009). The four front line 
countries of Elimination Eight (E8) include Botswana, Namibia, South Africa and 
Swaziland which are targeted first for malaria elimination (Malaria Elimination 8 Ministerial 
Meeting, 2009). The four second line E8 countries are Angola, Mozambique, Zambia and 
Zimbabwe which will eventually be targeted for malaria elimination (Malaria Elimination 8 
Ministerial Meeting, 2009). Although local malaria transmission within these countries 
might be declining, malaria remains a priority due to the risk of malaria epidemics and the 
associated high morbidity and mortality especially among poor and rural communities. 
 
Countries in the Eastern Mediterranean subregion have variable malaria transmission 
intensities (Figure 1.1). Predominately high malaria transmission occurs in South Sudan 
whilst primarily low malaria transmission occurs in Djibouti (Snow et al., 2012; WHO, 
2012). North Sudan and Somalia are characterised by both high and low malaria 
transmission (WHO, 2012).  
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Figure.1.1 Regional categorisation of Africa based on malaria epidemiology (adapted from 
WHO, 2012) 
 
Targeted interventions such as indoor residual spraying, use of bed nets, diagnostic 
testing as well as preventive and curative therapies, improved case surveillance and 
health promotion are being used to control the malaria burden across sub-Saharan Africa. 
The scale-up of such interventions is central to elimination efforts and it is vital that they 
should be sustained in areas that have achieved high coverage and expanded in areas of 
suboptimal coverage (Alonso and Tanner, 2013). Early diagnosis and prompt treatment of 
confirmed malaria cases is the primary malaria control tool in many parts of Africa 
(Mbacham et al., 2010). There is concern about the public health implications of both 
insecticide and drug resistance, as future options for both interventions are limited and 
there is no vaccine for malaria as yet. The emergence and spread of P. falciparum 
resistance to antimalarial drugs contributes significantly to malaria-specific morbidity and 
mortality in Africa (Trape, 2001; Plowe, 2003; Bjorkman and Bhattarai, 2005; Greenwood 
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et al., 2005; Korenromp et al., 2003). Regional differences in malaria mortality rates within 
Africa were attributed to the emergence of drug resistance. Malaria mortality increased 
significantly from the 1980s to the 1990s within East and Southern Africa where resistance 
was rising but there was no absolute increase in malaria mortality over time in West Africa 
(Korenromp et al., 2003). A background into the emergence of antimalarial drug resistance 
in Africa is presented next.  
 
A chronology of antimalarial drug use and spatial context of antimalarial resistance 
in Africa 
 
Chloroquine monotherapy was first introduced as treatment for uncomplicated malaria 
around 1946 (Warrell, 1993; Jensen and Mehlhorn, 2009). Across Africa chloroquine 
became widely available in clinics, shops and private pharmacies from the 1960s and was 
the antimalarial drug of choice because it was cheap, safe and well tolerated (Warrell, 
1993; Snow et al., 2012). Case reports of chloroquine resistance first emerged in South 
America and in Southeast Asia along the Cambodian and Thailand border in 1957 and 
resistance was confirmed in 1960 (WHO,1987; D, Payne, PhD Thesis, University of 
London, 19891; Warrell, 1993). Pailin province in Cambodia was identified as the focal 
point of chloroquine resistance (WHO, 1963). In Africa chloroquine resistance was 
reported much later than Asia, during the 1970s (Payne, 1987; WHO,1987).  
 
After the first report of chloroquine resistance in East Africa in 1978 it spread westwards 
across the continent (Charmot et al., 1991). Payne (1989) and Charmot et al., (1991) 
illustrated the stepwise geographic and temporal spread of chloroquine resistance since its 
initial occurrence in East Africa and subsequent dispersal across Africa during the 1980s 
(Figure 1.2). A description of these geographic analyses is provided later in this chapter. 
Resistant P. falciparum parasites were found in all tropical African countries from 1978 to 
1988 (Figure 1.2) (Trape, 2001; Charmot et al., 1991). Genetic studies later revealed that 
this was due to the progressive spread of the resistant form of the chloroquine resistance 
transporter (Pfcrt) gene (Fidock et al., 2000) and the African and Asian Pfcrt shared the 
same ancestry (Wootton et al., 2002). As chloroquine became ineffective against P. 
falciparum malaria nearly everywhere it was used, it was withdrawn as first line therapy. 
First line treatment is the official drug of choice for treatment of uncomplicated malaria 
(Malisa et al., 2010) as per the country’s treatment policy guidelines. 
 
1 referred to as Payne (1989) hereon 
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Figure 1.2 Progression of confirmed P. falciparum chloroquine resistance across Africa 
between 1978 and 1989 (adapted from Charmot et al., 1991) 
  
Pyrimethamine monotherapy was used for both malaria prophylaxis and treatment in the 
1950s (Peters, 1970) but resistance emerged rapidly at multiple sites (Warrell, 1993) and it 
was only when it was later combined with sulphadoxine that it came to be a reliable 
antimalarial treatment. The antifolate combination sulphadoxine pyrimethamine (SP) was 
adopted as second line malaria treatment and came to be used increasingly as 
chloroquine efficacy waned. Second line malaria treatment is the official policy 
recommended alternative when the first line treatment fails to clear infection (Malisa et al., 
2010). Eventually when chloroquine was rendered ineffective in an area, SP became the 
replacement first line therapy.  
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The SP combination was initially used as monotherapy in the 1990s in Africa. As with 
chloroquine resistance, the Thailand-Cambodia border was the source of the first reports 
of SP treatment failures during the late 1970s (Vinayak et al., 2010). Although the first 
case reports of SP resistance were sporadic, confirmation of clinical resistance came 
shortly thereafter and then resistance developed rapidly (White, 1992). In Thailand cure 
rates declined substantially within five years of replacing chloroquine with SP (Rieckman, 
Suebsaeng and Rooney, 1987). 
 
The emergence and spread of P. falciparum resistance to both chloroquine and SP 
necessitated the use of alternative combination therapies. The aim of using combination 
therapies was to prolong the useful therapeutic life of each drug and delay antimalarial 
resistance. The WHO released treatment guidelines early in 2006, advising that 
uncomplicated P. falciparum malaria should be treated with artemisinin combination 
therapies (ACTs) as first line treatment and not by artemisinins alone or any other 
monotherapy (WHO, 2006). Recently the WHO (2012) reported that most malaria endemic 
countries had changed their treatment policy to ACTs.  
 
The threat of resistance to antimalarial drugs is ever present and first reports of declining 
P. falciparum efficacy to artemisinin were reported in Thailand in 2003, along the North 
Western Thailand-Myanmar border and Western Cambodia during 2007-2008, as well as 
in Vietnam (Dondorp et al., 2009; WHO, 2012). Figure 1.3 illustrates the time lines for the 
development of resistance to chloroquine, SP and now decreased efficacy and resistance 
to artemisinin. Pailin province in Cambodia has become the epicentre of P. falciparum 
antimalarial drug resistance (Dondorp et al., 2009) given its precedent for first reports of 
both chloroquine and SP resistance. It took about 10 years for chloroquine resistance to 
be detected after its initial use and it took 17 years before it could be detected in East 
Africa (Figure 1.3). As mentioned earlier SP resistance was first detected in Southeast 
Asia in the 1970s and then it was detected in East Africa in the 1990s.  East Africa was the 
forerunner of antimalarial resistance within the African continent. 
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Figure 1.3 Time line of antimalarial resistance development 
 
Artemisinin resistance will have dire consequences for malaria control if it spreads across 
the globe. Whilst the mechanisms of artemisinin resistance have yet to be elucidated, 
strategies have been put in place for containing its spread (WHO, 2011b) especially as 
history has shown that once resistance emerges in one place it tends to spread to other 
places, even across continents. Efforts are underway to increase monitoring and 
surveillance of ACTs to detect outbreaks of artemisinin tolerance and resistance at new 
sites (Vijaykadga et al., 2006; Dondorp et al., 2009; WHO, 2011b). 
 
With limited effective antimalarials available for use as ACTs, SP continues to be used in 
specific settings in Africa as a preventative treatment and in combination with other drugs 
as first line therapy. There is a clear perception that the Eastern and Southern African 
regions have experienced the majority of SP resistance problems. A systematic spatial 
summary of SP resistance measures which might inform the continued use of SP for 
treatment or prophylaxis in sub-Saharan African countries is urgently needed.  The work in 
this thesis sets out the first attempt and possibly the only initiative of its kind to map the 
extent of SP resistance in sub-Saharan Africa.   
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Sulphadoxine Pyrimethamine use in the present day 
 
SP continues to be used as treatment both in combination with artemisinin and as 
monotherapy for chemoprevention (WHO, 2012). The combination of artesunate and SP is 
being used for first line treatment of unconfirmed malaria as well as first line treatment of 
P. falciparum (WHO, 2011a; WHO, 2012). SP is being used in combination with 
artesunate for first line treatment of P.falciparum in three countries namely Djibouti 
(adopted in 2008), Somalia (adopted in 2006) and North Sudan (adopted in 2006) where 
there is low transmission (WHO, 2011a; WHO, 2012).  In Eritrea, SP is being used with 
chloroquine as first line treatment for unconfirmed malaria and this policy was adopted in 
2007 (WHO, 2011a; WHO, 2012). The WHO recommends three chemoprevention 
strategies involving intermittent preventive treatment (IPT) among pregnant women (IPTp) 
and infants (IPTi) as well as seasonal malaria chemoprevention (SMC). IPT is an 
intervention recommended for high risk groups such as pregnant women and infants living 
in high malaria transmission areas (WHO, 2012). IPT involves administering a scheduled 
therapeutic dose of an effective antimalarial to these high risk groups during an intermittent 
and defined period, aiming to reduce parasite carriage within foci of transmission 
(Greenwood, 2007;Gosling et al., 2010; WHO, 2012).  
 
SP is viewed as the safest option for preventing malaria during pregnancy (Hyde, 2008). 
The three IPT strategies are discussed briefly here. The first chemoprevention strategy, 
IPTp recommends that all asymptomatic pregnant women living in moderate to high 
malaria transmission areas receive SP at each antenatal visit and the majority of African 
countries now use a two dose regimen (WHO, 2005; WHO, 2012). SP for IPT is only 
recommended in countries not using the SP+artesunate combination (WHO, 2009a). 
Although recent data show that SP for IPTp has been adopted in 37 sub-Saharan African 
countries (WHO, 2011a) (Figure 1.4) coverage among pregnant women who actually 
received the two doses of SP was low (WHO, 2012). Notably there was low SP-IPT 
coverage in the two highly populated countries of Nigeria and DRC (WHO, 2012). 
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Figure 1.4 Coverage of SP for IPT in pregnant women (after WHO, 2011a; WHO, 2012) 
Darker shades refer to later years and lighter shades refer to recent years. 
 
Chemoprevention in infants (IPTi) involves the scheduled administration of three doses of 
SP as part of the expanded programme on immunization in areas of moderate to high 
malaria transmission and low levels of SP resistance (WHO, 2010b, WHO, 2012). 
According to the WHO (2012) thus far only Burkina Faso has adopted this IPTi strategy as 
a national policy whilst other countries are planning to do the same. 
 
The third chemoprevention strategy, intermittent preventive treatment of malaria in children 
(IPTc) now referred to as SMC involves administering the full treatment dose of an 
antimalarial drug among children aged between three months and five years, residing in 
areas experiencing highly seasonal malaria where there is an average of ≥60% of clinical 
malaria cases within a four month period (WHO, 2012). Currently a combination of SP plus 
amodiaquine is recommended across the Sahel including Senegal, Mauritania, Mali, Niger, 
Chad, North Sudan, South Sudan and Eritrea provided that both drugs are still efficacious 
in these countries (WHO, 2012). Due to resistance to both amodiaquine and SP, this 
strategy is not recommended in the Southern and East African regions (WHO, 2012). The 
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WHO SMC strategy is a relatively new recommendation and thus far no malaria endemic 
country has implemented it (WHO, 2012).  
 
A description of antimalarial resistance is presented below with specific reference to SP. 
 
Antimalarial Drug Resistance 
 
There is a difference between treatment failure and drug resistance. When a drug fails, it 
implies that insufficient amounts of the drug or its active metabolite reached the parasites 
(WHO, 1986). This may be caused by several factors including inadequate absorption, 
unusual drug metabolism or excretion rates (WHO, 1965) as well as incorrect dosing, non-
compliance with the dosing regimen and poor drug quality (Bloland, 2001) along with 
misdiagnosis and re-infections. For drug resistance to occur, the parasite must have 
survived the specified drug treatment dosages (WHO, 1986). Thus drug resistance can 
cause treatment failures, but not all treatment failures are caused by parasite resistance to 
the drug.  
 
For uncomplicated malaria, a treatment drug should effectively eradicate parasites or 
reduce the parasite biomass to an acceptable point that the body can cope with the 
infection by its own immune defence (White, 1998; White, 2002). Therefore, an effective 
antimalarial drug treatment should cure malaria and thereby reduce morbidity associated 
with treatment failures (WHO, 2006). The success of any antimalarial drug depends on the 
varying response of the parasites and each stage of its life cycle differs in its susceptibility 
to different drugs (WHO, 1986). According to WHO (2005), antimalarial drug resistance is 
associated more with treatment failure than with prophylactic failure. When used 
curatively, the drug should clear malaria parasites and the clinical symptoms of infection 
(Molineaux, 1988) which is of public health significance. Antimalarial drugs are used for 
prophylaxis or treatment based on their stage specificity, safety profile and half-lives 
(Molineaux, 1988). These drugs are often characterised by the stage in the parasite’s life 
cycle they target (Warrell, 1993). 
 
The SP combination is a blood schizonticide that inhibits folate metabolism which is an 
essential biochemical pathway for P. falciparum survival (Gregson and Plowe, 2005). 
Sulphadoxine mimics para-aminobenzoic acid (PABA) in competing for the active site on 
the dihydropteroate synthase (DHPS) enzyme. The PABA interaction with DHPS would 
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normally lead to folic acid production in the parasite but it is interrupted in the presence of 
sulphadoxine (Desjardins, Doberstyn and Wernsdorfer, 1988; Olliaro, 2001). 
Pyrimethamine inhibits plasmodial dihydrofolate reductase (DHFR) and thereby prevents 
the nicotinamide adenine dinucleotide phosphate (NADPH) dependent reduction of 
dihydrofolate to tetrahydrofolate (Olliaro, 2001). The capitalised notations DHPS and 
DHFR refer to the enzymes whilst the lower case italicised dhps and dhfr denote the 
genes described below. Pyrimethamine is classified as a blood schizontocide but also 
inhibits sporozoite development (WHO, 2006). The synergistic effect of sulphadoxine with 
pyrimethamine has been effective as a combined antimalarial monotherapy. SP is effective 
during the asexual developmental phase of the parasite life cycle but is ineffective against 
mature gametocytes within the sexual developmental phase. SP increases gametocyte 
carriage but also reduces the infectivity of gametocytes to mosquitoes (Hogh et al., 1998). 
Resistance to SP is caused by point mutations in dhfr and dhps genes which normally 
confer susceptibility to inhibitors (White, 1998; Gregson and Plowe, 2005). This will be 
discussed further in chapter 2.  
 
Antimalarial treatments are designed to sustain blood concentrations which are sufficient 
to restrict a parasite multiplication rate of < 1 per cycle until the last viable parasite has 
been eliminated from the body (White, 1997). This is known as the minimum inhibitory 
concentration. To confirm that there is indeed antimalarial drug resistance, the treatment 
regime must be proven to be inefficient despite being in the body in sufficient amounts and 
time periods to target a minimum of four asexual parasite life cycles (approximately six 
days for P. falciparum)(White, 1998).  This property has been incorporated into the 
definition of antimalarial drug resistance. The definition of drug resistance is “the ability of 
the parasite strain to survive and/or multiply despite the administration and absorption of a 
drug in doses equal to or higher than those usually recommended but within the limits of 
tolerance of the subject” (WHO, 2005). Hence, any parasites remaining after an 
antimalarial treatment regime was completed, would signify resistance. Sibley and Price 
(2012) further characterise resistance as an operational term rather an absolute term, 
stating that different measures of resistance derived from genetic markers and in vitro 
tests contribute to our understanding of decreased drug susceptibility and ultimately drug 
resistance. Furthermore, these authors state that resistance is a relative term and is 
context dependent (Sibley and Price, 2012). 
 
While the definition of drug resistance remained largely unchanged since its inception, the 
WHO protocols to monitor drug efficacy underwent many changes since 1973. These 
changes were made in order to account for malaria transmission in different 
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epidemiological settings. The WHO protocols were based on in vivo tests which is the goal 
standard for measuring resistance and these were designed to measure parasitological 
and later, clinical outcomes for assessing a treatment during a specified follow-up period 
(WHO, 2005). As expected, the outcome measures for treatment success or failure would 
depend on the specific WHO protocol applied in a particular setting. The characterisation 
of treatment outcomes based on which protocol was used has direct implications for 
estimates of drug efficacy, especially in high malaria transmission areas (Dorsey et al., 
2004a). The WHO protocol changes for monitoring drug efficacy are discussed further in 
chapter 2.  
 
The Emergence and Spread of Drug Resistance 
 
An important factor for antimalarial drug resistance is the rate at which chloroquine and SP 
resistance developed and intensified. The emergence of resistance and subsequent 
spread of resistance are complex events arising from spontaneous mutations as 
mentioned earlier, as well as drug selection pressure. Smith et al., (2010) characterised 
the evolution of antimalarial drug resistance into three events: (1) appearance of 
mutations, (2) establishment of mutations and (3) spread of mutations. Firstly, the 
appearance of resistance is characterised by infections with de novo mutations whereby 
the sensitive parasites are initially the majority strain until treatment is administered and 
the proportion of resistant strains eventually outnumber the sensitive forms (Smith et al., 
2010). The second phase is when resistance becomes established after its initial 
appearance and as mutant parasites persist and spread within the population (Smith et al., 
2010). This establishment phase depends on the fitness cost of mutant parasite strains 
which in turn depends on its biological cost versus the benefits conferred by drug pressure 
(Smith et al., 2010). Parasites carrying mutations depend on sustained drug pressure and 
once this drug pressure is reduced, the mutant strains will eventually be outnumbered by 
sensitive strains. The third phase, `spread’ involves displacement of sensitive parasite 
strains with resistance strains within the population and this is affected by the malaria 
transmission intensity in communities, as discussed further below. 
 
According to Talisuna, Bloland and D’Allesandro et al., (2004a) the factors responsible for 
the emergence and spread of resistance are not fully known but there are a multitude of 
contributory factors at play. The amount of drug use, drug half-life which is the time taken 
for their concentrations to decline by 50% (WHO, 1986), host heterogeneity, parasite 
biomass, malaria transmission intensity, host immunity and intra-host dynamics and 
population movements are other contributory factors affecting the appearance of 
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resistance (Hastings and Watkins, 2005). There is a brief discussion below on selected 
factors contributing to the development of antimalarial drug resistance.  
 
Once random mutations appear, these mutant parasite strains are selected if the 
administered drug concentrations are sufficient to inhibit multiplication of the susceptible 
parasites but are insufficient to inhibit the mutant forms (Smith et al., 2010). Consequently, 
selection of resistant parasite strains occurs in the context of widespread drug use, 
especially with prolonged use of monotherapies (D’Allessandro and Buttiens, 2001; Smith 
et al., 2010). The most convincing evidence of this link came from the concomitant 
development of chloroquine resistance along with mass administration of the drug as 
monotherapy in the form of medicated salt (Payne, 1988). However, this relationship 
cannot always be inferred, as was observed in Uganda where SP resistance was high 
despite low SP use in an area of high transmission (Talisuna et al., 2004b). This could 
probably be attributed to population movements contributing to circulation of resistant 
parasites (discussed in chapter 6). 
 
Adherence to the proper treatment dosage is important, especially for drugs that are 
rapidly eliminated from the body. This was recognized decades ago when it was found that 
the administration of inadequate and badly timed doses of antimalarial drugs to infected 
people increased the probability of resistance (WHO, 1965). A single adult dose of SP was 
usually 1500 mg sulphadoxine and 75 mg pyrimethamine (WHO, 1986). Sulphadoxine and 
pyrimethamine have relatively long half-lives of 100-200 hours and 96-192 hours 
respectively (WHO, 1996). Once treatment doses of SP are administered it offers an 
advantageous protective effect of up to two months (Hastings, Watkins and White, 2002) 
against P. falciparum, but this property also increases the risk of exposure to sub-
therapeutic drug concentrations which contributes to the emergence of resistance 
(Watkins and Mosobo, 1993). 
 
As the occurrence of P. falciparum in the body elicits humoral and cellular responses, 
there is another factor which contributes to the protective effect. Repeated exposure to P. 
falciparum leads to the development of immunity in communities, which is acquired slowly 
(White, 2004). Some studies have found that people with this developed background 
immunity against malaria have better treatment outcomes when given antimalarial drugs 
compared to those with no background immunity (Mayxay et al., 2001). However, this 
protective effect of the immune response can mask or delay the observation of antimalarial 
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drug resistance in communities with repeated exposure because infections could be 
resolved successfully regardless of parasite drug sensitivity (White, 2004).  
Apart from achieving clinical cure, the secondary purpose of administering antimalarial 
drugs is to prevent malaria transmission by interrupting sporogony in the mosquito or by 
acting on infected gametocytes (Warrell, 1993). Malaria transmission is characterised by 
describing malaria stability, intensity and seasonality (Omumbo et al., 1998). There are 
several indices which can be used to assess the intensity of malaria transmission such as 
the entomological inoculation rate (EIR), parasite rate, annual parasite index and spleen 
rate (Shaukat, Breman and McKenzie 2010). The EIR which describes the number of bites 
from infected mosquitoes per person per unit time, is the most commonly used index of 
malaria transmission intensity (Kelly-Hope and McKenzie, 2009). Kelly-Hope and 
McKenzie (2009) provided annual estimates of EIR in Africa.   Burkina Faso, Cameroon, 
DRC, Equatorial Guinea, Gabon, Ghana, Ivory Coast, Republic of Congo, Sierra Leone in 
West Africa as well as Burundi and Tanzania in East Africa all had EIRs ≥100. Later 
Gething et al., (2011) provided updated estimates of malaria endemicity using the EIR and 
basic reproductive number. These authors showed that the highest risk of P. falciparum 
transmission still occurs in Africa where the malaria endemicity is highly variable and 
where an overall EIR of 10 was predicted whilst the rest of the world was predicted to have 
an EIR of <1 (Gething et al., 2011). Notably EIRs exceeding 100 were predicted in 
Northern Mozambique and the borders between Cameroon and Nigeria as well as Burkina 
Faso and Mali (Figure 1.5) (Gething et al., 2011). 
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Figure 1.5 Distribution of P. falciparum EIRs in 2010 after Gething et al., (2011) available 
at http://www.map.ox.ac.uk/browse-resources/entomological-innoculation-
rate/Pf_EIR/africa-plus/ 
Areas shaded grey represent unstable malaria transmission or no malaria risk. Areas 
shaded blue represent areas where EIRs where between 0.1 and 1.0. Areas shaded 
yellow to light orange have EIRs >1. The areas shaded dark orange have EIRs of 100 or 
more. 
 
Talisuna et al., (2004a) summarised three contrasting theories relating antimalarial drug 
resistance and malaria transmission intensity: (1) low transmission intensity increases the 
spread of resistance due to the dominance of monoclonal infections, (2) resistant parasites 
spread faster where malaria transmission is high compared to the rate of spread in low 
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transmission areas and (3) transmission intensity does not play a role in the early stages 
of parasite resistance development.  
 
The first theory is supported by observations that chloroquine resistance was first detected 
in foci of low transmission (White, 2004). Hastings and Watkins (2005) stated that acquired 
immunity is affected by transmission intensity, suggesting that transmission intensity has 
an indirect rather than a direct effect on the development of drug resistance. In low 
transmission settings, patients are symptomatic of malaria with little or no acquired 
immunity and it is possible to contain the infectious reservoir through prompt and effective 
treatment. In this context, the rate at which immunity is acquired is low (Hastings and 
Watkins, 2005), patients are generally treated with a specific antimalarial and selection of 
resistance develops in the context of a relatively large parasite biomass that encounter the 
drug within each patient (White, 2004). SP resistance evolved more rapidly in foci of low 
transmission than in foci of high transmission (White, 2004).  
 
Studies of molecular markers indicated that there was rapid development of SP resistance 
in mesoendemic areas in Uganda (Sendagire et al., 2005) which are areas characterised 
as having varying transmission intensities depending on local conditions (Gilles, 1993a). In 
holoendemic areas malaria transmission occurs all year long and its intensity confers a 
considerable immune protective advantage (Gilles, 1993a). Using mathematical models to 
estimate the impact of IPT among adults and infants on antimalarial drug resistance, 
O’Meara, Smith and McKenzie (2006) predicted that partial resistance was more likely to 
emerge and spread in areas of low malaria transmission whereas high levels of resistance 
was more likely to emerge in areas of high malaria transmission.  
 
In high transmission settings, asymptomatic people make up the bulk of the infectious 
reservoir and as they are continuously exposed to malaria they develop partial immunity 
from childhood. In these areas effective drug treatment, together with other interventions is 
recommended such as use of insecticide treated nets and indoor residual spraying (WHO, 
2006). White (2004) explained that in foci of high malaria transmission it is only during the 
first few years of life that large amounts of parasites are exposed to the drug, resulting in 
reduced probabilities of de novo selection and transmission of resistant parasites in these 
areas compared to low transmission areas. Given the significance of antimalarial drug 
resistance to malaria control efforts, various methods have been developed to measure 
and monitor resistance development. These are discussed next. 
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Monitoring Antimalarial Drug Efficacy 
 
There are four methods of assessing and monitoring antimalarial drug efficacy among 
communities. These include (1) in vivo studies which describe clinical and parasitological 
therapeutic outcomes, (2) in vitro studies to determine drug susceptibility, (3) clinical 
pharmacology tests which measure drug concentrations levels and (4) molecular 
genotyping to identify mutant genes (Sibley et al., 2008; WHO, 2010a). Advances in 
computing and web-based technology have made it possible to link networks across 
borders to collate and mine data representing different antimalarial resistance measures to 
support malaria control efforts.  
 
The descriptions of the spatial context of chloroquine resistance as documented by Payne 
(1987, 1989) and Charmot (1991) illustrate the use of clinical reports of resistance to track 
the emergence and spread of chloroquine resistance. These authors did not include data 
on molecular markers of resistance because these technologies did not exist at the time. 
Furthermore the digital age and geographic information systems (GIS) for mapping 
advanced only during the last 30 years (Moore and Carpenter, 1999).In the present day it 
has become increasingly important to have comprehensive and readily available 
information on antimalarial resistance to guide decisions about resistance containment and 
treatment changes. 
 
There has been a drive to create an open access web based database, recognizing the 
need for an accessible resource containing information on the levels of antimalarial drug 
resistance (Sibley and Ringwald, 2006). The WHO established a global database on 
antimalarial drug efficacy in 2000 and has since been collecting global efficacy data 
(WHO, 2010c). The World Wide Antimalarial Resistance Network (WWARN) embarked on 
an initiative in 2007 to collect and make available surveillance data emanating from 
different methods of detecting antimalarial resistance in countries across the globe (Sibley 
et al., 2008). One of the main goals of the network was to set up a system to standardise 
the varying data outputs associated with drug efficacy studies, especially those related to 
the different WHO protocols such as consolidating results obtained from 14 day trials 
versus those done over a 28 day follow-up period. Furthermore, Sibley and Ringwald 
(2006) highlighted the importance of gathering associated geographic and temporal 
information to enhance our understanding of the spread of resistance, which is one of the 
goals of this thesis.  
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The main purpose of establishing a digital warehouse of antimalarial drug efficacy studies 
is to streamline in vivo data and make it accessible to decision makers. The database can 
also be regularly updated and verified as information becomes available. The repository 
can be queried and analysed easily, which will facilitate meta-analysis of data from 
different sources i.e. published and unpublished reports. Sibley and Ringwald (2006) 
reviewed the need for a database of antimalarial drug resistance studies on a global scale. 
Meta-analyses of drug efficacy data are rare, probably due to the difficulty in drawing 
together data from different sources and standardising data and analytical methodologies 
in pooled analysis.  
 
Good examples of efforts to collate malaria data on a large scale are the Mapping Malaria 
Risk in Africa (MARA) database (http://www.mara.org.za), the Malaria Atlas Project 
(www.map.ox.ac.uk), the WHO database on antimalarial drug efficacy 
(http://globalatlas.who.int/) and the “Chronological atlas of the recorded response of P. 
falciparum to chloroquine” (Payne, 1989). A discussion of the latter two databases follows 
as these relate specifically to antimalarial drug resistance. 
 
In his seminal work to track the spread of chloroquine resistance, Payne (1989) collected 
data from 76 countries across the globe and recorded the first appearance of chloroquine 
resistance in each country. The data were gathered from scientific journals, WHO and Pan 
American Health Organisation publications, WHO/Global Monitoring Programme reports 
which were test reports on the response of plasmodia to antimalarial drugs, submitted to 
the WHO global monitoring programme, as well as unpublished reports. Confirmed reports 
of resistance were categorised into three groups including in vitro studies, in vivo studies 
and clinical reports backed by laboratory investigations. Sentinel (usually non-immune 
expatriates) and indigenous cases were also recorded. It must be noted that White (1992) 
cautioned against the use of sentinel reports of drug efficacy as they do not represent 
indigenous communities.  
 
Payne (1989) used these data to draft time series maps of resistance using symbols to 
illustrate reports of efficacy studies done in each year. These data were then used to 
document spatially referenced point data on maps to infer the path and spread of 
chloroquine resistance as illustrated in Figure 1.2. Payne (1989) found three main foci of 
chloroquine resistance and concluded that there was spontaneous but independent 
emergence of chloroquine resistance in South America and in Southeast Asia in the late 
1950s. These maps showed that chloroquine resistance emerged later in East Africa 
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(during the 1970s) compared with the American and Asian continents. Payne (1989) went 
further to suggest that chloroquine resistance spread gradually from these initial foci. He 
also mentioned a possibility of a fourth focus in West Africa. This work clearly illustrates 
the value of mining antimalarial resistance data to detect patterns in the spread of 
resistance. 
 
The WHO http://globalatlas.who.int/ collated antimalarial drug resistance data from 
published articles, unpublished sources and data from surveillance studies. The purpose 
of this database was to support treatment policy change decisions in Africa.  Data 
summaries were available online in the form of graphs and map illustrations depicting 
trends in chloroquine and SP failure rates in individual African countries. Whilst these data 
provided a good overview of the resistance pattern within a country, it offered limited 
scope for further analysis because it did not provide access to the individual patient data 
(Sibley and Ringwald, 2006), which could assist the assessment of the impact of 
resistance on vulnerable populations. As Bjorkman and Bhattarai (2005) point out, such 
estimates are important to provide an indication of the magnitude of the problem to help 
with improving policies and control. Since SP continues to be used both as treatment and 
intermittent prevention in some countries described previously, this suggests that the drug 
combination is still effective in specific areas and that there is value in understanding the 
geographic variation in the distribution of resistance.  
 
Scope of thesis 
 
The goal of this study was to gather and compile the large literature of in vivo and 
molecular measures of SP resistance in sub-Saharan Africa and collate these in a 
geographical and temporal framework. The various indices of resistance when 
summarised together, allow the African geography of SP resistance to be examined in a 
new way. This work seeks to address fundamental questions relating to the distribution of 
SP resistance in sub-Saharan Africa by applying statistical tests to better understand the 
spatial and temporal characteristics of molecular markers of resistance and in vivo 
measures of SP resistance. Each chapter is structured in a similar manner with its own 
background, discussion, limitations and recommendations. A description of each chapter 
follows. 
 
Chapter 2 contains an overview of SP resistance studies in sub-Saharan Africa gathered 
from the literature. Efficacy studies measured in vivo and studies of molecular markers 
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were included in the review. Collation and geo-referencing of these data in a relational 
database made it possible to map all the various indices of resistance. In this chapter the 
data collection and data recording methods are described, together with methodological 
trends in molecular surveillance and the most frequently used WHO protocols for in vivo 
efficacy tests. Finally the mapped measures of SP resistance are used to identify country-
specific gaps in surveillance data.  
 
In chapter 3 the spatial and temporal variation in prevalence of seven individual SP point 
mutations in the dhfr and dhps genes are analysed. The geographical distributions of point 
mutations are mapped and their temporal trends examined by first categorising prevalence 
data according to region and analysing the major trends over time. Statistical analyses are 
conducted to assess the effect of regional and temporal risk factors on the prevalence of 
each point mutation. 
 
Chapter 4 similarly describes spatial and temporal changes in molecular markers, but this 
time examining the combinations of point mutations known as allelic haplotypes, in sub-
Saharan Africa.  There are two major allelic haplotypes at dhfr namely the sensitive allelic 
haplotype (51N/59C/108S) and the dhfr triple mutant allelic haplotype (51I/59R/108N) and 
three major dhps allelic haplotypes namely 437G/540E (GE), 437G/540K (GK) and 
437A/540K (AK). The frequencies of each of these allelic haplotypes are presented 
graphically and mapped. Statistical analyses are performed to assess the influence of 
regional and temporal factors on the frequencies of these allelic haplotypes.  
 
Chapter 5 assesses the association between dhfr and dhps haplotypes and in vivo 
measures of SP efficacy. The in vivo data are recalibrated and this chapter proposes a 
system of classification for these data to guide spatial and temporal analyses. The in vivo 
studies from the standardised and calibrated subset are then matched with dhfr and dhps 
allelic haplotype frequencies, according to nearest geographic location and study year. 
Statistical analyses are performed to assess the influence of allelic haplotype frequencies, 
and any region differences on phenotypic outcomes of SP efficacy. 
Chapter 6 concludes by giving an overview of the major findings in each chapter. The 
implications of this work for the broader context are discussed. Recommendations, 
limitations and possibilities for future work are described. 
 
36 
 
Chapter 2 Review of Sulphadoxine Pyrimethamine resistance studies in Africa and 
documenting data on in vivo efficacy and molecular markers in a relational database 
 
2.1 Introduction 
 
Whilst SP is still being used in sub-Saharan Africa for intermittent preventative therapies, it 
is useful to describe the spatial context of SP resistance. As shown in chapter 1 historic 
documentation of the geography of chloroquine resistance has illustrated the importance 
of mapping to improve our understanding of the emergence and progressive spread of 
drug resistance in P. falciparum malaria, globally (Payne, 1987; Payne, 1989), in Africa 
(Charmot et al.,1991) and more recently in India (Shah et al., 2011). These early studies 
mapped primarily clinical reports of resistance since molecular markers of resistance had 
not yet been described. Innovations in both molecular DNA typing techniques and newly 
available GIS technologies now mean that geographical mapping of the spread of 
resistance in time is possible and the timing of the emergence of SP resistance in Africa 
sometime after the emergence of chloroquine resistance meant that studies of resistance 
–both in vivo and molecular spanned the period of time during which SP resistance was 
emerging in Africa. 
 
The purpose of collecting and tracking SP resistance data is threefold: firstly, to identify 
spatial and temporal patterns of resistance at a population level and secondly, to highlight 
gaps in the data coverage which are useful for improvement of surveillance initiatives. 
Thirdly since in vivo studies are no longer carried out for SP due to resistance, reliance on 
molecular markers has increased. By examining spatial and temporal changes in 
resistance using both in vivo and molecular data, the relationship between molecular 
markers and drug efficacy in vivo can be elucidated.     
 
Although in vivo studies are the gold standard of resistance measures, molecular markers 
have an advantage over in vivo tests because numerous surveys for detecting point 
mutations can be rapidly completed over many sentinel sites covering foci (large areas) or 
hot spots (small areas) (Plowe, Kublin and Doumbo, 1998; Talisuna et al., 
2004a).Therefore, molecular markers have become useful for tracking the geographic 
spread of antimalarial drug resistance. In this study in vivo and molecular measures of SP 
resistance were identified from the literature and mapped with the aim of quantifying and 
geographically tracking the occurrence of SP resistance in sub-Saharan Africa. This 
chapter describes how the studies were identified, how they were mapped and how the 
37 
 
resistance data were standardised and incorporated into a database, Finally it examines 
what coverage was achievable using the refined standardised datasets which go on to be 
analysed in subsequent chapters. In this chapter the in vivo data will be described first, 
followed by the molecular data. 
 
The in vivo therapeutic response for measuring and monitoring SP resistance 
 
In an in vivo test, the parasitological and therapeutic response of a group of symptomatic 
and parasitaemic people over a defined follow-up period is determined. According to 
Bloland (2001) in vivo test results most closely reflect the presiding clinical or 
epidemiological situation in an area and thus offers the best information about a drug’s 
efficacy. Clinical studies using in vivo tests of antimalarials for clinical and parasitological 
efficacy are conventionally the gold standard for assessing drug efficacy and have been 
the cornerstone of in-country sentinel site surveillance and the primary evidence used for 
guiding antimalarial drug policy and monitoring drug efficacy (WHO, 1996). In an in vivo 
test the specified follow-up period after treatment should allow adequate time to assess 
the parasites’ responses to the drug and guidelines on standardisation of duration of 
follow-up have undergone significant revisions over time. The use of a standardised 
protocol is important for accurate evaluation of antimalarial drug efficacy (Sibley and Hunt, 
2003). The WHO protocols underwent significant revisions three times between 1973 and 
2001 to accommodate malaria control programme needs, changing malaria epidemiology 
and testing for resistance (Table 2.1a and b) (WHO, 1996; WHO, 2002; WHO, 2009b, 
WHO, 2010c).  
 
The evolution of in vivo efficacy test systems 
 
The WHO devised standardised protocols to regulate in vivo efficacy studies so that their 
results could be interpreted and compared for surveillance and monitoring. Tables 2.1a 
and 2.1b summarise the major changes incorporated into these protocols over time, 
starting with the WHO (1965) protocol which defined sensitive/resistant responses to 
treatment during three to 11 days follow-up. Some modifications and revisions were 
applied to the protocols in other years but the main protocols are listed in Tables 2.1a and 
b.  
 
The early protocols formulated between1964-1972 were performed mainly among non-
immune patients and the goal was to assess parasitological response rather than clinical 
38 
 
response to drugs, which are important for developing treatment policies (WHO, 1996). 
Antimalarial resistance was measured by a non-reduction in parasite density, persistent 
parasitaemia or an increase or reappearance of parasitaemia. 
 
A major change occurred from the 1973 protocol to the 1996 protocol as the emphasis 
shifted to clinical responses as the primary criteria for treatment policy change and 
parasitological testing were reduced to a minimum, within safety protocols. The aim was 
not to disregard the importance of parasitological monitoring completely but rather to factor 
in clinical responses into drug efficacy studies. Study participants were selected on the 
basis of clinical evidence and microscopically confirmed P. falciparum malaria, especially 
in infants and young children in intense malaria transmission areas in the WHO (1996) 
protocol so as to guide national drug policies. The efficacy data generated through field 
application of this protocol were used to assess the practical efficacy of a drug regimen 
and to then guide decisions on whether or not an alternative drug should be used. This 
was achieved by re-defining the study end points for assessing antimalarial drug efficacy 
in vivo (Tables 2.1a and b).   
 
The WHO first developed a system of grading the parasitological response of P. 
falciparum over seven, 14 or 28 day intervals after a standard dosing regimen of 
chloroquine was administered over three days (WHO, 1973). Response to the drug was 
then categorised as S, RI, RII or RIII. The response curves obtained from plotting the daily 
parasitaemia load in study participants became the grading system in the standard field 
test, which was used by in-country malaria control programmes to assess the efficacy of 
antimalarials. The standard field test measured parasitological response of P. falciparum 
daily in non-immune people after antimalarial treatment over seven days. Little attention 
was given to clinical response or immunity although the study participant’s clinical 
condition was of primary importance (WHO, 1973).  Due to the short duration of the seven 
day follow-up period, the difference between an S and RI response could not be 
determined easily. This was addressed with the extended test. Rieckmann (1990) provided 
a simplified version of the standard seven day test which measured parasite density on 
three days (0, 2, 7) rather than every day.  
 
With the first protocols circa 1973, observations of high parasitaemia loads within the first 
two days of the follow-up period indicated a high grade resistance (RIII) whilst latter day 
parasitaemia indicated low grade resistance (RII or RI). As is evident from this grading 
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system, the conventional indicator of antimalarial resistance at that time was the observed 
persistence of parasites during the follow-up period (WHO, 2005; WHO, 2006).  
 
Briefly, the new 1996 test system consisted of clinical examination, measurement of 
axillary temperature (on days 1, 2, 3, 7 and 14) and parasitological assessment (on days 
2, 3, 7 and day 4), measured haematocrit and haemoglobin as well as supervised 
administration of the antimalarial. The protocol also defined specific inclusion and 
exclusion criteria for participation in a study.  
 
White (2002) described the major limitations of the 1996 protocol, highlighting the fact that 
the early treatment failures (ETFs) specified fever with parasitaemia on day three post-
treatment, even though non-immune children could still harbour parasitaemia despite 
having a drop in their parasite loads. Conversely an adequate clinical response (ACR) 
could describe a person with no fever but who may still have persistent parasitaemia 
(White, 2002).  
 
Of further importance, was the need to differentiate between those parasites that were 
recrudescent or new infections to ascertain whether there was true resistance or not. 
Recrudescence is caused by survival of blood stage parasites bringing on a renewed 
manifestation of the original infection (WHO, 1963). There is a shortened time between the 
administration of a first line treatment and recrudescence, as the degree of drug resistance 
increases. Cure of malaria infection and hence treatment success could be achieved if the 
antimalarial prevented parasite recrudescence (WHO, 2006). 
 
This is different from a re-infection, which is an entirely new infection that appears after all 
the original infection’s parasites have been cleared in a person (WHO, 1963). During the 
early days of resistance detection it was not possible to differentiate between recrudescent 
and new infections by microscopy alone. Detection of recrudescent and new infections 
became feasible as polymerase chain reaction (PCR) techniques developed, allowing the 
identification of genetic markers of resistance. Currently P. falciparum merozoite (MSP1, 
MSP2) and the glutamate-rich protein (GLURP) are established molecular genotyping 
markers used to distinguish between recrudescent and new infections. However 
standardised definitions of recrudescent and new infections based on these markers are 
required as the characterisation also depends on the method of genotyping (WHO, 2002).  
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The WHO 1996 protocol needed updating by 2001 primarily because many countries in 
sub-Saharan Africa had already started using antimalarial combination therapies rather 
than monotherapies (WHO, 2002). The subsequent WHO (2001) protocol was ratified at 
the end of 2001 and published in 2002 (WHO, 2002). Within this protocol children younger 
than five years of age in all types of endemicity areas were targeted. That age group is 
more likely to have an unsatisfactory response to antimalarial drugs compared to other 
age groups, even in areas with acquired immunity. If there were difficulties in recruiting 
young children, all age groups could be enrolled but it was recommended that results be 
stratified by age. Parasitological response was included in the 2001 protocol as part of the 
clinical response (ACPR) assessment. Late treatment failures (LTF) were categorised into 
late clinical failure (LCF) and late parasitological failure (LPF) in the 2001 protocol which 
characterised clinical and parasitological response separately. In addition molecular 
assessment to distinguish recrudescence from re-infections were included in the 2001 
protocol. The protocol was modified in 2005 to accommodate high transmission areas. The 
changes related to the care of late parasitological failures and duration of follow-up with 42 
days being optimal and 28 days being adequate (WHO, 2005). 
 
During the previous decade, the revisions to the WHO guidelines for conducting in vivo 
efficacy studies were targeted at different endemicity settings but the recommendation in 
2009 used the same definitions of classification endpoints for all transmission settings, 
with the intention of using only effective treatments to reduce morbidity and mortality 
associated with treatment failure and development of severe malaria (WHO, 2009b; WHO, 
2010c). In 2009 the WHO recommended that molecular markers be used simultaneously 
with therapeutic efficacy tests to assess antimalarial resistance and these surveys should 
be conducted every year (WHO, 2009b). 
 
As mentioned previously each WHO guideline for antimalarial drug efficacy was designed 
to standardise the methods applied in field tests and to improve the comparability of 
results across borders and time periods. However protocols were also sometimes modified 
to accommodate local conditions at sentinel sites. Some studies reported using WHO 
(1994) and WHO (2003) protocols, which are not strictly WHO protocols which would have 
well defined outcomes. Thus these types of user specific protocols are excluded from 
Tables 2.1a and b. According to the WHO (1994) report the role of the classification of 
parasitological response is to assess whether or not drug resistance is responsible for a 
reduced clinical response. The WHO (1994) report defined three categories (A, B & C) of 
parasitological response within a seven day follow-up period rather than the traditional S-
RIII system. 
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Thus depending on the in vivo protocol used, different classification end points are 
reported (Tables 2.1a and b) and these influence the direct comparability of the results 
generated. The term “study end points” used here refer to the response categories defined 
for each protocol, based on the drug efficacy in vivo. Tahar and Basco (2007) highlighted 
the inconsistent results that occur due to the use of various protocols and different 
definitions of antimalarial treatment failure. The differences arise due to the exclusive or 
combined use of clinical and parasitological measurements, the duration of follow-up and 
whether or not there was any adjustment for recrudescent and new infections.  
 
Importantly, the use of either parasitaemic or clinical measures as the primary indicator of 
efficacy had implications for malaria treatment in Africa (Sibley and Hunt, 2003). For 
example, if clinical response was the primary measure in high transmission areas, people 
might still harbour parasites which recrudesced despite resolution of clinical symptoms 
during the specified follow-up period. According to Machekano, Dorsey and Hubbard 
(2007) the success or failure of an antimalarial drug in removing parasites can be clinically 
undetermined whilst Rieckmann (1990), stated that parasitaemia is a more precise 
indicator of treatment response compared to clinical measurements alone. Indeed some 
studies used parasitaemia as the primary measure of response in asymptomatic or 
symptomatic people on the seventh day of follow-up (Tahar and Basco, 2007).    
 
Price et al., (2007) stated that individual investigators will likely continue to use varying 
study designs and the challenges of comparing the treatment efficacies from different 
studies will persist. Thus consideration should be given as to what information might be 
useful to compare such studies within these constraints. As the advent of molecular 
genotyping proved to be a useful new tool to detect antimalarial resistance, the WHO 
recommended that surveillance of antimalarial resistance in countries of decreasing 
malaria transmission should include tests for both in vivo efficacy and molecular markers 
and that the latter be used to confirm the results of in vivo efficacy studies (WHO, 2009b, 
WHO, 2011a).   
 
Recommendations for molecular methods to detect resistant mutations were included for 
the first time by a WHO working group on monitoring antimalarial drug resistance in 2001 
(WHO, 2002). As mentioned above molecular markers were subsequently recommended 
as indicators of antimalarial resistance and this was an optional component of surveillance 
of antimalarial drug efficacy (WHO, 2009b). The recommendation was to collect blood 
spots on filter paper from people participating in regular therapeutic efficacy tests, on the 
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day of enrolment (day 0) and on the day of treatment failure within the follow-up period. 
The WHO specified that the method used to identify the point mutations should be 
described to allow standardisation of molecular methods among research groups (WHO, 
2001; WHO 2009b). Furthermore it was recommended that the molecular marker assays 
should be conducted on an annual basis in these areas.  
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Table 2.1a Summary of study end points for WHO protocols (1965-2009) 
 
Protocol 
Classification 
Endpoints Follow-up days 
Defining             
features 
1. WHO(1965) 
Sensitive/Resistant Sensitive/Resistant
3 days up  to 11 
days 
Resistance indicated by 
lack of reduction in 
parasite density or an 
increase in parasite 
density, persistence of 
patent parasitaemia or 
reappearance of asexual 
parasites with or without 
clinical symptoms within 
two months of first 
treatment. 
   
2. WHO (1973)   Introduction of grading 
system with specific 
follow-up period. No 
clinical measures 
reported. Only 
parasitological outcomes 
reported. 
Standard field test S/RI, RI, RII, RIII 7 days 
Extended field test S,RI,RII,RIII  28 days 
Single 
dose/alternative 
test S/RI, RI,RII, RIII 7 days 
3. WHO (1996) 
 
 
adequate clinical 
response (ACR) 
early treatment 
failure (ETF) 
late treatment 
failure (LTF) 
14 days 
 
Inclusion and exclusion 
criteria specified. 
Targeted febrile infants 
and children aged 6-59 
months in areas of high 
transmission.  In low 
transmission areas, all 
age groups could be 
included. Clinical 
measures included and 
clinical failures reported. 
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Table 2.1b Summary of study end points for WHO protocols (1965-2009) continued 
 
 
 
 
Protocol 
Classification 
Endpoints Follow-up Days 
Defining              
features 
4. WHO (2001)  
adequate clinical 
and parasitological 
response (ACPR) 
early treatment 
failure (ETF) 
late clinical failure 
(LCF) 
late parasitological 
failure (LPF) 
14 days and if 
possible 28 days 
 
 
Different protocols for 
high transmission and 
low/moderate 
transmission areas. 
Inclusion and exclusion 
criteria updated 
accordingly. Studies 
longer than 14 days 
duration should include 
PCR to distinguish 
recrudescence from re 
infection. Measured 
fever and day two blood 
slides for ETF. Focus 
on clinical cure. 
4.1 High 
transmission 
areas 
 
 
 
4.2 
Low/moderate 
transmission 
areas 
 
 
 
adequate clinical 
and parasitological 
response (ACPR) 
early treatment 
failure (ETF) 
late clinical failure 
(LCF) 
late parasitological 
failure (LPF) 
28 days 
 
 
Any person older than 
five years included if it 
was difficult to get 
sufficient numbers of 
under- fives. History of 
fever could be used if 
reliable. Measured 
increase in fever on day 
three for ETF. Both 
clinical and 
parasitological 
measures used. 
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Molecular markers to measure and monitor SP resistance  
 
As mentioned in chapter 1, the enzymes DHPS and DHFR from P. falciparum are 
essential to the folate biosynthesis pathway and are the target of sulphadoxine and 
pyrimethamine respectively (Peterson, Walliker and Wellems, 1988; Triglia and Cowman, 
1994).  In the late 1980s and 1990s specific point mutations of the dhfr and dhps gene 
encoding DHFR and DHPS were implicated in SP resistance (Cowman et al., 1988; 
Peterson et al., 1988; Brooks et al., 1994; Triglia and Cowman, 1994). Mutations at seven 
dhfr codons (16, 50, 51, 59, 108, 140 and 164) and five dhps codons (436, 437, 540, 581 
and 613) have since been isolated as molecular markers for SP resistance. The amino 
acid substitutions and the underlying sequence changes in the three letter code for each 
codon are listed in Table 2.2.   
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Table 2.2 Molecular markers for dhfr and dhps 
dhfr  
Codon 
16 50 51 59 108 140 164 
Sensitive GCA Cys(C)   
TGT 
Asn(N)  
AAT 
Cys(C)   
TGT 
Ser(S)   
AGC 
Val(V)  
GTT 
Ile(I)  
ATA 
Resistant Ser(S) 
TCA 
Arg(R) 
CGT 
Ile(I)   
ATT 
Arg (R)  
CGT 
Asn(N)  
AAC   
Leu(L)  
CTT 
Leu(L)  
TTA 
Val(V) 
GTA 
 Thr(T)  
ACC  
 
dhps 
Codon 
436 437 540 581 613  
Sensitive Ser(S)   
TCT 
Ala(A)   
GCT 
Lys(K) 
AAA 
Ala(A) 
GCG   
Ala(A)  
GCC 
 
Resistant Ala(A)  
GCT 
Gly(G)  
GGT    
Gly(E) 
GAA 
Gly(G) 
GGG 
Ser(S) 
TCC 
 
 Cys(C) 
TGT 
   Thr(T)  
ACC 
 
 Phe(F)  
TTT  
     
 
 
The first step in genotyping dhfr and dhps point mutations is to collect a blood sample by 
finger prick and transfer it onto commercially available treated filter papers or cards (WHO, 
2007, Collins et al., 2006). The air dried blood spots can then be used to extract parasite 
DNA. Early laboratory methods for molecular detection of P. falciparum malaria were 
formulated in the 1980s and involved hybridisation of specific probes targeting DNA 
(WHO, 1986; Singh, 1997, Steenketse et al., 2009). Since then advances have been made 
in refining high throughput genotyping protocols involving PCR based assays. 
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It is now well documented that the presence of multiple polymorphisms correlates with 
declining efficacy of an antimalarial drug. Several studies have shown that as the number 
of mutations progressively accumulate so do the levels of resistance. Allelic haplotypes 
are combinations of these point mutations. Haplotypes with many mutations tend to be 
more highly resistant than those with few mutations. Further discussion of haplotypes is 
presented in chapters 4 and 5.  
 
Large-scale surveys determining the prevalence of dhfr and dhps point mutations from 
filter paper blood spots can be achieved relatively easily and quickly especially if combined 
with the existing operational structures for conducting in vivo efficacy studies. This is 
evident from the growing popularity of molecular surveys in certain sub-Saharan African 
countries since the 1990s, which are being reviewed and quantified in this study.  However 
assessment of molecular markers is still not routinely carried out across sub-Saharan 
Africa (Mockenhaupt et al., 2007) and for the first time regional and country-specific data 
gaps will be characterised by the work described in this thesis. By collating and geo-
referencing all published data on in vivo and molecular measures of SP resistance it is 
possible to summarise what is known about the appearance of SP resistance at sentinel 
sites and the spread of the mutations in dhfr and dhps that underpinned the emergence of 
SP resistance in Africa.  
 
2.2 Aims and Objectives 
 
The aim of chapter 2 is to describe the literature search and the in vivo and molecular data 
which it generated. The standardisation, georeferencing and input of these data into a 
relational database will be described. Coverage of the in vivo and molecular surveillance 
studies included in the database is described and country-specific gaps are identified. 
 
2.3 Methods 
 
Search strategy 
 
Online searches for published studies containing the free text term “malaria” were 
conducted between 2005 and 2011. The online databases available in Pubmed, African 
Healthline, African Journal Online, ISI web of Science, Bioline databases and Google 
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Scholar were cross-referenced for malaria related studies. From these, references with the 
following terms were selected: sulphadoxine or sulfadoxine or pyrimethamine or Fansidar 
or SP or PS or antifolate or dhfr or pfdhfr, or dihydrofolate reductase or dhps or pfdhps or 
dihydropteroate synthase. Specific exclusion and inclusion criteria were applied to further 
refine the selection of suitable studies for analysis and these are detailed in Table 2.3.  
Table 2.3 Inclusion and exclusion criteria applied to the selection of in vivo studies 
Criteria for study selection Description 
Inclusion criteria SP monotherapy only where it was 
administered in vivo as the first line drug in 
clinical studies on pure P. falciparum 
infections in an African country. 
Study participants could be symptomatic or 
asymptomatic having uncomplicated malaria. 
Studies which might include cases of malaria 
imported between African countries.  
Exclusion criteria Any SP therapy administered as second line 
treatment, after another drug was 
administered as first line treatment. 
SP in combination with another drug. 
Participants with complicated or severe 
malaria. 
Prophylaxis, vaccine, in vitro and animal 
studies. 
Studies of travellers, malaria cases imported 
to non-African countries. 
Unrestricted criteria language of publication, study participants’ 
age or gender, malaria transmission 
intensity, duration of SP use in each African 
country, method of analysis of study 
outcomes (e.g. per-protocol or intention to 
treat) 
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The full texts of suitable in vivo studies were read and the data abstracted. This data 
collection strategy for reviewing SP resistance was part of the MARA project to collect data 
on antimalarial resistance in Africa and follows the strategy described elsewhere (MARA 
Technical Report, 1998; Omumbo and Snow, 2004). The molecular marker studies 
identified in the literature searches were read and abstracted in a similar manner as 
detailed below. 
 
Data collection tools 
 
Terminology 
A ‘study’ refers to primarily a journal article or source document from which data were 
abstracted.  A single study can contain data for multiple surveys conducted at different 
sites or at different time points.   
A ‘survey’ refers to in vivo or molecular measures of resistance carried out at one 
particular time in one specific site. The data contained in each survey makes a single data 
point. The unit of analysis is a data point, which describes a unique location and a unique 
time point.  
After applying the inclusion and exclusion criteria, suitable studies were abstracted by 
hand onto a predesigned template with specific data fields, called a Proforma. Thereafter 
these data were double entered into an electronic relational data entry system within 
Microsoft Access so that any variances that occurred during the double data entry process 
could be reconciled. Both tools are described in the following sections.  
 
The Proforma  
 
The Proforma (Appendix 1) consists of four major sections listed below: 
Section 1: Data reference: A record of the names of the author(s) and the publication 
details of the study 
Section 2: Survey location: This section described the geographic location including the 
country in which the study was done and the name of the study site. A small proportion of 
studies reported the latitude and longitude of the study sites.  The latitude and longitude 
co-ordinates for the study site were geo-coded using Geoname digital gazetteer (GDE 
Systems, 1995), GEOnet names server (GNS) (National Geospatial Intelligence Agency, 
1994), African Data Sampler (ADS) (World Resources Institute, 1995), the MARA 
50 
 
prevalence survey database or Google earth. Multiple sites from a single study were 
grouped if surveys were conducted at the same time and if the results were pooled. Any 
information on the drug policy as stated in the study was also recorded.    
Section 3: Antimalarial drug resistance: The goal was to use specific data fields that 
would allow systematic recording of information while accommodating the different types 
of data that are reported by in vivo efficacy studies. This section was divided further into 
subsections for methods and results. 
Study methodology: This sub-section listed the names and dosages of drugs studied, 
recorded the follow-up period, the study’s inclusion and exclusion criteria, PCR correction 
if used and WHO protocol where indicated.  
Study results: This sub-section described the study population characteristics such as 
study start and end dates, reported malaria transmission season, number of participants 
enrolled and completing the study as well as the age of enrolled participants. 
SP efficacy: This section recorded parasite clearance times and fever clearance times. It 
identified the number or proportion of participants classified according to their 
parasitological and/or therapeutic response. For studies spanning more than one year, the 
start year of the study was used in the analysis. Since individual patient-level data were 
not reported, the resistance outcome as reported in each study was maintained. A similar 
method was adopted by others looking at spatial and temporal trends of chloroquine 
resistance (Shah et al., 2011). There was no restriction based on the type of analytical 
approach used. In the per protocol approach, which was frequently used since 2000, any 
participant who was lost to follow-up for any reason would be dropped from the efficacy 
analysis (WHO, 2010c) whilst in the intention-to-treat analysis participants were classified 
as failures even though they might not represent true biological failures (Price et al., 2007).  
Molecular markers: This section captured individual dhfr and dhps point mutations and 
combinations of point mutations (haplotypes). The number of samples tested for each 
mutation was recorded along with the number of samples that tested positive for both 
sensitive and mutant forms. From this, the prevalence for each sensitive and mutant form 
could be calculated. The type of method used for the molecular assay was also indicated.  
Both mixed mutant and pure mutant infections were included in this analysis as outlined in 
Table 2.2. The prevalence of each mutation was determined by calculating the proportion 
of infections containing that mutation relative to the total number of people sampled. 
Where available, the number of haplotypes found and total haplotype count were recorded 
separately. An inclusive approach was followed to include studies with both mutation 
prevalence and frequency data. Pre-and post- treatment samples were recorded 
separately, if available. The next step was to capture the data from the proforma into the 
data entry system. 
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Data Entry System 
 
A relational database was designed using Microsoft Access to facilitate data entry and 
subsequent querying of fields for export and analysis. The system was structured to 
accommodate one-to-many relationships and vice versa. This facility was useful for 
querying multi-layered data i.e. one study could have information for different locations and 
methods as well as different drugs studied over varying time periods, thus producing many 
data points. 
 
Data validation 
 
The data were captured through a process of double entry into two separate databases. 
An error checking programme was developed to identify variances between the two 
databases. Any anomalies between the two databases were systematically identified and 
error reports were generated. The anomalies were corrected by referring to the data within 
the Proforma or source document if necessary. This process was continued until there 
were no variances between the first and second data entries.  
 
Mapping within a Geographic Information System 
 
Survey sites were geo-coded as point data and vector maps were produced in Mapinfo 
Professional ver 9.5 (Pitney Bowes Software Incorporated). The continental African 
boundaries were obtained from the ADS (World Resources Institute, 1995). 
 
The 48 countries in sub-Saharan Africa are based on the Roll Back Malaria (RBM) 
classification of malarious countries in Africa where the majority of cases occur (RBM 
2008) (Figure 2.1).  This was updated to mark the independence of the Democratic 
Republic of South Sudan from North Sudan in July 2011 and the geographic boundaries 
for these two new countries are indicated separately as North and South Sudan on the 
maps. The North African countries of Algeria, Egypt and Morocco have residual malaria 
and hence were excluded from this geographic analysis. The Comoros island group 
includes Mayotte.  
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Figure 2.1 Sub-Saharan African countries  
 
2.4 Results 
 
This section describes the in vivo and molecular data that were extracted during the data 
collection phase. The review to select source documents with SP monotherapy in Africa 
produced 313 studies (Table 2.4).   
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Table 2.4 Electronic search strategy results 
Search terms Source document 
Malaria 49003 
sulphadoxine or sulphadoxine or Fansidar or SP or PS  
or antifolate  
1471 
SP monotherapy  313 
dhfr or pfdhfr, or dihydrofolate reductase  154 
dhps or pfdhps or dihydropteroate synthase 126 
Both dhfr and dhps 121 
 
The studies emanated from 36 of 48 malarious sub-Saharan countries with English journal 
articles making up the majority of the source documents (Table 2.5). The time frame for 
these data was 1980-2007. Studies among children under five years of age accounted for 
44% (n=313) whilst 45% of studies included participants who were older than five years of 
age. The remaining studies did not indicate the ages of the enrolled participants. There 
were varying durations of follow-up with the majority of the studies using 28 days (38%) 
and 14 days (35%).  A short follow-up period of seven days was reported by 11% of the 
studies and the same proportion did not indicate any follow-up period. A long follow-up 
period of 42 days was indicated by 5% of studies. 
 
SP in vivo Studies 
 
Approximately equal proportions of studies (40%-41%) reported parasitological or 
therapeutic outcomes and 13% reported both measures while the remainder (6%) did not 
report a standard measure. Only 17% of the studies with 28 day follow-up corrected for 
recrudescent and new infections using PCR and 11% of these studies were conducting 
among children below five years of age. 
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Table 2.5 Summary of studies with SP monotherapy in vivo data 
 
 
 
 
 
Description Number of studies 
SP monotherapy  313
Number of African countries 36
Type of source document Journal  268
Ministry of Health Report 28
Other type of Report  17
Language English  296
French  17
Time frame during which studies were done at all 
sentinel sites 
1980-2007
Studies with children under 5 years 138
Studies with participants over 5 years 142
Studies with 7 day follow- up period  33
Studies with  14 day follow- up period 111
Studies with 28 day follow- up period 118
Studies with 42 day follow- up period 16
Classified treatment response using 
parasitological measures – S/RI/RII/RIII 
124
Classified treatment response using therapeutic 
measures – ACR/ACPR/ETF/LTF  
128
Classified treatment response using 
parasitological and therapeutic measures 
42
Surveys with 28 day or more follow- up and PCR 
correction for recrudescence/re-infection 
53
Surveys with 28 day or more follow- up and PCR 
correction for recrudescence in children under five 
years of age  (including mean age) 
34
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Standardisation of WHO Protocols  
 
The most common in vivo efficacy outcome measures are described here. These outcome 
measures were identified by the WHO protocol used to describe them, where available. 
Some studies explicitly stated which WHO protocol was used in the study e.g. WHO 1994 
and WHO 2003 whereas others did not. For the latter, the WHO protocol was inferred by 
the reported classification endpoints. Figure 2.2 summarizes the different protocols that 
were obtained after this process. Some studies (9%) used a combination of protocols such 
as WHO 1973 and WHO 1996. These were added to the protocol tally as individual 
protocols. The WHO 1973 and 1996 protocols were the most common, accounting for 34% 
and 32% respectively (n=326). The WHO 2001 protocol proved less popular (9%). 
Approximately 10% of the studies could not be assigned a protocol. In addition, 
adaptations of the major protocols were also used to accommodate different field 
conditions and these were extracted as they were reported by the study authors. Figure 
2.2 shows the major protocols, highlighted by the red boxes and gives an indication of the 
scope of modified protocols. These modified protocols accounted for 15% of the studies. 
    
Figure 2.2 Standardised WHO Protocols for SP monotherapy studies 
  NA = not assigned 
            Red boxes indicate major WHO protocols.   
 
0
5
10
15
20
25
30
35
P
er
ce
nt
ag
e 
(%
) o
f a
ll 
S
P
 m
on
ot
he
ra
py
 
st
ud
ie
s
WHO Protocol 
56 
 
A sub set of in vivo studies from 21 countries where surveys were conducted among any 
age group with 28 day or longer follow-up period with PCR correction (Figure 2.3) were 
matched by geographic site and survey year and these are described in chapter 5. No 
data were available for Botswana, Burundi, Cape Verde, Central African Republic, 
Comoros/Mayotte, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Guinea, Guinea-Bissau, 
Ivory Coast, Liberia, Mauritania, Mauritius, Namibia, Niger, Nigeria, Rwanda, Sao 
Tome/Principe, Senegal, Somalia, Swaziland, Togo and Zimbabwe. 
 
 
Figure 2.3 Countries where SP in vivo surveys were conducted among any age group with 
28 day or longer follow-up period and where PCR correction was done 
 
Molecular studies 
 
After applying the inclusion and exclusion criteria, 153 dhfr and 126 dhps source 
documents were identified for review (Table 2.4).   
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Synopsis of methods used in molecular studies of SP 
 
There were seven different methods used for genotyping dhfr and dhps mutations. The 
PCR Restriction Fragment Length Polymorphism (PCR-RFLP) was the most commonly 
used methodology for genotyping dhfr and dhps mutations (Figure 2.4).  This and the other 
methods listed in Figure 2.4 are described below.  
 
 
Figure 2.4 Summary of mutation screening methods used among all studies of dhfr 
and dhps 
 
The PCR-RFLP method was first described by Duraisingh et al. (1998) and uses a nested 
PCR to amplify the dhfr or dhps sequence, followed by digestion with a panel of restriction 
enzymes. Each restriction enzyme digest is designed to identify the presence of a specific 
sequence variant. Different restriction enzymes recognise and cut specific sequences and 
the enzymes used in this method are selected to recognise known sequence variants of 
dhfr and dhps associated with SP resistance. The change in fragment size resulting from 
the digestion can be visualised easily using agarose gel electrophoresis and reference 
samples for comparison. The use of reference samples as controls allows mixed samples 
and incomplete digestion to be differentiated from one another.  
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Nested PCR amplification generates sufficient PCR product even from the small amounts 
of DNA template typically extracted from patient finger prick blood spots. The limits of 
detection for minority genotypes in mixed infections depend to some degree on the 
efficiency of the initial PCR amplification and ultimately on the visibility of fragments from 
the minor variant on an agarose gel.   
 
Ranford-Cartwright et al., (2002) found the PCR-RFLP assay had a high specificity as it 
was able to correctly identify alleles that were absent in mixtures.  There was a small 
difference in the sensitivity of PCR-RFLP, 10 parasites per sample could not always be 
detected at the lowest (0.002%) parasite densities.  
 
Direct sequencing was the second most common methodology used. As with the previous 
method, the dhfr or dhps sequence is PCR amplified first and then subjected to direct 
sequencing. This method on its own is capable of detecting novel mutations which have 
not been previously described either at the commonly genotyped known codon positions 
or at any other codon position in the amplified fragment. The use of this methodology can 
sometimes elucidate new mutations, for example a novel I431V mutation of Nigerian origin 
was observed through analysis by PCR and direct DNA sequencing (Sutherland et al., 
2009).  
 
Nested PCR amplification generates sufficient PCR product for sequencing even from 
finger prick blood collected from patients with low density parasitaemia. The limit of 
detection for minority genotypes in mixed infections is determined by its peak height on the 
sequence electropherogram. Depending on the efficiency of sequencing and clarity of 
signal this may vary. 
 
Like all other commonly used genotyping methods, the third commonly used technique of 
dot blotting begins by nested PCR amplification of the dhfr or dhps sequence. The 
amplified PCR products are spotted into a membrane, fixed onto the membrane by cross 
linking and hybridisation with oligonucleotide probes detects the presence of variant 
sequences. Sequence-specific oligonucleotide probes are designed to complement the 
known sequence variants in dhfr and dhps and fluorescence or radioactive labelling is 
used to detect their hybridisation to the PCR products fixed to the membrane. Three 
variations of these methods have been described in Abdel-Muhsin et al., (2002), Pearce et 
al. (2003) and Alifrangis et al., (2005). These authors used identical probe sequences but 
different methods of visualisation.  
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As mentioned previously, the nested PCR amplification generates sufficient PCR product 
even from quantities of blood obtained by finger prick extraction. The limit of detection for 
minor genotypes in mixed infections relies upon the stringency of hybridisation conditions 
in each experiment. A high background level of hybridisation can obscure minor genotypes 
which would otherwise be detectable in high stringency conditions. Abdel-Muhsin et al., 
(2002) reported that their dot blotting technique was specific, sensitive and robust. They 
detected dhfr alleles in <100 parasites/µl blood and distinguished minority genotypes at 
very low proportions (1%) in mixed clonal infections.  
 
Another PCR specific amplification method was described by Plowe et al., (1995) and 
Doumbo et al., (2000). As with the other methodologies nested PCR is used to amplify the 
variant dhfr and dhps sequences. However in this method the primers in the second round 
of PCR are designed to be variant specific. When the primer complements a variant 
sequence in the DNA sample, a reaction is primed and a PCR product created. If it does 
not complement a variant sequence, then no fragment is amplified.  
 
This PCR specific amplification methodology is reliant entirely on the stringency of the 
PCR conditions because false positives might arise from primers annealing to non-target 
sites (mis-priming). Therefore the threshold of detection is determined with reference to 
the specificity of the nested PCR reaction. Furthermore, this method assumes the 
sequence for the sensitive dhfr 50C codon in their primer for the dhfr 51 codon. This 
practice is acceptable in Africa as currently mutations at dhfr 50R have only been found in 
South America (Cortese et al., 2002).  
 
The less common genotyping techniques were nucleotide sequencing, automated scoring 
of single nucleotide polymorphisms, use of micro arrays and mass spectrometry. The fifth 
method that was reported refers to a method of dhfr and dhps single nucleotide 
polymorphism (SNP) genotyping by primer extension designed by Nair et al. (2002). 
Genotyping was performed by primer extension and the products scored on a capillary 
sequencer by fragment size analysis. Multiple mutations can be genotyped in a single 
reaction and scored concurrently, which is the main advantage of this primer extension 
method. Multiple infections can be relatively easily characterised by primer extension using 
the different migration properties of oligonucleotides. Nair et al., (2002) did not conduct a 
sensitivity and specificity analyses of this method in differentiating among mixed and pure 
infections and stated that multiple infections could be distinguished using artificial mixtures 
of parasites with known alleles.   
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The micro array technique involves nested PCR, SNP primer extension and then 
sequence specific hybridisation and scanning by micro array as described by Crameri et 
al., (2007). The method is based on parallel PCR amplification of dhfr and dhps 
sequences, followed by primer-extension-mediated mini sequencing. Sequence variants 
are then detected by sequence-specific hybridization on a microarray.  
 
This technique is sensitive to the DNA quality used and requires a suitably large enough 
amount of DNA template of low parasite density cases. The authors reported that the 
method is sufficiently sensitive for clinical malaria cases and most asymptomatic cases, as 
it was able to detect approximately 15 parasites/µl (Crameri et al., 2007). Furthermore the 
estimated specificity of the test was 94% compared to the gold standard of sequencing. 
 
The final method listed in Figure 2.4 is matrix assisted laser desorption ionisation-time of 
flight mass spectrometry-based analysis (MALDI-TOF MS), referred to as mass 
spectrometry and it is based upon primer extension  as described in Marks et al.(2004)  
and Marks et al. (2005). The results of MALDI-TOF MS were compared to those obtained 
by DNA sequencing and this method was more sensitive to the detection of minor 
genotypes in mixed infections (Marks et al., 2004). 
 
Relative accuracy of genotyping methodologies 
 
Generally, the accuracy of genotyping using these various methodologies was compared 
to direct sequencing as a gold standard, with the exception of the microarray technique 
which was compared to RFLP. When comparing these methods, their ability to 
differentiate between single mutations and mixed infections is important. When samples 
contain a single genotype the results of the different genotyping methods are highly 
consistent. However, the results obtained from genotyping mixed infections are less 
repeatable due to the detection accuracy of minor sequence variants rather than the 
detection accuracy of the majority genotype. It is estimated that minor genotypes are likely 
to be out-competed in the first few rounds of amplification if they are less than 1:10 ratio 
with the majority sequence (Contamin et al., 1995).  
  
Since all the commonly used genotyping methodologies begin with PCR amplification, it 
may be argued that all methods are similarly constrained in the extent to which they are 
likely to amplify minor genotypes in mixed infections. However, one exception may be the 
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PCR specific amplification method which has primers specifically designed to target 
variant sequences even if it is significantly outnumbered. This may make render it more 
sensitive than other methods in detecting minor sequence variants in mixed infections. 
 
Ranford-Cartwright et al., (2002) compared PCR-RFLP, dot blotting and mutation specific 
PCR and recommended the dot-blot hybridisation technique for large scale genotyping 
surveys.  The dot blot technique proved to be similarly specific and sensitive to PCR-
RFLP, but it was recommended instead of the other two assays on the basis of 
consistency of the results generated using this method.  
 
 
There are no experiments to directly compare the sensitivity of all the methods described 
here, specifically in their detection of minor genotypes from mixed infections. In combining 
molecular surveillance data from many laboratories using different methods, equipment, 
reagents and research questions it is necessary to be aware of potential systematic 
confounders.  
 
If for example direct sequencing is less sensitive to the detection of minor genotypes in 
mixed infections and there has been a trend toward increasing use of this method in 
molecular surveillance overall, then caution should be exercised in analysing temporal 
trends in prevalence measures. The difference between prevalence and frequency 
measures are discussed in Chapter 4. Briefly, prevalence measures the rate of detection 
of any mutation among a number of samples and includes major and minor variant 
sequences detected. Frequency estimates which take only one sequence variant per 
sample (in mixed infections the majority sequence) are not vulnerable to this problem, and 
this measure is more robust to variation in methodological sensitivity, transmission 
intensity and age-dependent effects on multiplicity of infection in different transmission 
settings. 
 
The maps below show the coverage of dhfr and dhps point mutations and allelic 
haplotypes and highlight where gaps exist in the coverage of these. 
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Distribution and coverage of dhfr and dhps in sub-Saharan Africa 
 
For dhfr I164L, 184 sites (Figure 2.5) were surveyed and there are gaps in 37.5% of 
countries (Figure 2.5, Table 2.6). 
 
 
  
Figure 2.5 Sites surveyed for dhfr I164L 
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There were 232 surveys for dhps A437G extending across 39 African countries with data 
gaps in Burundi, Chad, Eritrea, Sierra Leone, Somalia, Togo (Figures 2.6 & 2.14 and 
Table 2.6). The coverage of dhps 437 ranked second best among all codons studied. 
 
 
 
Figure 2.6 Sites surveyed for dhps A437G 
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For dhps K540E 261 sites were surveyed (Figure 2.7). The coverage for dhps K540E was 
the best among all codons studied but there were no data at all in nine countries (Figure 
2.14, Table 2.6). 
 
 
 
Figure 2.7 Sites surveyed for dhps K540E 
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The dhps A581G point mutation was surveyed in 121 sites across Africa. Figure 2.8 and 
Table 2.6 shows the data gaps in 19 countries for this point mutation.  
 
 
 
Figure 2.8 Sites surveyed for dhps A581G 
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Coverage of dhps S436A spanned 153 study sites (Figure 2.9). Gaps were observed in 12 
countries namely Benin, Botswana, Burundi, Cape Verde, Chad, Eritrea, Liberia, Mauritius, 
Niger, Sierra Leone, Somalia and Togo (Table 2.6). 
 
 
Figure 2.9 Sites surveyed for dhps S436A 
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The dhps A613S/T codon was surveyed in 92 sites as illustrated in Figure 2.10. There 
were no dhps A613S in 20 countries and no A613T data in 22 countries (Figure 2.14, 
Table 2.6). Generally there was lesser coverage of dhps A613S/T compared to the other 
point mutations. 
 
 
 
Figure 2.10 Sites surveyed for dhps A613S/T       
Note: dhps A613T is absent in Gabon and Ghana. 
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Coverage of the dhfr IRN and dhps GE/GK/AK allelic haplotypes were comparable to that 
of the individual point mutations. The dhfr triple mutant haplotype was surveyed in 197 
sites (Figure 2.11). No data were found for 13 countries namely Benin, Botswana, Burundi, 
Cape Verde, Chad, Djibouti, Equatorial Guinea, Eritrea, Mali, Mauritius, Sierra Leone, 
Somalia and Togo (Figure 2.14, Table 2.6).  
 
Figure 2.11 Sites surveyed for dhfr IRN  
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The dhfr NCS sensitive allelic haplotype was surveyed in 195 sites (Figure 2.12). No 
coverage was found in 13 countries namely Chad, Equatorial Guinea, Burundi, Djibouti, 
Eritrea, Somalia, Botswana, Mauritius, Mali, Benin, Sierra Leone, Togo, Cape Verde 
(Figure 2.14, Table 2.6).  
 
Figure 2.12 Sites surveyed for dhfr NCS 
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The dhps 437 and 540 GE, GK and AK haplotypes were monitored in 152 sites (Figure 
2.13). No coverage was found in 11 countries namely Cape Verde, Chad, Burundi, 
Djibouti, Eritrea, Somalia, Botswana, Mauritius, Zimbabwe, Sierra Leone and Togo (Figure 
2.14, Table 2.6). 
 
 
 
Figure 2.13 Sites surveyed for dhps GE 
After reviewing the maps of molecular markers, consistent data gaps were identified in 
nine countries namely, Botswana, Burundi, Cape Verde, Chad, Eritrea, Mauritius, Somalia, 
Sierra Leone and Togo. The dataset for dhps A437G and K540E (GE) had the least 
amount of country data gaps with no data for 19% of malarious sub-Saharan countries 
(Figure 2.14). At the country level, surveillance of mutations at dhfr 164 and other dhps 
alleles were relatively poor compared with the other alleles (Table 2.6). No SP in vivo or 
molecular resistance data were found in the following seven countries: Botswana, Burundi, 
Cape Verde, Eritrea, Mauritius, Somalia and Togo.   
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Table 2.6 Gap analyses: countries where no data were found for each point mutation and 
allelic haplotype  
 
 
 
 
                                        No data available 1987-2008 
Codon Number of  
Countries (%)#
                                      Countries  
dhfr 164 18 (37.5) Angola, Benin, Botswana, Burundi, Cape Verde, Chad, Eritrea, 
Gambia, Guinea, Guinea-Bissau, Liberia, Mauritius, Namibia, 
Niger, Sierra Leone, Somalia, Togo, Zimbabwe  
dhps 436 12(25) Benin, Botswana, Burundi, Cape Verde, Chad, Eritrea, Liberia, 
Mauritius, Niger, Sierra Leone, Somalia, Togo 
dhps 437 9 (18.8) Botswana, Burundi, Cape Verde, Chad, Eritrea, Mauritius, Sierra 
Leone, Somalia, Togo 
dhps 540 9 (18.8) Botswana, Burundi,  Cape Verde, Chad, Eritrea, Mauritius, Sierra 
Leone, Somalia, Togo 
dhps 581 19 (39.6) Benin, Botswana, Burkina Faso, Burundi,  Cape Verde, Chad, 
Eritrea, Gambia, Guinea, Guinea-Bissau, Liberia, Mauritius, 
Namibia, Nigeria, Sierra Leone, Somalia, Togo, Zambia, 
Zimbabwe 
dhps 613S 20 (41.7) Benin, Botswana, Burkina Faso, Burundi,  Cape Verde, Chad, 
Eritrea, Gambia, Guinea, Guinea-Bissau, Liberia, Mauritius, 
Namibia, Niger, Nigeria, Sierra Leone, Somalia, Togo, Zambia, 
Zimbabwe 
dhps 613T 22 (45.8%) Benin, Botswana, Burkina Faso, Burundi,  Cape Verde, Chad, 
Eritrea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, 
Mauritius, Namibia, Niger, Nigeria, Sierra Leone, Somalia, Togo, 
Zambia, Zimbabwe 
dhfr IRN       13 (27.1%) Benin, Botswana, Burundi, Cape Verde, Chad, Djibouti,Equatorial 
Guinea, Eritrea,  Mali, Mauritius, Sierra Leone,  Somalia, Togo 
dhfr NCS 13 (27.1%) Cape Verde, Chad, Equatorial Guinea, Burundi, Djibouti, Eritrea, 
Somalia, Botswana, Mauritius, Mali,  Benin, Sierra Leone, Togo 
dhps 
GE/GK/AK 
11 (22.9%) Cape Verde, Chad, Burundi, Djibouti, Eritrea, Somalia, 
Botswana, Mauritius, Zimbabwe, Sierra Leone, Togo 
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Figure 2.14 Gap analysis:Molecular surveillance coverage of all dhfr and dhps point mutations from studies in sub-Saharan Africa    
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2.5 Discussion 
 
Previous attempts at geographic mapping of antimalarial resistance have used different 
measures of resistance in a variety of presentations. As mentioned in chapter 1 the 
seminal work mapping the global spread of chloroquine resistance was completed in 1989 
and contained data for 33 African countries from 79 sites in a sequence of hand drawn 
maps (Payne, 1989). Much later the WHO released online global maps containing 
summaries of antimalarial drugs including chloroquine and SP efficacy results, expressed 
as treatment failure rates (%)(WHO, 2010c). These maps are available at 
http://apps.who.int/globalatlas/. However, no synopsis of antimalarial efficacy data and 
molecular markers has been done at a continental level. In this chapter a review of 
available in vivo efficacy data and molecular markers of SP are presented and gaps in the 
data are highlighted. 
 
Different approaches might be used when reviewing and reporting data from different 
studies for comparison purposes. Systematic reviews can be performed with or without 
meta-analysis depending on the study objectives and type of information required. Shah et 
al., (2011) conducted a systematic review without a meta-analysis with the aim of showing 
overall trends in chloroquine resistance in India. Strict inclusion criteria would have 
precluded many in vivo studies and this can result in very poor data coverage in mapping 
studies. There is therefore a trade-off between data coverage and quality which must be 
resolved to optimise coverage while also creating a clean and well-standardised dataset. 
In this study a general review of studies was undertaken in the first instance and more 
specific inclusion and exclusion criteria were applied to select a subset of these studies for 
further specific analysis. In reviewing studies of SP and chloroquine for the purpose of 
identifying general geographic trends, Talisuna et al., (2004a) also did not apply strict 
inclusion and exclusion for study selection as prescribed by standard meta-analyses 
methods for randomised studies. These authors stated that if such strict criteria were to be 
applied it would preclude many in vivo studies.  
 
The 118 SP monotherapy studies with 28 day follow-up that were identified in this review 
of primary published work is comparable to the 90 reported for Africa from the WHO global 
database on antimalarial drug efficacy (WHO, 2010c). The WHO collated data from 
studies done between 1996 and June 2010 for SP with a minimum 28 day follow-up. In 
this thesis the review of dhfr and dhps point mutations and allelic haplotypes produced in 
excess of 120 journal articles. This amount is comparable to the 100 articles on dhfr and 
dhps found from 31 African countries prior to 2009 by Sridaran et al., (2010). When taking 
into consideration both in vivo and molecular data for SP resistance, gaps were identified 
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consistently in the following seven countries: Botswana, Burundi, Cape Verde, Eritrea, 
Somalia, Togo and Mauritius. These gaps could represent a genuine absence of 
resistance surveillance activity in these countries or perhaps just a lack of availability of 
surveillance data in the public domain. 
 
The WHO standard efficacy test provides the minimum essential information for deciding 
on a malaria treatment policy (WHO, 2009b; WHO, 2005; Vestergaard and Ringwald, 
2007). Studies with the basic design formed the basis of surveillance for monitoring 
changes in drug efficacy over time and were useful if they were conducted in many 
appropriately selected sentinel sites. As described earlier in this chapter, the standard 
efficacy test protocols changed over the years to accommodate the different antimalarial 
drugs and the different therapeutic response categories also adapted to reflect the growing 
knowledge about antimalarial treatment failure and resistance.  
 
As the goal of these tests were to standardise the classification endpoints to assess 
therapeutic failure or success, it is useful to quantify the proportion of studies that adhered 
to a specific WHO protocol as described here. 
 
A fair degree of variation was observed in the utilisation of WHO protocols for SP in vivo 
studies and in some cases combinations of protocols were used in the same study. This 
finding is consistent with outcomes of other reviews, for instance, after completing a review 
of 108 chloroquine studies in Africa over a seven year period (1996-2002) Talisuna et al., 
(2004a) also observed marked variability in the application of WHO protocols for 
antimalarial in vivo efficacy tests. This variability is indicative of the varying operational 
conditions in sub-Saharan African countries.  In a similar review in India Shah et al. (2011) 
found variation in the classification endpoints of in vivo efficacy studies and they resolved 
this by maintaining the endpoints described as they were reported and by forming a 
composite definition of treatment failure using per protocol for their spatial and temporal 
analysis. This composite definition of treatment failure allowed comparison of results from 
different protocols. 
 
The WHO mentioned the difficulty in comparing study results from the WHO 1973 protocol 
in high transmission areas (WHO, 2005). This protocol used S/RI/RII/RIII parasitological 
responses. It was recommended only in low or moderate transmission areas where the 
parasitological response categories (RI+RII+RIII) from the WHO 1973 protocol could be 
related to (ETF+LCF+LPF) from the WHO 1996 and 2001 protocols (WHO, 2005, WHO 
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2010c). As mentioned previously White (2002) discussed the limitations of the WHO 1996 
14 day test, stating that this protocol was actually applied both in high and low 
transmission areas. This illustrates the variability in the application of these tests and 
provides support for the use of a composite definition of treatment failure which will be 
presented in chapter 5, to optimise the available data for analysis of resistance patterns.  
 
The data obtained through conducting in vivo efficacy tests within sub-Saharan Africa have 
been used as the primary evidence which has informed decisions on drug policy and they 
remain an important component in defining the antimalarial resistance profile in each 
country. However, with the advent of tools to measure the genetic basis of resistance, 
surveillance of molecular markers has become increasingly important in policy decision 
making. The mapped coverage of molecular markers indicated in this chapter shows that 
monitoring of molecular markers to detect resistance in Africa has gained momentum in 
Africa. However many gaps exist. There is a dearth of SP molecular data in Burundi, 
Chad, Sierra Leone, Somalia and Togo. The Southeast African region representing Kenya 
and Tanzania amongst others, has the best overall coverage of SP molecular data. The 
review of the dhfr triple and dhps double mutants in Africa by Sridaran et al. (2010) also 
found a high proportion of studies done in East African countries like Kenya and Tanzania.  
 
Unlike the standardised protocols for in vivo efficacy studies, there are no equivalent 
standardised protocols for analysis and reporting of molecular markers. Whilst a variety of 
molecular methods are used, PCR-RFLP emerged as the most commonly used method in 
this review, confirming the view of Mockenhaupt et al., 2007. The PCR assay using a 
RFLP probe (PCR-RFLP) is a relatively simple and rapid method (de Pecoulas et al., 
1995). Menard et al., (2006) working in Central African Republic stated that PCR-RFLP is 
a robust method which has been widely used in other African countries whilst 
Mockenhaupt et al., (2007) also indicated that PCR-RFLP was the most common 
technique for dhfr typing.  
 
There is no reason to suppose that different methods would generate contradictory results, 
although there might be varying test sensitivities and specificities. The complicating factor 
is mixed infections (where one person is simultaneously infected with multiple genotypes), 
and there is still a need for a standardised framework for reporting molecular data.  Two 
metrics to standardise point mutation and allelic haplotype data across many sites will be 
described and employed in the spatio-temporal analysis presented in chapter 3. The 
WWARN collaboration (http:www.wwarn.org) has created a platform for sharing 
experiences, protocols and data with the aim of assisting under resourced laboratories to 
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conduct molecular genotyping studies. It is envisaged that this initiative will contribute to 
streamlining such data. Importantly it is necessary to clarify the types of measures of 
molecular data which are meaningful for policy makers. This will be discussed further in 
chapter 4. Standardisation of the molecular measures will alleviate some of the 
comparability issues experienced with in vivo efficacy data.  
 
If there are large local differences in the prevalence of molecular markers, such as that 
observed in the DRC, to adequately assess the antimalarial drug resistance profile in such 
a country would require data generated from many molecular studies at various sites. It 
was proposed that existing drug resistance networks carry out population-based surveys 
among 200–250 randomly selected participants at various geographically dispersed sites 
with different drug use practices and malaria transmission rates (Talisuna et al., 2004b).  
 
Generally it is difficult to gain access to patient level data at a country level. The WWARN 
collaboration has thus far obtained SP data for a few studies from Angola, Chad, DRC, 
Mali, Mozambique, Sierra Leone, Uganda and South Africa and efficacy rates are 
available online only in a summarised form (http://www.wwarn.org/resistance/explorer).  
 
Limitations 
 
There are several limitations to using summarised data with the primary one being the 
diversity in the methods including varying follow-up periods, use of asymptomatic or 
symptomatic participants and outcome measures reported from in vivo efficacy studies. In 
extracting data from these in vivo efficacy studies, it was assumed that the summarised 
treatment outcomes were identified correctly as they were collated from primarily 
published studies, which would have passed through peer-review. Furthermore 
summarised data from various different time frames and spatial scales are restrictive in the 
types of analyses that can be performed and requires caution when making inferences 
about these data or when interpolating sparse data in regions. Within these constraints, 
this thesis aims to characterise the spatial and temporal trends of SP resistance, beginning 
with chapter 3 where the analyses of point mutations are presented. 
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Chapter 3 Spatial and temporal changes of individual Sulphadoxine Pyrimethamine 
point mutations in sub-Saharan Africa 
 
3.1 Introduction 
 
P. falciparum parasites are genetically complex single celled organisms which are haploid 
for most of their development and diploid only during the zygote stage in the mosquito 
(Gilles, 1993b).The haploid blood stage of P. falciparum has genetic markers. Single 
nucleotide polymorphisms (SNPs) or polymorphic microsatellites are useful for genetic 
studies showing how drug resistance evolves, emerges and spreads. The appearance and 
accumulation of mutant SNPs in dhfr and dhps genes have been associated with tolerance 
to SP treatment. Although SP was once the standard treatment for clinical P. falciparum 
malaria, due to the spread of SP resistance which systematically eliminated sensitive 
genotypes, SP is no longer recommended as treatment. However, SP continues to be 
used for IPTp and it is recommended for infants as IPTi where the drug is still efficacious 
(WHO, 2009a). 
 
Assessment of the prevalence of dhfr and dhps mutant SNPs among infected individuals 
sampled at specific sites provides an indication of the local SP resistance rate. Point 
mutations must be transmitted at a faster rate than the sensitive forms, in order for them to 
displace the sensitive forms and spread successfully in a population, increasing their 
prevalence and ultimately reaching fixation where only the mutated form remains (Malisa 
et al., 2010). Molecular studies using the same methodologies, conducted at similar times 
but at different sites have found varying point mutation prevalence rates (Mugittu et al., 
2004; Alker et al., 2008; Mbacham et al., 2010). Predictably there have been observations 
of heterogeneity in the point mutation prevalence at different sentinel sites. 
 
Possible biological explanations for the emergence, spread and subsequent heterogeneity 
in point mutation prevalence have been put forward. One theory is that point mutations 
could have emerged de novo due to varying degrees of drug selection pressure and 
transmission intensities at those sites, whilst another theory is that the point mutations 
could have arrived from other sites at different times through gene flow (Hastings, 2004; 
Anderson et al., 2003; Nair et al., 2003; Roper et al., 2003; Roper et al., 2004). 
Furthermore, ethnographic reasons influence the movement of people across porous 
national and international borders, thereby contributing to the mixing of parasite 
populations and dispersal of resistant parasites.  
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Generally, the degree of SP resistance is proportional to the number of point mutations 
found in dhfr and dhps genes (Gregson and Plowe, 2005). Thus, point mutations confer 
varying degrees of resistance to SP either individually or when found in combination with 
other point mutations. A brief synopsis of each of the following point mutations is described 
next: dhfr 164L, dhps 436A, dhps 437G, dhps 540E, dhps 581G and dhps 613S/T. 
 
The dhfr 164L mutation was identified in Southeast Asia during the late 1980s 
(Sirawaraporn et al., 1997). Although it has subsequently emerged at some sites in Africa, 
it is still relatively rare (McCollum et al., 2006; Hyde, 2008; Ochong et al., 2008; Gesase et 
al., 2009). Nzila at al., (2005) proposed two possible explanations for the rarity of dhfr 
164L in Africa: (1) the use of the standard PCR-RFLP protocol which is not sensitive 
enough to detect rare point mutations especially in polyclonal P. falciparum infections and 
(2) the possibility that a fitness cost of the 164L mutation makes it less sustainable in 
African P. falciparum. 
 
As shown in chapter 2, PCR-RFLP was identified as the most common method used in 
genotyping studies and further work is required to assess it sensitivity for detecting rare 
mutations. The dhfr 164L mutation is highly resistant when found together with the dhfr 
51I+59R+108N as the quadruple mutant (Foote, Galatis and Cowman, 1990; Peterson, 
Milhous and Wellems, 1990) and this combination compromises the therapeutic 
usefulness of pyrimethamine, chlorproguanil and dapsone (Lapdap) and its combination 
with artesunate (Ochong et al., 2008).  
 
Resistant forms of dhps emerged circa 1993 and foresaw the arrival of SP treatment 
failure in Africa (Naidoo and Roper, 2010). SP resistance is magnified when dhps 
mutations occur together with dhfr mutations (Anderson et al., 2003). The dhps point 
mutations are discussed next. 
 
Opinions are divided as to whether or not the dhps 436A point mutation is associated with 
in vivo resistance. Some studies did correlate the presence of dhps 436A with SP 
treatment failure in areas of low endemicity, where there was low acquired immunity (Khalil 
et al., 2002; Alifrangis et al., 2003). It was found to be common in areas where there was 
low SP use or minimal SP resistance in vivo (Gregson and Plowe, 2005; Plowe et al., 
1997, Khalil et al., 2002), suggesting that it is not important in SP resistance and rather 
that it may be ancestral and an alternative of the sensitive dhps 436S sensitive form 
(Pearce et al., 2009). Another suggestion is that the occurrence of dhps 436A precludes 
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the progressive accumulation of other point mutations (Gregson and Plowe, 2005; Plowe 
et al., 1997), but in fact under increased drug pressure, it is equally probable that the 436A 
like the 436S is displaced by other point mutations. 
 
Similar to dhps 436A, the dhps 437G point mutation was not linked substantially to 
resistance after initial in vitro studies and it was the least resistant of all the mutations after 
testing using enzyme kinetic studies (Gregson and Plowe, 2005). The dhps 437G mutant 
is thought to be among the first point mutations to be selected under sulphadoxine drug 
pressure and is thus a precursor for in vivo resistance (Triglia et al.,1997; Gregson and 
Plowe, 2005).  Other studies observed that the dhps 437G single point mutation, combined 
with the dhfr triple mutant showed some association with treatment failure (Kun et al., 
1999; Dunyo et al., 2006; Ndounga et al., 2007). The 437G mutation was common among 
field isolates and found either on its own or in combination with the 540E (Sibley et al., 
2001). The 437G single mutant confers a lesser degree of SP tolerance than that 
conferred by the combination of 437G and 540E when observed in vitro (Brooks et al., 
1994; Triglia et al., 1997). 
 
Thus whilst dhps 437G is commonly found alone in many sites in this state it is not 
predictive of SP in vivo treatment failure on its own (Marks et al.,2005; Mobula et al., 
2009). However in many populations it is commonly found together in combination with 
dhps 540E as a double mutant (Anderson et al., 2003; Pearce et al., 2009). The double 
mutant allele is most common in East Africa (Naidoo and Roper, 2010) and when 
occurring with the dhfr triple mutant combination as the quintuple mutant, has a strong 
association with clinical SP treatment failure (Omar, Adagu and Warhurst, 2001; Staedke 
et al., 2004; Kublin et al., 2002). In these populations the dhps 540E is a good resistance 
marker, predicting the occurrence of the dhps double mutant (437G+540E) and the 
quintuple mutant (dhfr 51I+59R+108N+dhps 437G+540E (Kublin et al., 2002; Anderson et 
al., 2003). Tahar and Basco (2007) suggested that monitoring of the 540E point mutation 
may serve as an early warning indicator for reduced SP efficacy. Indeed the WHO recently 
recommended that a dhps 540E prevalence of 50% is the threshold that should be used to 
determine whether or not SP-IPTi is feasible for implementation in Africa (WHO, 2009a; 
Naidoo and Roper, 2011).  
 
An additional point mutation, the dhps 581G is newly emerging in East Africa and when 
found together with the dhps double mutant and dhfr triple mutant described above it 
confers even higher levels of SP tolerance. When it occurs in isolation the 581G has not 
been associated with resistance, but occurring where SP resistance is well established 
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and in combination with 437G or 540E it is now recognised as a significant threat to SP 
efficacy (Gregson and Plowe, 1995; Plowe et al., 1997). Examples of dhps 581G 
increasing in prevalence in East Africa include a study done in Korogwe District, Tanzania 
where it increased from 11.7% to 55.6% during 2003-2007 (Alifrangis et al., 2009). In 
Muheza, Tanga region in Tanzania, the efficacy of IPTp was compromised among 
pregnant women carrying the dhps 437G+540E+581G haplotype (Harrington et al., 2009). 
In the Hale, Tanga region of Tanzania the same haplotype was found among 55.2% 
(n=87)of children under five years of age in 2006 and the 581G was found on its own in 
54.5% (n=11) of the symptomatic children at enrolment (Gesase et al., 2009).  
 
The dhps 613S/T point mutations are still rare in Africa. It has been shown to confer 
resistance against sulphadoxine despite initial doubt about its role (Plowe et al., 1997). 
Plowe and others (1997) stated that the 613S/T was correlated with in vitro resistance but 
not in vivo resistance.  
 
Surveillance of the dhfr and dhps point mutations has been carried out by numerous 
workers at many sites in sub-Saharan Africa, for the purposes of quantifying their 
prevalence, frequency and/or relating these measures to clinical SP resistance. Prior to 
the current study, no syntheses of these point mutation data were conducted. This chapter 
chronicles the prevalence and rate of spread of seven different SP point mutations on the 
African continent, including island populations, with a view to determining whether or not 
any trends exist at a population level. It is known that SP resistance spread quickly across 
the continent but a comprehensive study of the changing patterns of dhfr and dhps point 
mutations over any length of time has not been conducted. Differences in the distribution 
patterns of dhfr and dhps point mutations have been documented within African countries 
and some regional trends in the prevalence of dhps point mutations have been studied 
(Alker et al., 2008; Basco et al., 2006; Pearce et al., 2009; Mbacham et al., 2010). 
However no descriptions or comparisons between the dispersal patterns of dhfr and dhps 
point mutations have been made on a regional or continental level. To better understand 
the emergence and spread of SP mutations, data were compiled from many records of SP 
resistance from multiple sites and study years in an ecological study using summarised 
prevalence data. The scope of the data was described in chapter 2.  
 
This data set affords the opportunity to observe trends in the occurrence of the different 
point mutations over time, at a continental scale. The point mutation prevalence data 
collected for this chapter were grouped to test whether or not there were any regional 
trends as per the regions described by Pearce et al., (2009). In their study Pearce et al., 
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(2009) characterised lineages of dhps allelic haplotypes among multiple sites in 20 sub-
Saharan African countries and reported that parasite circulation occurred in five distinct 
mainland African regions. However, whilst using allelic haplotype data, these authors did 
not go further into analysing any other spatial or temporal trends. The dhfr and dhps point 
mutation data are a constructive starting point for trend analyses in sub-Saharan Africa. 
The data used in this chapter covers a 20 year period from 1988 to 2008, with a 
geographic coverage in excess of 170 unique sites, within 30 sub-Saharan African 
countries, including three island populations. 
 
3.2 Aims and objectives 
 
This chapter describes the prevalence of seven point mutations namely, dhfr 164L, dhps 
436, dhps 437, dhps 540, dhps 581, dhps 613S and dhps 613T. Given the importance of 
the 437G and 540E to SP treatment efficacy, these point mutations were analysed further 
statistically and models were developed to characterise the joint effect of time and region 
on their prevalence.    
 
3.3 Methods 
 
Data collection  
 
Data collection methods were described in chapter 2. The Microsoft Access database was 
queried to extract data points for prevalence of dhfr 164L, dhps 436A, dhps 437G, dhps 
540E, dhps 581G, dhps 613S and dhps 613S/T point mutations. These studies included 
surveys of any age group as well asymptomatic or symptomatic people.  
 
Countries with dhfr and dhps data were categorised into five regions as described in 
Pearce et al., (2009) (Table 3.1) wherein five distinct regional clusters were described 
based on shared dhps allelic haplotypes.  A sixth island cluster was added in this study to 
assess the heterogeneity of point mutations and allelic haplotypes among island 
populations. Further discussion on the coverage of dhps and dhfr data for each region are 
presented here and in chapter 4.  
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Table 3.1 Regional classification of countries 
 
 
 
 
 
 
 
 
 
 
 
The DRC was allocated to both Southeast and Southwest Africa for the regional analyses, 
due to the significant geographic differences in SP efficacy in this large country, which 
spans more than two million square kilometres (Bonnet et al., 2009). The spatial mapping 
and statistical model development are discussed next. 
 
3.3.1 Spatial mapping of point mutation prevalence  
 
For each mutation, the prevalence was calculated using equation one: 
Equation 1:  
y = [number of samples positive for point mutations/total number of samples tested] X 100 
Where y = prevalence of point mutations 
 
Vector thematic maps were constructed in Mapinfo showing the prevalence of each point 
mutation in sub-Saharan Africa. The maps included studies with no study year. 
 
 
Region Country 
Central Cameroon, Central African Republic 
Northeast Djibouti, Ethiopia, North Sudan, South Sudan 
Southeast Democratic Republic of Congo (east), Kenya, 
Malawi, Mozambique, Rwanda, South Africa, 
Swaziland, Tanzania, Uganda, Zambia, Zimbabwe 
Southwest Angola,  Democratic Republic of Congo (west), 
Gabon, Namibia, Republic of Congo 
West Burkina Faso, Ivory Coast, Gambia, Ghana, Guinea, 
Guinea-Bissau, Mali, Mauritania, Nigeria, Senegal 
Islands Comoros, Madagascar, Sao Tome/Principe 
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3.3.2 Statistical model development 
 
Graphs were constructed in Stata Intercooled Version 12.0 (StataCorp LP, College 
Station, USA) showing the prevalence of each point mutation with binomial 95% 
confidence intervals, for each study year and region. The countries were classified into the 
five regions as described in Table 3.1. Surveys that had a missing study year were 
excluded from the spatial and temporal analysis. 
 
Multivariable regression analyses for point mutations 
 
Logistic models were constructed to assess whether or not there was any association 
between the outcome variable (prevalence of point mutation) and the risk factors study 
year (time) and region. The construction of the model is described in equation four. The 
log odds of the outcome (point mutation present = 1) was used. Odds ratios, confidence 
intervals and cumulative p value are reported for all the model estimates. The odds ratio of 
each risk factor describes its relative contribution to the prevalence outcome, whilst 
controlling for the influence of other risk factors (Bagley, White and Golomb, 2001). 
Dummy variables were created for each region category and coded as listed in Table 3.2. 
 
The Southeast region was used as the reference region because it had good coverage of 
data points over the 20 year period (Table 3.2). Island populations were included in these 
analyses. After running the logistic regression, the likelihood ratio test was performed to 
compare the models with and without point mutation prevalence changing over time and 
allowed an assessment of the strength of the evidence for any observed temporal change. 
 
Further multivariable regression analyses for dhps 437G and 540E 
 
The aim was to assess whether or not there was any association between the outcome 
variable (prevalence of point mutation) and the risk factors study year (time) and region. In 
this study logistic regression analysis with robust standard errors allowing for clustering by 
country, was performed for each point mutation as described in equation four. This was 
done to model the effect of time on prevalence, using odds ratios. Thereafter the goal was 
to assess if any observed trend differed between regions. This was demonstrated by fitting 
a logistic model with an interaction term between the study year and region, as shown in 
equation five. Island populations were excluded in these analyses because it had the least 
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amount of data points and these populations differ widely from each other. The Southeast 
region was used as the reference region throughout. 
Equation 4: log(p/1-p) or xβ = β0 + β1x1 + β2x2  
where  
p = probability of point mutation being present 
1-p = probability of point mutation being absent 
x1   = study year 
x2 = region 
x3 = region x study year 
β0  = constant 
Equation 5: log(p/1-p) or xβ =  β0 + β1x1 + β2x2 + β3x3 
 
 
Table 3.2 Coding of geographic regions to create dummy variables 
 
Region Code 
Central 1 
Northeast 2 
Southeast 3 
Southwest 4 
West 5 
Island 6 
Post estimation 
 
After running the logistic regression, the Wald test was performed to assess the strength of 
evidence for differences in prevalence of the dhps 437G and 540E point mutations among 
regions. This test tests the null hypothesis that the prevalence is the same in all regions, 
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apart from sampling variation. Akaike information criterion (AIC) was generated to estimate 
the goodness of fit of each model and to compare the models. Lower AIC values indicate 
the better fitted model. 
Linear combinations 
 
Estimating the linear combinations of the odd ratios sequentially for each region as in 
equation six below, provided the difference in the effect of time on the likelihood of the 
point mutation occurring, between each region and the reference Southeast region. 
 
Equation 6: log(p/1-p) or xβ =  β1x1 + β2 nx2 + β3x3 
Where n = each region 
In Stata, graphs were constructed using the model estimates of the predicted probabilities 
of positivity (Y=1) in each region.   
 
Assumptions and missing data 
 
Each dhps point mutation was independently sampled within each country. Between-
country variation in responses was modelled using Stata’s option for robust estimates. 
Surveys with missing data were excluded, for example where the study year was missing. 
 
3.4 Results 
3.4.1 Spatial mapping of point mutation prevalence  
 
This section contains a series of seven maps illustrating the country-level prevalence of 
each point mutation in sub-Saharan Africa.  
 
Table 3.3 outlines the data represented in the seven maps. Countries without point 
mutation data are the gaps reported previously in chapter 2. Some sites on the maps 
indicate both presence (red dots) and absence (blue squares) of point mutations. This 
occurs where different studies were conducted at the same site but at different times. The 
percentage in brackets in Table 3.3 indicates the proportion of samples that were positive 
for point mutations from the samples tested. In the following sections `n’ represents the 
number of samples tested in a particular survey. In the map legends, the numbers in 
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brackets refer to the number of study sites. The references used for each mutation are 
provided in appendices two through eight. 
 
3.4.2 Change in point mutation prevalence over time 
 
The coverage of surveys available for statistical analyses is presented in Tables 3.4a and 
3.4b. The prevalence for each point mutation is presented in a series of graphs with 
confidence intervals based on the proportion positive for each survey. These data are 
aggregated for each of the six regions. The results of the logistic regression analyses are 
presented thereafter. Generally the models showed evidence of a temporal change among 
all point mutations over time. The prevalence of dhfr 164, dhps 437G, dhps 540E and dhps 
581G increased over time whilst that of dhps 436A and dhps 613S/T decreased over time.
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Table 3.3 Summary of surveys available with prevalence data for point mutations 
 
* % mutant = [number of samples positive for point mutation /number of samples tested]*100 
# incorporates studies where sensitive alleles were reported or could be deduced from data provided
Point 
mutation 
Surveys Samples 
tested 
Samples  
mutant (%)* 
Samples  
Sensitive
# 
Unique  
Sites 
Countries  
with 
point 
mutation 
Countries 
without  
point 
mutation 
Study  
year  
range 
Number of 
surveys  
with no  
study years 
dhfr 164 184 19923 130 (0.7) 18958 116 7 21 1988-2008 6 
dhps 436 153 19033 2929 (15.4) 15988 107 33 2 1993-2008 5 
dhps 437 232 28851 14705 (51) 13222 152 38 0 1988-2008 6 
dhps 540 261 30291 10346 (67.2) 18811 172 28 10 1988-2008 7 
dhps 581 121 15398 782 (5.1) 14526 80 13 15 1993-2008 6 
dhps 613S 91 10312 134 (1.3) 10180 75 10 17 1993-2007 5 
dhps 613T 88 10152 11 (0.1) 10035 64 3 22 1988-2008 5 
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Regions Southeast Northeast West Southwest Central Island All 
Regions 
Surveys of I164L 100 13 33 5 21 6 178 
Samples tested for I164L 13232 1099 2125 395 1513 1368 19732 
Samples positive for 164L 78 0 0 0 1 51 130 
Samples positive for I164 12468 1099 2125 367 1390 1318 18767 
Surveys unresolved I164 3 0 0 0 2 0 5 
Unique sites with I164L 58 9 18 5 15 4 109 
Countries with I164L 10 4 7 3 2 3 29 
Surveys of S436A 72 13 25 11 11 5 137 
Samples tested for S436A  10540 904 2223 1020 1487 1071 17245 
Samples positive for 436A 826 59 969 254 741 52 2901 
Samples positive for S436 9659 846 1207 823 831 993 14359 
Surveys unresolved S436 2 0 0 0 0 0 2 
Unique sites with S436A 46 10 22 8 4 4 94 
Countries with 436A 11 4 10 4 2 3 34 
Surveys of A437G 121 27 39 13 17 9 226 
Samples tested for  A437G   17860 1531 4450 1201 2269 1294 28605 
Samples positive for  A437G 9109 644 1990 881 1276 599 14499 
Samples positive for  A437 8931 886 1074 410 1104 729 13134 
Surveys  unresolved A437 12 0 9 0 0 0 21 
Unique sites with  A437G 65 13 32 9 9 8 136 
Countries with  A437G 11 4 13 5 2 3 38 
Surveys of K540E 127 27 42 20 21 17 254 
Samples tested for   K540E    18602 1537 4543 1755 2109 1278 29824 
Samples positive for   540E 9408 609 65 69 9 30 10190 
Samples positive for   K540 9604 928 2820 1719 2092 1254 18417 
Samples unresolved K540 10 0 4 0 0 0 14 
Unique sites with   K540E 82 13 32 15 11 12 165 
Countries with   K540E 11 4 13 5 2 3 38 
Table 3.4a Summary of surveys available with prevalence data for point mutations by region 
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Table 3.4b Summary of surveys available with prevalence data for point mutations by region 
 
 
 
 
 
 
 
Regions Southeast Northeast West Southwest Central Island All Regions 
Surveys of  581G 69 12 15 5 9 5 115 
Samples tested for  A581G 10846 835 859 275 1220 1071 15106 
Samples positive for 581G 657 34 26 0 14 1 732 
Samples positive for A581 10185 801 726 275 1208 1070 14265 
Surveys unresolved   581G 1 0 2 0 0 0 3 
Unique sites with  581G 43 9 11 4 4 3 78 
Countries with 581G 9 4 6 3 2 3 27 
Surveys of S613A 49 11 13 3 6 4 86 
Samples tested for  S613A 6893 754 735 184 798 778 10142 
Samples positive for  S613A 23 1 88 0 20 1 133 
Samples positive for  S613 6871 753 649 184 779 775 10011 
Surveys unresolved   S613A 0 0 0 0 0 0 0 
Unique sites with  S613A 33 8 10 3 2 4 60 
Countries with  S613A 9 4 5 3 2 3 26 
Surveys of  S613T 49 10 12 2 5 5 83 
Samples tested for   S613T 6893 717 609 146 546 1071 9982 
Samples positive for   S613T 1 0 7 0 0 3 11 
Samples positive for   S613 6871 716 531 146 535 1067 9866 
Samples unresolved  S613T 0 0 0 0 0 0 0 
Unique sites with   S613T 33 10 8 2 2 3 58 
Countries with   S613T 9 4 4 2 2 3 24 
 90
Prevalence of dhfr 164L  
 
The dhfr 164L point mutation was found to be absent in 21 countries (Naidoo and Roper, 2011). It 
occurred in the following seven countries: Central African Republic (0.6%, n=167) (Menard et al., 
2006), Comoros (1.1%, n=269) (Andriantsoanirina et al., 2009); Kenya (3.4%, n=58) (Oesterholt 
et al., 2009), Madagascar (8.8%,n=273) (Andriantsoanirina et al., 2009), Malawi (4.7%,n=85) 
(Alker et al., 2005), Rwanda (11.8%,n=391) (Karema et al., 2010) and Uganda (13.7%, n=51) 
(Lynch et al., 2008), where it occurred in four different sites, surveyed in 1999, 2004 and 2005 
(Figure 3.1). In Madagascar four surveys were done at various sites across the island between 
2006 and 2008, where 164L occurred at a prevalence ranging between 0.9% to 8.8% (Menard et 
al., 2008; Andriantsoanirina et al., 2009). The cumulative continental prevalence of mutant dhfr 
164L was 0.7% (130/19923) between 1998 and 2008 (Table 3.3). 
 
Figure 3.1 Prevalence of dhfr 164L 
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Regional prevalence of dhfr 164L point mutation over time 
 
The dhfr 164L point mutation occurred only in the Southeast, Central and Island regions and was 
not found in the Northeast, West and Southwest regions (Table 3.4a, Figure 3.2). Out of 100 
surveys in the Southeast region, the overall prevalence was 0.59% (n=13232) from eight surveys 
where dhfr 164L was reported. The earliest report of 1.2% (n=82) prevalence occurred in 1999 in 
Kampala, Uganda (Staedke et al., 2004). In the Islands, the most recent prevalence was reported 
in Madagascar 2008 (Andriantsoanirina et al., 2009).   
 
The logistic model predicted an overall higher likelihood in dhfr 164L prevalence over time. For 
every year, the likelihood of a person having a dhfr 164L point mutation was 1.4 times higher (CI 
1.3-1.6)(Table 3.5). The likelihood of dhfr 164L occurring among the Island populations was 
greater than it was for the Southeast region (OR 2.1, CI 1.3-3.2) and comparatively lower in the 
Central region (OR 0.2, CI 0.0-1.6) (Figure 3.3). The low p value (p =0.001) for the Island region 
suggested there was strong evidence for this effect. The likelihood ratio test comparing models 
with and without dhfr 164L prevalence changes over time provided strong evidence to suggest 
that the regional prevalence of dhfr 164L was affected by time (p< 0.001) (Table 3.5). Coverage 
for dhfr 164L was better in the Southeast and Central regions compared with the Islands. Notably 
there were only six surveys available within the island populations, with a single survey done in 
2002 and five surveys between 2006- 2008.  
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Figure 3.2 Surveys of dhfr 164L prevalence (with 95% confidence intervals) conducted during 
1988-2008 and displayed according to their geographic region 
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Table 3.5 Model for dhfr 164L 
 
 
 
 
 
Model to estimate effect of time and region on 
prevalence of dhfr 164L 
Model to estimate effect of 
region on prevalence of dhfr 
164L 
Covariate Proportion 
(%) of  
samples 
positive 
[95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio [95% 
confidence 
interval] 
P value
Time (per study 
year)  
0.9[0.6-0.8] 1.4[1.3-1.6] <0.001   
Region Southeast 0.6 [0.5-0.7] 1  1  
Central 0.1 [0.0-0.4] 0.2 [0.0-1.6]  0.128 0.1[ 0.0-0.8]  0.029 
Island 3.7[2.8-4.9]  2.1 [1.3-3.2] 0.001 6.5 [4.6-9.3] <0.001 
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Figure 3.3 Predicted probabilities of dhfr 164L over time 
Prevalence of dhps 436A 
 
The dhps 436A mutation occurred in 32 countries after sampling from 107 unique sites (Figure 
3.4, Table 3.3). Only Ethiopia and Swaziland did not report this mutation (Gebru-Woldearegai et 
al., 2005; Schunk et al., 2006). The highest prevalence of 436A was 80% and this occurred in 
Central African Republic and Ghana (Menard et al., 2006; Pearce et al., 2009). Angola, Burkina 
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Tinto et al., 2007; Menegon et al., 2009; Pearce et al., 2009; Mbacham et al., 2010). Lower 
prevalence than this occurred in Rwanda (0.5%-5.5%) (Karema et al., 2010). 
 
On the Comoros island the prevalence was 1.1% (n= 269) (Andriantsoanirina et al., 2009). In 
Djibouti it was 5.3-6.5% (Rogier et al., 2005), in the DRC it ranged between 3.7%-24.3% from two 
studies done in 2002-2004 (Swarthout et al., 2006; Alker et al., 2008), in Equatorial Guinea it was 
16.7% (n=12) (Berzosa, Puente and Benito, 2005) and in Kenya the prevalence ranged between 
3%-23.8% from seven studies conducted between 1993-1999 (Wang et al., 1997; Plowe et al., 
1997; Nzila et al., 2000a; Nzila et al., 2000b; Omar et al., 2001; Mberu et al., 2002; Zhong et al., 
2008; Pearce et al., 2009; Oesterholt et al., 2009). 
 
By 2006 in Madagascar 436A was 0.6% (Andriantsoanirina et al., 2009), in Malawi it was 7% 
(Plowe et al., 1997) and in Namibia it was 12% (Pearce et al., 2009). In Mozambique it was <8% 
after 12 surveys were conducted between 2000 and 2004 (Alifrangis et al., 2003; Enosse et al., 
2008; Pearce et al., 2009; Raman et al., 2008). In the Republic of Congo it was <18% between 
1999-2004 (Nsimba et al., 2005; Ndounga et al., 2007; Pearce et al., 2009).  
 
Two studies done in South Africa reported 2.4% and 5.8% prevalence between 1999 and 2000 
(Roper et al., 2003; Pearce et al., 2009). In Uganda it was 16% (Jelinek et al., 1999). In Zambia 
two surveys done separately in 2004 reported <2% prevalence (Pearce et al., 2009). Finally, the 
dhps 436A prevalence was <13% (n=5) in Zimbabwe (Mlambo et al., 2007). Overall, 15.4% of the 
samples contained dhps 436A (n=19033) between 1993 and 2008 (Table 3.3). 
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Figure 3.4 Prevalence of dhps 436A 
 
Regional prevalence of dhps 436A point mutation over time 
 
The dhps 436A point mutation was found in all six regions (Table 3.3, Figure 3.5). The prevalence 
was ≥ 50% in the West, Southwest and Central regions during 1994-2005. In the Southeast 
region the highest prevalence of 38.2% (n=68) was recorded in Kibaha Hospital, 30 km from Dar 
es Salaam in 1988 (Alifrangis et al., 2003). In the Northeast region the highest prevalence was 
44% (n=75) in Akuem, Yargot Payam district, Bahr El Gazal, South Sudan in 2002 (Anderson et 
al., 2003). Among the Islands the prevalence ranged between 0–42.3% from five surveys 
(Andriantsoanirina et al., 2009; Tahar et al., 2007; Cravo, 2004). Overall, the Central region had 
the highest regional prevalence of 49.8% (n=1487) (Table 3.4a). 
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Figure 3.5 Surveys of dhps 436A prevalence (with 95% confidence intervals) conducted during 
1988-2008 and displayed according to their geographic region 
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The logistic regression model predicted an overall lower likelihood in dhps 436A over time. For 
every year, the likelihood of a person having a dhps 436A point mutation was 0.9 times lower (CI 
0.9-0.9). Compared to the Southeast region, the likelihood of dhps 436A occurring in the West 
(OR 9.0, CI 8.0-1.0), Southwest (OR 3.8, CI 3.3-4.5) and Central (OR 11.9, CI 10.5-13.5) regions 
was greater and the evidence for this was strong (p<0.001) (Table 3.6). Figure 3.6 shows the 
declining rates of dhps 436A prevalence over time in all regions.  The likelihood of dhps 436A 
occurring in the Northeast (OR 0.8, CI 0.6-1.0) and Island (OR 0.8, CI 0.6-1.1) regions was lower 
than it was for the Southeast region, although the high p values suggested there was weak 
evidence for this (Table 3.6). The likelihood ratio test comparing models with and without the 
effect of time provided strong evidence to suggest that the regional prevalence of dhps 436A was 
affected by time (p< 0.001). 
Table 3.6 Model for dhps 436A 
   
 
 
 
Model to estimate effect of time and region on prevalence 
of dhps 436A 
Model to estimate effect of 
region on prevalence of  dhps 
436A 
Covariate Proportion 
(%) of  
samples 
positive [95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio [95% 
confidence 
interval] 
P value 
Time (per study 
year)  
16.8[16.3-17.4] 0.9[0.9-0.9] <0.001  
Region Southeast 7.8 [7.3-8.4] 1  1  
Northeast 6.5[5.0-8.3] 0.8[0.6-1.0] 0.064 0.8[0.6-1.1] 0.158 
West 43.6[41.5-45.7] 9.0[8.0-1.0] <0.001 9.1[8.1-10.1] <0.001 
Southwest 24.9[22.3-27.7] 3.8[3.3-4.5] <0.001 3.9[3.3-4.6] <0.001 
Central 49.8[47.3-52.4] 11.9[10.5-
13.5] 
<0.001 11.7[10.3-13.2] <0.001 
Island 4.9[3.6-6.3] 0.8[0.6-1.1] 0.163 0.6[0.5-0.8] 0.001 
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Figure 3.6 Predicted probabilities of dhps 436A over time 
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Prevalence of dhps 437G 
 
High prevalence of dhps 437G occurred heterogeneously across Africa and was found in all 37 
countries surveyed among 152 unique sites (Figure. 3.7, Table 3.3). Studies done in Ethiopia 
(2004) (Gebru-Woldearegai et al., 2005), Kenya (2006) (Bonizzoni et al., 2009), Sao 
Tome/Principe (2004) (Salgueiro et al., 2010), South Sudan (2003) (Pearce et al., 2009) and 
Uganda (2003-2006) (Malamba et al., 2010, Lynch et al., 2008) all reported 100% dhps 437G.  
 
In Kilifi, Kenya 76.3% (n=76) dhps 437G prevalence was reported by Ogutu et al. (2005) whilst 
Nzila et al. (2000b) reported 48% (n=52) prevalence during 1993-1995. In Blantyre, Malawi the 
prevalence was consistently high (≥ 90) between 2001 and 2005 (Alker et al., 2005; Nkhoma, 
Molyneux and Ward, 2007). In Maputo province, Mozambique the prevalence was found to 
increase over time. During 2004-2006, the prevalence was <50% and increased to 64.5%(n=141) 
in 2007 (Raman et al., 2010) whilst in 2008 it was 75% (n=76) (Raman et al., 2010).  
 
In Tanzania 34 surveys were obtained and 437G prevalence was heterogeneous. For instance, in 
Kilombero and Ulanga it was measured at 13% (n=365) in 2000, 10% (n=519 and 214) in 2001 
and 27% (n=603) in 2002 (Malisa et al., 2010). Later in 2004 it was reported at 57.3% (n=561) 
(Pearce et al., 2009). In Korogowe it was consistently high during 2004-2007 (85%-97%) 
(Alifrangis et al., 2009). Similarly in Magoda the prevalence was 78.5%-91% during 1995-1999 
(Jelinek et al., 1998; Alifrangis et al., 2009). In Muheza, the prevalence of 437G was 86% (n=50) 
in 1995 (Curtis, Duraisingh and Warhurst, 1998) and 96% (n=28) during 1998-1999 (Mutabingwa 
et al., 2001). However in Rufigi, it was just 8.6% (n=417) in 2000 but it was 25% (n=596) when 
assessed in 2002 (Malisa et al., 2010). 
 
In Kampala, Uganda the prevalence was 58% (n=81) in 1999 (Staedke et al., 2004) and 89% 
(n=118) in 2000 (Sendagire et al., 2005). In Kasangati,Uganda the prevalence rose from 58.8% 
(n=97) in 2002 to 86.3% (n=183) in 2003 (Sendagire et al., 2005; Maiga et al., 2007). In Tororo, 
Uganda the prevalence was 62.5% (n=251) in 2001-2002 (Malamba et al., 2006), 98.5% (n=333) 
in 2002-2004 (Francis et al., 2006), reaching 100% in another study done during 2003-2006 
(Malamba et al., 2010). All 17 sites from Uganda had prevalence in excess of 57%. 
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In Macha, Zambia the prevalence was 4.5% (n=110) in 1998 and rose to 40.8% (n=49) in 2000 
but declined to 32% in 2003 (Mkulama et al., 2008). In Chibombo, Chipata and Isoka the 
prevalence was 66.6% (n=15), 70.3% (n=54) and 75% (n=12) respectively (Pearce et al., 2009). 
Lower prevalence than those described above were found in Djibouti (< 38.7%) since 1998 
(Rogier et al., 2005) and in Nigeria where it was < 47% (Pearce et al., 2009; Happi et al., 2005). 
Similarly in South Africa, it was found to reach 48% (n=73) between 1996-2002 (Roper et al., 
2003; Barnes et al., 2008; Pearce et al., 2009). In 2001 in Guinea-Bissau it was 28.8% (n=97) 
(Kofoed et al., 2004). In Central African Republic in 2004 it was reported to be 18.6% (n=183) 
(Menard et al., 2006). In Mauritania in 1998 it was <22% (Eberl et al., 2001). In Zimbabwe, 437G 
was assessed in 2003 in three different sites and all reported <17% prevalence (Mlambo et al., 
2007). 
 
In Namibia the prevalence was relatively high at 86.8% (n=76) as reported by Pearce et al. 
(2009). In the Republic of Congo the prevalence ranged from 68.3%-85% between 1999-2004 
(Nsimba et al., 2005; Ndounga et al., 2007; Pearce et al., 2009). Karema et al. (2010) reported 
high 437G prevalence of 80%-96% in Rwanda during 2005-2006. In Sao Tome/Principe 
consistently high prevalence of >75% was reported since 2000 by Cravo et al. (2004) and others 
(Tahar et al., 2007; Salguiero et al., 2010). 
 
In Sotuba and Bancoumana, Mali, a study with small sample sizes (n=10; n=8) also reported 
100% 437G (Wang et al., 1997). Among the eight other studies done in Mali, the highest 
prevalence was found in Bandiagara in 2000 where 59% (n=66) was recorded by Thera and 
others (2005). In Pikine, Senegal 437 prevalence ranged from 17% (n=23) in 2000 to 40% (n=15) 
in 2003 (Ndiaye et al., 2005).  In Niakhar, Senegal the prevalence was 91.1% (n=45) in 2004 
(Sokhna et al., 2008). In Sudan, there were 17 surveys done during 1996-2003 with a wide 
prevalence range of 4.4%-100%. In Asar, Daraweesh, Kajara and Gedaref the reported 
prevalence was >70% in 2003 (A-Elbasit et al., 2007; Al-Saai et al., 2009; Pearce et al., 2009).  
 
In Lambarene, Gabon the prevalence was 27.7% in 1995-1996 (n=36) (Kun et al., 1999) and 75% 
by 2007 (n=64) (Pearce et al., 2009). Similarly in Haut Ogooue, Gabon the prevalence increased 
from 36.8% in 1998 (n=36) (Mawili-Mboumba et al., 2001) to 63.63% (n=110) in 2000 (Aubouy et 
al., 2003). In Farafenni, Gambia the prevalence was 48.8% (n=86) during 2001-2004 (Dunyo et 
al., 2006) whilst Pearce et al., (2009) reported it as 46.45% in 2004 (n=127). In Ghana six surveys 
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reported prevalence ≥ 74% since 2001 (Marks et al., 2005; Mockenhaupt et al., 2005; Owusu-
Agyei et al., 2009, Pearce et al., 2009). 
 
In Angola two studies done in 2004 by Pearce et al., (2009) and Menegon et al.,(2009) reported 
92.5% (n=40) and 92% (n=66) 437G respectively. In a study done in Benin during 2003-2005, 
Nahum et al. (2009) reported 88% (n=65) prevalence. In Burkina Faso three surveys reported 
58%-78% prevalence (Dokomajilar et al., 2006; Tinto et al., 2007; Pearce et al., 2009). 
 
Two studies done in Mutengene, Cameroon reported 84.1% (n=202) prevalence in 2004 (Pearce 
et al., 2009) and 85.5% (n=200) between 2004-2006 (Mbacham et al., 2010). In Yaounde, 
Cameoon seven surveys found 437G prevalence from 16.6% in 1995 (n=6) (Basco et al., 1998) to 
65% during 2001-2005 (n=252) (McCollum et al., 2008) and 62% in both 2004 (n=143) (Pearce et 
al., 2009) and during 2004-2006 (n=145)( Mbacham et al., 2010)(Basco and Ringwald, 1998; 
Basco et al., 2000, Tahar and Basco, 2007). 
 
In the DRC, the prevalence ranged from 24.4% (n=135) in Kilwa (2003-2004) (Cohuet et al., 
2006), to 93.1% (n=102) in Kinshasa (2008) (Mobula et al., 2009). In the Ivory Coast two surveys 
in Abidjan (2006) and Yopougan (2001) found 437G at 56.6% (n=106) (Djaman et al., 2010) and 
51.7% (n=118) respectively (Djaman, Mazabraud and Basco, 2007).  
 
In Swaziland it was 7.4% (n=27) in 1999 (Dlamini, Beshir and Sutherland, 2009). Even lower 
prevalence than this were reported in Comoros in 2006 (6.3%, n=269) (Andriantsoanirina et al., 
2009). Overall, of the 28851 samples tested for dhps 437G between 1998 and 2008, 51% were 
positive (Table 3.3).  
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Figure 3.7 Prevalence of dhps 437G 
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Regional prevalence of dhps 437G point mutation over time 
 
The dhps 437G point mutation prevalence tended to increase over time, as ≥50% prevalence was 
reported at sites within each region. The 437G prevalence was 100% in the Southeast and 
Northeast regions in 2003 and on the Sao Tome/Principe Islands in 2004 (Figure 3.8) (Pearce et 
al., 2003; Malamba et al., 2010; Salgueiro et al., 2010).  Overall, the Southwest region had the 
highest prevalence (73.3%; n=1201) among the regions (Table 3.4a). 
 
This observation was confirmed by the logistic regression model which predicted an overall higher 
likelihood of dhps 437G over time. For every year, the likelihood of a person having a dhps 437G 
point mutation was 1.1 times higher (CI 1.1-1.1) and there was strong evidence for this (p<0.001) 
(Table 3.7). Figure 3.9 shows the increasing rates of dhps 437G prevalence over time in all 
regions. 
 
The likelihood of dhps 437G occurring in the Southwest (OR 2.5, CI 2.2-2.9) and Central (OR 1.3, 
CI 1.2-1.4) regions was greater than the likelihood of it occurring in the Southeast region and the 
evidence for this was strong (p<0.001) (Table 3.7). The likelihood of dhps 437G occurring in the 
Northeast (OR 0.9, CI 0.8-1.0), West (OR 0.6, CI 0.6-0.7) and Island (OR 0.5, CI 0.5-0.6) regions 
was lower than it was for the Southeast region and the low p values (< 0.001) suggested there 
was strong evidence for this only in the Western and Island regions (Table 3.7). The likelihood 
ratio test comparing models with and without the effect of time provided strong evidence to 
suggest that the regional prevalence of dhps 437G was affected by time (p< 0.001). 
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Figure 3.8 Surveys of dhps 437G prevalence (with 95% confidence intervals) conducted during 
1988-2008 and displayed according to their geographic region 
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              Table 3.7 Model for dhps 437G 
 
The dhps 437G prevalence data were analysed further, without the Island populations in section 
3.4.3. The Island populations were excluded in subsequent analysis of dhps 437G because this 
region had the least amount of surveys over time ie nine surveys since 2000. 
Model to estimate effect of time and region on prevalence 
of dhps 437G 
Model to estimate effect 
of region on prevalence 
of  dhps 437G 
Covariate Proportion (%) 
of  samples 
positive [95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
50.7[50.1-51.3] 1.1[1.1-1.1] <0.001  
Region Southeast 51.0[50.3-51.7] 1  1  
Northeast 42.1[39.6-44.6] 0.9[0.8-1.0] 0.032 0.7[0.6-0.8] <0.001 
West 44.7[43.3-46.2] 0.6[0.6-0.7] <0.001 0.8[0.7-0.8] <0.001 
Southwest 73.4[70.8-75.8] 2.5[2.2-2.9] <0.001 2.6[2.3-3.0] <0.001 
Central 56.2[54.2-58.3] 1.3[1.2-1.4] <0.001 1.2[1.1-1.3] <0.001 
Island 46.3[43.5-49.1] 0.5[0.5-0.6] <0.001 0.8[0.7-0.9] 0.001 
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Figure 3.9 Predicted probabilities of dhps 437G over time 
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Prevalence of dhps 540E 
 
As indicated in chapter 2 and Table 3.4 the best data coverage of all point mutations was for dhps 
K540E. The dhps 540E dataset was updated in 2011 with one additional study and 67.2% of the 
samples tested positive for 540E from 30291 samples tested since 1998 to 2008 (Table 3.3). The 
dhps 540E mutation was found in 27 countries and was absent in 10 countries (Figure 3.10). 
Generally high prevalence was observed in East Africa and relatively low prevalence in Central 
and West Africa. For instance in Ibadan, Nigeria the prevalence was 23.8% (n=109)(Happi et al., 
2005). In Angola the prevalence ranged from 1.9% (n=54) to 38.9% (n=18) in 2007 (Fortes et al., 
2011). Within the western parts of the DRC the prevalence ranged from 0.8% in 2003-2004 
(n=112) in Basankusa (Cohuet et al., 2006) to 9.5% (n=105) in 2008 in Kinshasa (Mobula et al., 
2009) whilst in the eastern parts of the country Alker et al., (2008) found 67% in Rutshuru, near 
the Rwandan border in 2002. In Ghana the prevalence was 0.79% to 2.6% between 2001 and 
2005 (Mockenhaupt et al., 2005; Marks et al., 2005; Pearce et al., 2009). In Mali, the prevalence 
was 1.0% in two surveys conducted among 902 and 578 people in Kolokani during 2007 (Dicko et 
al., 2010).  
 
Regional prevalence of dhps 540E point mutation over time 
 
The dhps 540E point mutation was highly prevalent in the Southeast and Northeast regions where 
it was ≥50% at 74 sites (Figure 3.10). Overall the Southeast region had the highest regional 
prevalence of 51% (n=18602) (Table 3.4a).  It reached 100% at three sites in the Southeast 
region and at one site in the Northeast region (Gebru-Woldearegai et al., 2005; Nkhoma et al., 
2007; Lynch et al., 2008; Naidoo and Roper, 2011). The prevalence was consistently <50% in the 
West, Southwest, Central and Island regions over time (Figure 3.11).  
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Figure 3.10 Prevalence of dhps 540E 
 
Prevalence in the Islands ranged from 0.4% in 2006 at six sites in the Comoros 
(Andriantsoanirina et al., 2009) to 19.4% in 2004 in Angolares, Sao Tome/Principe (Salgueiro et 
al., 2010). 
 
 110
 
Figure 3.11 Surveys of dhps 540E prevalence (with 95% confidence intervals) conducted during 
1988-2008 and displayed according to their geographic region 
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The logistic regression model predicted increasing trends in dhps 540E prevalence over time 
(Table 3.8, Figure 3.12). The likelihood of the dhps 540E point mutation occurring in all five 
regions was lower than it was for the Southeast region, with low odds ratios (<0.934) (Table 3.8).  
There was strong evidence for this (p<0.001) in all but the Northeast region where p = 0.234 
(Table 3.8).  The likelihood ratio test provided strong evidence to suggest that the regional 
prevalence of dhps 540E was influenced by time (p< 0.001).  Further analyses of the dhps 540E 
point mutation are presented in section 3.4.4 where the Island regions were excluded. The Island 
populations were excluded in that analysis as it had the least amount of surveys over time ie 17 
surveys since 2000. 
 
     Table 3.8 Model for dhps 540E 
 
 
Model to estimate effect of time and region on prevalence 
of dhps 540E 
Model to estimate effect of 
region on prevalence of  
dhps 540E 
Covariate Proportion 
(%) of  
samples 
positive 
[95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
34.2[33.6-
34.7] 
1.3 [1.2-1.30 <0.001  
Region Southeast 50.6[49.9-
51.3] 
1  1  
Northeast 39.6[37.2-
42.1] 
0.934          
[0.834-1.045] 
0.234 0.641                 
[0.577-0.713] 
<0.001 
West 1.4[1.1-1.8] 0.008         
[0.006-0.011] 
<0.001 0.014        
[0.011-0.018] 
<0.001 
Southwest 3.9[3.1-4.9] 0.022     
[0.170-0.028] 
<0.001 0.040        
[0.031-0.0510] 
<0.001 
Central 0.4[0.2-0.8] 0.004         
[0.002-0.007] 
<0.001 0.004        
[0.002-0.008] 
<0.001 
Island 2.3[1.6-3.3] 0.011         
[0.007-0.015] 
<0.001 0.023        
[0.016-0.034] 
<0.001 
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Figure 3.12 Predicted probabilities of dhps 540E over time 
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Prevalence of dhps 581G 
 
The 581G mutation occurred in 13 countries and was absent in 15 countries between 1988 
and 2008 (Figure 3.13; Table 3.3). In Sotuba and Bancoumana,Mali Wang and others 
(1997) found 100% and 87.5% dhps 581G although sample sizes were small (<10). In 
Hale and Korogwe, Tanzania the prevalence was 54%-55.5% as observed by Gesase et 
al., (2009) and Alifrangis et al., (2009). The prevalence of dhps 581G  at seven other sites 
was low i.e. <38% (Curtis et al., 2002; Mbugi et al., 2006; Schonfeld, et al., 2007; Wang et 
al., 1997). The cumulative prevalence of 581G was only 5.1% (14526/15398) between 
1993 and 2008.  
 
 
 
Figure 3.13 Prevalence of dhps 581G 
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Regional prevalence of dhps 581G point mutation over time 
 
The dhps 581G point mutation was absent only in the Southwest region and overall the 
prevalence was the highest in the Southeast region at 6.1% (n=10846) (Table 3.4b, 
Naidoo and Roper, 2011). Generally the prevalence was <50% in 24 of 27 sites where 
dhps 581G was found (Figure 3.14). This synopsis excludes a single study for which no 
study year was available, where the prevalence was 100% among a small sample size of 
10 people as mentioned previously (Wang et al., 1997).  
 
The logistic regression model predicted increasing trends in dhps 581G prevalence over 
time (OR 1.5, CI 1.5-1.6) (Table 3.9, Figure 3.15). The likelihood of the dhps 581G point 
mutation occurring in the Northeast region was similar to the Southeast region (OR 1.1) 
with weak evidence for this (p=0.760) (Table 3.9). For the other four regions the likelihood 
of the dhps 581G occurring there was lower than it was for the Southeast region and there 
was strong evidence for this (p<0.001) in the Central and Island regions (Table 3.9). The 
likelihood ratio test comparing models with and without temporal variation provided strong 
evidence to suggest that the regional prevalence of dhps 581G changed over time (p< 
0.001).   
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Figure 3.14 Surveys of dhps 581G prevalence (with 95% confidence intervals) 
conducted during 1988-2008 and displayed according to their geographic region 
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Table 3.9 Model for dhps 581G 
 
 
 
 
 
 
 
 
 
 
 
 
Model to estimate effect of time and region on prevalence 
of dhps 581G 
Model to estimate effect of 
region on prevalence of   
dhps 581G 
Covariate Proportion 
(%) of  
samples 
positive 
[95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
4.8[4.5-2.5] 1.542        
[1.481-1.605] 
<0.001  
Region Southeast 6.1 [5.6-6.5] 1  1  
Northeast 4.1[2.8-5.6] 1.058       
[0.738-1.516] 
0.760 0.658     
[0.463-0.936] 
0.020 
West 3.0[2.0-4.4] 0.786     
[0.521-1.184] 
0.250 0.484-     
[0.325-0.721] 
<0.001 
Central 1.1[0.6-1.9] 0.283     
[0.165-0.484] 
<0.001 0.180     
[0.106-0.307] 
<0.001 
Island 0.1[0.0-0.5] 0.004     
[0.001-0.032] 
<0.001 0.014      
[0.002-0.103] 
<0.001 
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Figure 3.15 Predicted probabilities of dhps 581G over time 
 
Coverage of dhps 613S was generally poorer than the other mutations with 91 surveys 
available (Table 3.3).  
 
Prevalence of dhps 613S  
 
The dhps 613S mutation occurred in 10 countries and was absent in 16 countries (Figure 
3.16; Table 3.3). Four surveys conducted in Yaounde, Cameroon in 1994, 1999 and 2001 
found ≤3% 613S (Basco and Ringwald, 1998; Basco et al., 2000; Tahar and Basco, 2007; 
McCollum et al., 2008). In the Ivory Coast, the prevalence was higher than that found in 
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Cameroon (Figure 3.16). Two studies done in Ivory Coast reported prevalence of 25.4% 
(n=118) during 2000-2001 (Djaman et al., 2007) and 22.6% (n=100) in 2006 (Djaman et 
al., 2010). In 1995, Mali the prevalence of 613S was reported at 11.8% (n=59) (Plowe et 
al., 1997) and 16.7% (n=48) (Diourte et al., 1999) in Bamako and Sotuba (5 km east of 
Bamako) respectively. In 2005, in Hodh el Gharbi district of Mauritania the prevalence was 
6.7% (n=59) in 1998 (Eberl et al., 2001). Generally, the prevalence of dhps 613S in Africa 
was low at 1.3% (134/10312) (Table 3.3). 
 
Figure 3.16 Prevalence of dhps 613S 
 
Regional prevalence of dhps 613S point mutation over time 
 
The dhps 613S point mutation was absent only in the Southwest region (Table 3.4b) and 
only 1.4% (n=73) samples were positive in the Islands when surveyed in 2000 (Cravo et 
al., 2004). A similar proportion of 1.3% (n=10142) samples tested positive overall whilst 
the Western region had the highest regional prevalence of 12% (n=735) (Table 3.4b). The 
prevalence of dhps 613S was <33% from 1993 to 2006 (Figure 3.17).  
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Figure 3.17 Surveys of dhps 613S prevalence (with 95% confidence intervals) 
conducted during 1988-2008 and displayed according to their geographic region 
 
Generally, there was strong evidence for a lower likelihood of dhps 613S over time 
(OR 0.9, CI 0.8-0.9, p<0.001)(Table 3.10, Figure 3.18). The likelihood of the dhps 
613S point mutation occurring in the Northeast (OR 0.4, CI 0.0-2.6) and Island 
(OR 0.6, CI 0.1-4.7) regions was lower than it was for the Southeast region with 
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weak evidence for this as indicated by high p values (Table 3.10). Among the 
Central and Island regions, the likelihood of dhps 613S occurring was higher than 
it was for the Southeast region with strong evidence for this as p<0.001 (Table 
3.10). The likelihood ratio test comparing models with and without temporal 
variation provided strong evidence to suggest that the regional prevalence of dhps 
613S varied over time (p< 0.001).   
      
Table 3.10 Model for dhps 613S  
 
 
 
 
 
 
 
 
 
 
 
 
Model to estimate effect of time and region on prevalence 
of dhps 613S 
Model to estimate effect 
of region on prevalence 
of  dhps 613S 
Covariate Proportion (%) 
of  samples 
positive [95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
1.3 [1.1-1.6] 0.9[0.8-0.9] <0.001  
Region Southeast 0.3[0.2-0.5] 1  1  
Northeast 0.1[0.0-0.7] 0.4[0.0-2.6] 0.314 0.4[0.0-2.9] 0.366 
West 12.0[9.7-14.5] 33.4      
[20.8-53.8] 
<0.001 40.6      
[25.5-64.7] 
<0.001 
Central 2.5[1.5-3.8] 5.9[3.2-10.8] <0.001 7.7[4.2-14.0] <0.001 
Island 0.1[0.0-0.7] 0.6[0.1-4.7] 0.648 0.4[0.1-2.9] 0.350 
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Figure 3.18 Predicted probabilities of dhps 613S over time 
 
Prevalence of dhps 613T 
 
Three countries had the dhps 613T point mutation and it was absent in 21 countries 
(Figure 3.19; Table 3.3). The mutation was reported in Bamako, Mali (11.8%, n=59)(Plowe 
et al., 1997), Blantyre, Malawi (1.1%, n=89) (Alker et al., 2005) and at 12 sites in 
Madagascar with pooled data (≤0.5%) (Andriantsoanirina et al., 2009). The cumulative 
prevalence of dhps 613T in Africa was the lowest of all mutations at 0.1% (11/10152) 
between 1988 and 2008 (Table 3.3). 
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Figure 3.19 Prevalence of dhps 613T 
 
Regional prevalence of dhps 613T point mutation over time 
 
The dhps 613T point mutation was observed in the Southeast, West and Island regions 
and 0.11% (n=9982) samples tested positive overall (Table 3.4b). The Western region had 
the highest regional prevalence of 1.1% (n=609) (Figure 3.20).  
 
There was strong evidence for a decreasing temporal trend in dhps 613T prevalence (OR 
0.7, CI 0.6-0.9,p=0.002) (Table 3.11, Figure 3.21). The likelihood of dhps 613T occurring 
in the West and Island regions were much higher than that of the Southeast region (Table 
3.11). However the relatively high odds ratios and wide confidence intervals must be 
interpreted with caution given the low prevalence of dhps 613T in all three regions and 
relatively limited number of surveys available. The results of further multivariate analyses 
for dhps 437G and 540E are presented next. 
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Figure 3.20 Surveys of dhps 613T prevalence (with 95% confidence intervals) 
conducted during 1988-2008 and displayed according to their geographic region        
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Table 3.11 Model for dhps 613T 
 
     
 
 
 
 
 
 
 
 
Model to estimate effect of time and region on 
prevalence of dhps 613T 
Model to estimate effect of 
region on prevalence of  
dhps 613T 
Covariate Proportion 
(%) of  
samples 
positive 
[95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio [95% 
confidence 
interval] 
P value 
Time (per study 
year)  
0.1[0.1-0.2] 0.7[0.6-0.9] 0.002  
Region Southeast 0.01[0-0.1] 1  1  
West 1.1[0.5-2.4] 41.4          
[5.0-341.3] 
0.001 80.1[9.8-652.4] <0.001 
Island 0.3[0.1-0.8] 103.1         
[7.6-1402.6] 
<0.001 19.4[2.0-186.3] 0.010 
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Figure 3.21 Predicted probabilities of dhps 613T over time 
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3.4.3 Further analysis of dhps 437G  
 
The logistic regression estimated the joint effects of time and region and assumed there 
was no interaction between the effect of study year and region on the mutation prevalence. 
The results of the regression model for the effect of time (study year, 1988-2008) and 
region on dhps 437G prevalence are tabulated in Table 3.12. Overall the prevalence of 
dhps 437G was 50.9%, (n=28605) (Tables 3.4a and 3.12).  
Table 3.12 Further analysis of dhps 437G 
 
The effect of time 
The model predicted that for every year, the likelihood of a person having a dhps 437G 
mutant  was 1.2 times higher (CI 1.0-1.3, p=0.030, Table 3.5). This suggests that there is a 
steady increase in the point mutation prevalence with time.  
 
Regions as risk factors 
The Wald test provided evidence to suggest that there were regional differences in the 
prevalence of dhps 437G overall (p=0.0034).  For the Central and Southwest regions the 
likelihood of the 437G mutant occurring there was greater than it was for the Southeast 
region (OR 1.3, CI 0.5-3.3 and OR 2.5, CI 1.0-6.1 respectively; Figure 3.22). Conversely, 
the likelihood of the dhps 437G mutation occurring in the Northeast (OR 0.9, CI 0.3-3.0) 
and Western region (OR 0.6, 0.1-2.4) was lower than it was for the Southeast region 
Covariate Proportion (%) of 
samples positive 
[95% confidence 
interval] 
Odds ratio [95 % 
confidence 
interval] 
P value 
Time (per study year) 1988-2008) 50.9 [50.3-51.5] 1.2 [1.0-1.3] 0.030 
Region Southeast               51.0 [50.3-51.7] 1  
Northeast  42.1 [39.6-44.6] 0.9 [0.3-3.0] 0.869 
West  44.7 [43.3-46.2] 0.6 [0.1-2.4] 0.473 
Southwest  73.4 [70.8-75.8] 2.5 [1.0-6.1] 0.047 
Central  56.2 [54.2-58.3] 1.3 [0.5-3.3] 0.616 
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(Figure 3.22). The relatively high p values indicated that the strength of the evidence for 
this was weak (Table 3.12).  
 
Figure 3.22 Predicted probabilities of regional dhps 437G prevalence over time 
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Interaction between region and time 
 
Given the observed increasing trend of dhps 437G prevalence over time, an interaction 
term between time (study year) and region was introduced into a logistic model to assess 
whether or not the relationship between the 437G prevalence and time differed among the 
five regions.  The stratum–specific odds ratios for each region are presented in Table 3.13 
quantifying the extent to which the odds ratios for time (study year) and each regional 
group, differs from those in the reference Southeast region. 
 
The odds ratios differed between regional strata, providing evidence to suggest that there 
was an interaction between time (study year) and region and the likelihood of dhps 437G 
prevalence i.e. higher temporal trend in prevalence differed depending on the regional 
categorisation and there was strong evidence for this (p <0.001), based on chi2 and 4 
degrees of freedom (Table 3.13). The AIC for the model without interaction was 1.337 
whilst the model with interaction had an AIC of 1.287 providing support for the model with 
interaction between region and time. 
 
The main difference between the two models was in the Western region where the 
temporal trend was lower, although there was weak evidence for this (OR 0.9, CI 0.8-1.0, 
p=0.097) (Figure 2.23). There was strong evidence for increasing prevalence of dhps 
437G in the Northeast and Southwest regions (p<0.001) (Table 3.13). 
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Table 3.13 Model for dhps 437G with interaction between time and region 
 
 
 
 
Region Difference in slope (per 
year) for each region 
For each year compared to 
Southeast region. Study year 
X region  
Odds ratio [95 % 
confidence interval
P value Odds ratio [95 % confidence 
interval] 
Southeast        1.2 [1.0-1.4] 0.019 1 
Northeast  2.4 [1.8-3.2] <0.001 2.0 [1.4-2.8] 
West  0.9 [0.8-1.0] 0.097 0.7 [0.6-0.9] 
Southwest  1.2 [1.1-1.3] <0.001 1.0 [0.8-1.2] 
Central  1.0 [0.9-1.2] 0.471 0.9 [0.7-1.0] 
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Figure 3.23 Predicted probabilities of dhps 437G prevalence with interaction effects 
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3.4.4 Further analysis of dhps 540E   
 
The effect of time  
The model predicted that for every year, the likelihood of a person having a dhps 540E 
mutant was 1.3 times higher (CI 1.1-1.5, p=0.004) (Table 3.14). This provided evidence to 
suggest that there was an increase in the point mutation prevalence with time, as was 
observed with the dhps 437G mutant. The overall prevalence of dhps 540E was 34.2% 
(n=29824) (Tables 3.4a and 3.14). 
 
Regions as risk factors 
The likelihood of the dhps 540E in the Central, Southwest and Western regions was lower 
than it was for the Southeast region, and this likelihood difference was large as the ORs 
were low (Figure 3.24, Table 3.14). This evidence was strong for the Central, Southwest 
and Western regions (p<0.001, Table 3.14). The Wald test provided evidence to suggest 
that there were regional differences in the prevalence of dhps 540E overall (p<0.001). 
Hence, the interaction between time and region was analysed next.  
Table 3.14 Further analysis of dhps 540E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Covariate 
Proportion of 
samples 
positive (95% 
confidence 
interval) 
Multivariable analysis for 
dhps 540E prevalence 
Odds ratio 
[95 % 
confidence 
interval] 
P value 
Time (per study year) (1988-2008)  34.2[33.6-34.7] 1.258           
[1.1-1.473] 
0.004 
Region Southeast               50.6[49.9-51.3] 1  
Northeast  39.6[37.2-42.1] 0.940       
[0.292-3.024] 
0.917 
West  1.4[1.1-1.8] 0.008      
[0.002-0.044] 
<0.001 
Southwest  3.9[3.1-4.9] 0.0216      
[0.006-0.079] 
<0.001 
Central  0.43[[0.2-0.8] 0.004       
[0.001-0.020] 
<0.001 
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Figure 3.24 Predicted probabilities of regional dhps 540E prevalence over time 
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There was strong evidence of a temporal trend which differed among the regions (p 
<0.001, based on chi2 and 4 degrees of freedom). The AIC for the model without 
interaction was 0.962 whilst the model with interaction had an AIC of 0.942 providing 
support for the model with interaction.  
Interaction between region and time 
 
The likelihood of the dhps 540E occurring under conditions of an interaction between time 
and region, compared with the Southeast regions was higher, in all but the Western 
region. There was strong evidence for an increased likelihood of 540E in the Northeast 
and Southwest regions (p< 0.001, Table 3.15, Figure 3.25). 
 
Table 3.15 Model for dhps 540E with interaction between time and region 
 
 
                
 
Covariate 
Difference in slope (per 
year) for each region 
Multivariable analysis 
with interaction for 
study year x region 
Odds ratio [95 % 
confidence 
interval] 
P value Odds ratio [95 % 
confidence interval] 
Region Southeast               1.2 [1.0-1.4] 0.014 1 
Northeast  2.7 [1.8-3.9] <0.001 2.2 [1.5-3.3] 
West  1.1[0.9-1.2] 0.374 0.9 [0.7-1.0] 
Southwest  1.7[1.3-2.3] 0.001 1.4 [1.0-2.0] 
Central  2.9 [1.1-7.6] 0.031 2.4 [0.9-6.4] 
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Figure 3.25 Predicted probabilities of dhps 540E prevalence with interaction effects 
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3.5 Discussion 
 
This chapter describes regional temporal and spatial variation in dhfr and dhps point 
mutation prevalence. It shows that the dhfr 164L and dhps 613S/T are rare on the 
continent, whereas the dhps 437G and 540E mutants have systematically increased in 
prevalence through time across sub-Saharan Africa. Using the observed distributions of 
these point mutations they can be characterised into three broad categories which reflect 
the degree of SP resistance conferred: (1) scarce or not fully resistant (dhps 436A, dhps 
613S), (2) emerging foci of resistance (dhfr 164L, dhps 581G) and (3) widespread, major 
resistance (dhps 540E, dhps 437G). The point mutations that fall into each category will be 
discussed in turn and thereafter some limitations of this study and recommendations for 
future work will be presented. 
  
The first group describes those point mutations that are neither abundant nor fully 
resistant. The dhps 436A point mutation was reported across sub-Saharan Africa with the 
highest prevalence reported among Western African countries. Closer inspection of the 
dhps 436A distribution as well as the results of the logistic model, show that it has not 
increased in prevalence, but rather it has decreased over time and is possibly being 
displaced by the 436S sensitive forms or the other mutant alleles which dominate in these 
regions. This lends support to the suggestion that it confers no resistance to SP and that it 
is an ancestral variant which may have emerged or been lost many times over (Pearce et 
al., 2009). Pearce et al., (2009) found that the 436S/437A/540K allelic haplotype was no 
more resistant than the 436A/437A/540K allelic haplotype. The 436A occurs predominately 
in West African countries and is less prevalent in the Eastern region. The 613S/T point 
mutations also belong to this group, due them to being absent in the majority of sub-
Saharan African countries with sporadic foci in the Southeast and Western regions.   
 
The second group describes point mutations with distinctly emerging foci of resistance 
namely the dhfr 164L and dhps 581G point mutations. As described in chapter 2, there 
was reasonably good coverage of studies that looked at the dhfr 164L point mutation and it 
is apparent from its low prevalence that it is different from the other dhfr point mutations. 
Generally the 164L has a restricted distribution in sub-Saharan Africa, but it has emerged 
in seven countries primarily in East and Central Africa. Although it is still relatively rare 
across Africa, it is associated with high levels of pyrimethamine resistance when occurring 
with the dhfr triple mutant, which is cause for concern for the IPT strategies in these 
regions. Indeed the logistic model presented here predicted an increase in dhfr 164L over 
time. Hamel et al., (2008) did not find evidence for an association between dhfr 164L and 
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treatment failure in their study in Kisumu, Kenya during 2002-2003 unlike their Asian 
counterparts (Hyde et al., 2008). It is possible that the effect of 164L in the quadruple 
mutant is complex and the ecological context under which this haplotype combination 
occurs differs from the situation in Asia (Hyde et al., 2008, McCollum et al., 2008).   
 
The dhps 581G point mutations are newly emerging in some foci but are absent in most of 
sub-Saharan Africa. The dhps 581G when found on its own is not as powerful an indicator 
of resistance as when it is found in conjunction with the dhps double mutant (437G+540E) 
and dhfr triple mutant (51I+59R+108N). The dhps 581G is increasing in East Africa and 
was found at low prevalence (<40%) in West Africa within Mali, Niger and Ghana. In East 
Africa there is an association between dhps 581G and SP resistance but it is unclear 
whether or not such an association occurs in West Africa.  
 
The third group describes the dhps 540E and dhps 437G point mutations both of which are 
widespread and confer major resistance when found together. These point mutations were 
analysed further in this chapter because the distribution of dhps 540E is more regionally 
distinct than that of dhps 437G and dhps 437G is generally found together with dhps 540E.  
 
Generally dhps 437G and 540E point mutations were found predominantly in the 
Southeast regions and were less prevalent in the Western regions. This was supported by 
the finding that the predicted probabilities of dhps 437G and 540E in the Western and 
Southwestern regions were generally less than that found in the Southeast region. Thus 
they appear at a slower rate in the Western region compared with the Eastern region. 
Furthermore, the analyses showed that dhps 437G and 540E prevalence are generally 
increasing over time within sub-Saharan Africa, but there are apparent differences in the 
prevalence rates between the Eastern and Western countries.  
 
Countries in Central Africa represent a watershed for the distribution of antimalarial 
resistance (Taylor et al., 2013). The DRC was allocated to both Southeast and Southwest 
Africa in this study. This is supported by chloroquine and SP efficacy studies in the DRC 
showing that the highest proportion of treatment failures occurred in the Eastern areas 
(Kazadi et al., 2003) where SP was used since 1995 (Alker et al., 2008). The dhps 
437G/540E double mutant occurred at higher proportions in sites in Eastern DRC 
(Kisangani, Kilwa) compared with Western DRC (Basankusa, Boende) (Cohuet et al., 
2006). Furthermore, in Rutshuru, which is in Eastern DRC near the Rwandan border, point 
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mutations at dhps 437G and 540E were strongly associated with SP treatment failure 
(Alker et al., 2008).  
 
Generally, relatively higher prevalence of dhps 437G was observed since 2000. Although 
there was high prevalence of dhps 437G (>80%) within the West African region, the model 
estimates of the predicted probabilities of dhps 437G prevalence with interaction of region 
and time showed an anomalous declining trend in the Western region. This finding could 
be attributed to several factors including the following: (1) outliers of relatively low dhps 
437G prevalence ie 20.6% (n=911) and 18.8% (n=648) in Kolokani, Mali (Dicko et al., 
2010) and 37.5% (n=40) in Ndoffane, Senegal (Cisse et al., 2009) which contributed to the 
decreasing trend in prevalence since 2006, (2) the effects of sampling variation among the 
studies, (3) the region encompasses a diverse spectrum of communities as it represents 
13 countries, covering an area of approximately six million square kilometres and (4) less 
drug pressure in these West African countries due to low SP use (Frosch, Venkatesan and 
Laufer, 2011) compared to the other regions.  
 
The likelihood of dhps 437G were the same in the Southeast and Southwest regions (p< 
0.001), suggesting that similar temporal trends occur in both these regions. This finding 
was consistent among the models with and without the interaction effect of time and 
regional location. For dhps 437G the Southern African countries were similar to each other 
and different from the Western, Central and Northeast regions. 
 
As stated above dhps 437G is generally found where dhps 540E occurs and this pattern 
was observed distinctly in the Southeast and Northeast regions but not in the West, 
Southwest, Central and Island regions. There are sufficient longitudinal studies measuring 
the prevalence of these point mutations in the Southeast and Northeast regions, 
suggesting that these analyses do reflect changes in prevalence over time. However, 
further systematic sampling of these point mutations is needed among West African 
countries, which would allow close inspection of the changes in the prevalence of these 
point mutations over time. 
 
Generally the logistic models provided evidence of increasing dhfr 164L, dhps 437G, dhps 
540E dhps 581G prevalence over time and decreasing dhps 436A, dhps 613S/T 
prevalence over time at a population level and that relationship is conditional depending on 
the region. The models showing the interaction between time and region provided a better 
138 
 
fit compared to the models without interaction. This regional effect could be due to 
variation in drug exposure among the regions. Frosch et al., (2011) reported that SP use 
was more prolific in East African countries compared to West African countries and this 
frequency of SP use was related to the seasonality of malaria transmission being different 
among these regions. 
 
Notably the prevalence of each point mutation was different among the Islands compared 
with the other regions. For example, in the Island region the 164L mutant was found in a 
unique combination of point mutations that has not been reported in mainland Africa to 
date (Naidoo and Roper, 2011).  Island populations were excluded from the statistical 
model development because dhps point mutations evolved independently from mainland 
Africa (Naidoo and Roper, 2011).  
 
Limitations 
 
The differences in prevalence of the point mutations reflect the duration and magnitude of 
SP use and to some extent they predict population levels of in vivo SP resistance. The 
correlation between molecular markers and in vivo (phenotypic) resistance is discussed 
further and investigated in chapter 5. Prevalence measures of individual point mutations 
are a crude estimate of resistance levels and alternative means of quantifying resistance 
mutations in a population are employed in chapters 4 and 5 to characterise the 
frequencies of both individual and combinations of point mutations. Frequencies have the 
effect of smoothing mutation data in highly endemic and high transmission areas. Allelic 
haplotypes describe combinations of point mutations and reflect the joint effect of 
individual mutations which occur together. Using frequency and haplotype data may offer 
further insight into the spatial and temporal changes of resistance markers.   
 
Recommendation 
 
There is a need for further epidemiological surveillance of dhfr and dhps point mutations 
across Africa, specifically dhfr 164L, dhps 540E and dhps 581G. These mutations are of 
the greatest significance for policy in the context of continued use of SP for IPTp and the 
potential implementation of SP-IPTi in Africa. The prevalence of resistance markers 
amongst pregnant women participating in IPTp programmes can differ from background 
levels, hence there is a need for regular regional surveillance of the prevalence of SP point 
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mutations in high risk groups such as pregnant women, infants and children where SP will 
be employed.  
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Chapter 4 Spatial and Temporal Changes of Sulphadoxine Pyrimethamine allelic 
haplotypes in sub-Saharan Africa 
 
4.1 Introduction 
 
People who are bitten by many P. falciparum infected mosquitoes often harbour super-
infections with multiple genotypes co-infecting individuals. Blood stage parasites are 
haploid and separate genotypes within the same infection are referred to as clones. These 
haploid parasite clones are a precursor for the diploid zygotic stage of the parasite life 
cycle which occurs in the mosquito when gametocytes fuse and genetic material exchange 
through meiosis in the oocyst. Within any given P. falciparum infection sampled at the 
blood stage (usually by finger prick, sometimes by venipuncture) multiple haploid 
clones/genotypes can be detected. There are records of as many as seven distinct clones 
or genotypes in one infection (Hastings, Paget-McNicol and Saul, 2004) and this number is 
referred to as the multiplicity of infection (MOI). 
 
Within a mixed infection there can be sensitive forms alone, mutant forms alone or 
mixtures of both mutant and sensitive forms. The prevalence data for individual point 
mutations that were used in chapter 3 recorded the proportion of infections in which a 
specific mutation was detected regardless of the underlying MOI of those infections. 
Hastings, Nsanzabana and Smith (2010) pointed out that genotype prevalence - defined 
as the proportion of blood samples (people) that carry a particular marker - does not 
distinguish whether or not one or more clones in the sample carry that marker. Prevalence 
of individual point mutations is the most commonly reported measure in genotyping 
studies, but it can be an imperfect way of assessing the level of resistance in a parasite 
population because it does not take any account of MOI and crucially it is the combination 
of point mutations that determines the level of drug sensitivity of any given parasite 
genotype.  
 
Only a subset of the studies identified in the review conducted in this study, actually 
recorded the combination of point mutations at all codon positions in the dhfr or dhps 
genes in individual infections. These studies can be used to identify which specific 
combinations of mutations are commonly circulating among the parasite populations in 
Africa. Point mutations have different properties when found in such combinations. These 
combinations of point mutations are referred to hereon as allelic haplotypes in this thesis. 
An allelic haplotype describes a combination of point mutations which occur in the same 
gene. Allelic haplotypes can only be verified in non-mixed infections and cannot be 
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deduced from mixed infections due to the unknown ratio of mutant to sensitive forms in 
neighbouring codon positions. Analyses of haplotypes assist in assessing the intensity of 
SP resistance. 
Researchers would generally exclude mixed infections from their analysis in order to 
provide definitive summaries of the combinations of point mutations that are in circulation. 
To compare levels of SP resistance in different populations, the number of non-mixed 
infections with each combination of point mutations is counted and these are used as a 
measure of the relative frequency of each allelic haplotype in a given population. Hastings 
et al., (2010) defined frequency in this context as the proportion of the parasite population 
which carry the marker. The frequency is measured by counting the numbers of individual 
parasite clones that have the marker and in so doing, the different resistance rates that 
arise from populations residing in different transmission intensities are standardised. Thus, 
the frequency measure is important for comparing SP resistance levels among 
populations. 
 
In any study site, the number of mixed infections depends on the intensity of malaria 
transmission in that area, so the exclusion of mixed infections from calculations of allelic 
haplotype frequencies is most extreme in surveys conducted in highly endemic areas. 
Thus this is particularly an African issue where malaria endemicity tends to be high in foci 
and hotspots. In this chapter haplotype frequency data are analysed in order to better 
understand the spatio-temporal changes observed among the single point mutation 
prevalence data which were examined in chapter 3. 
 
As mentioned in chapter 2, the most common resistance haplotype of dhfr in Africa is the 
51I/59R/108N triple mutant but there are also mildly resistant haplotypes which have fewer 
mutations, as well as the sensitive allelic haplotype which are shown in Table 4.1. The 
amino acids are abbreviated into three and single letter codes in Table 4.1. Combinations 
of point mutations are indicated by shading.  
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Table 4.1 Common dhfr haplotypes in Africa 
 
 
 
 
 
 
 
 
 
 
The two most common dhps resistant haplotypes are the single mutant 437G and the 
double mutant 437G/540E which are shaded in Table 4.2. 
Table 4.2 Common dhps haplotypes in Africa 
 
 
 
 
 
 
 
The combinations of dhfr and dhps allelic haplotypes differ in the resistance levels they 
confer.Table 4.3 shows the increasing trend in SP resistance as the number of mutations 
accumulate with the highest resistance levels associated with the quintuple mutant (dhfr 
triple mutant plus dhps double mutant). For instance, based on in vitro studies, the dhps 
GK allelic haplotype is less resistant than the dhps GE double mutant due to the presence 
of the dhps 540K sensitive form in this combination. Although the dhfr IRN triple mutant 
Codon 50 51 59 108 140 164 
 
Sensitive 
 
Cys (C) 
 
Asn (N) 
 
Cys (C) 
 
Ser (S) 
 
Val (V) 
 
Ile (I) 
Single 
mutant 
 
Cys (C) 
 
Asn (N) 
 
Cys (C) 
 
Asn (N) 
 
Val (V) 
 
Ile (I) 
Double 
mutant 
 
Cys (C) 
 
Ile(I) 
 
Cys (C) 
 
Asn (N) 
 
Val (V) 
 
Ile (I) 
Double 
mutant 
 
Cys (C) 
 
Asn (N) 
 
Arg (R) 
 
Asn (N) 
 
Val (V) 
 
Ile (I) 
Triple 
mutant 
 
Cys (C) 
 
Ile(I) 
 
Arg (R) 
 
Asn (N) 
 
Val (V) 
 
Ile (I) 
Codon 436  437  540   581  613  
Sensitive Ser  
(S or A)  
Ala (A)  Lys (K)  Ala (A)  Ala  (A)  
Single 
mutant 
Ser  
(S or A) 
Gly (G)  Lys (K) Ala (A) Ala  (A) 
Double 
mutant 
Ser  
(S or A) 
Gly (G)  Glu (E) Ala  (A) Ala  (A) 
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was a good general indicator of emerging SP resistance in areas where SP was newly 
introduced, it is its combination with the dhps double mutant (Table 4.2), known as the 
quintuple mutant mentioned above, that is predictive of in vivo treatment failure (Tables 4.2 
and 4.3) (Nzila et al., 2000a; Kublin et al., 2002; Bwijo et al., 2003) and this is associated 
with full SP resistance. 
  Table 4.3 Combinations of dhfr and dhps haplotypes and levels of SP resistance 
 
 
Chapter 3 showed that dhps 540E predominates in East Africa and is comparatively less 
common in West and Central Africa. The dhps 437G single mutant haplotype in 
combination with the dhfr IRN triple mutant is found throughout West and Central Africa 
but this quadruple genotype is not as fully resistant as the quintuple genotype that is found 
in East Africa (Table 4.3).  
 
In this chapter, haplotype data for the dhfr sensitive allelic haplotype (51N/59C/108S), dhfr 
triple mutant allelic haplotype (51I/59R/108N), dhps GE double mutant, dhps GK single 
mutant and dhps AK sensitive alleles are summarised and spatio-temporal trends in their 
distribution are analysed. 
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mutant
NCN 
Double 
mutant 
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Double 
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4.2 Aims and Objectives 
 
1. To gather data on the frequency of the dhfr sensitive allelic haplotype 
(51N/59C/108S), dhfr triple mutant allelic haplotype (51I/59R/108N)  and the three 
dhps haplotype alleles 437G/540E (GE), 437G/540K (GK) and 437A/540K (AK) 
within sub-Saharan Africa.  
2. To investigate the influence of temporal and regional factors on the frequencies of 
these haplotypes. 
 
4.3 Methods 
 
Data processing 
 
The data collection methods and systematic data abstraction methods were described in 
chapter 2. Data points containing the allelic haplotypes dhfr NCS, dhfr IRN as well as dhps 
GE, GK and AK were collated, then extracted from the database and imported into Stata. 
Each data point was assigned into five regions namely Southeast, Northeast, West, 
Southwest and Central. Countries which fall into each region are listed in Table 3.1 in 
chapter 3.    
 
Only studies which reported haplotypes could be included in these analyses. Samples with 
mixed infections (where haplotypes could not be determined) were excluded from the 
analyses. No further exclusions were applied based on age and whether or not patients 
were symptomatic for malaria. 
 
The data were first mapped to observe the spatial distribution of the allelic haplotypes. 
Thereafter multivariable regression analyses were performed to further assess the relative 
contributions of the risk factors (time and region) on the allelic haplotype frequencies. The 
methods are discussed next. 
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4.3.1 Data Analysis 
 
Spatial mapping of allelic haplotype frequency 
 
For each survey, the frequency was calculated as the number of samples with the allelic 
haplotype/total number of samples analysed, after excluding mixed infections as described 
in equation one. 
Equation 1:  
y = [number of samples with the allelic haplotype/total number of samples tested for which 
an allelic haplotype could be determined] X 100 
Where y = frequency of allelic haplotype 
Vector maps were created in Mapinfo to illustrate the spatial distribution of haplotypes. The 
maps included studies where the study year was not available. 
 
Multivariable regression analyses for allelic haplotypes 
 
The same approach was followed as in chapter 3. The data were converted into binary 
format (0/1) and expanded using the total number of people with haplotype determined, so 
that logistic regression analyses could be performed in Stata. A logistic model was 
constructed to assess whether or not there was any association between the outcome 
variable (frequency of allelic haplotype) and the risk factors study year (time) and region.  
 
The log odds of the outcome (allelic haplotype present = 1) was used for logistic 
regression analysis with robust standard errors allowing for with and without clustering by 
country to model the effect of time on each allelic haplotype frequency (equation four). 
Odds ratios, 95% confidence intervals and cumulative p values are reported for the model 
estimates for each allelic haplotype. Island populations were included in the preliminary 
analyses. After running the logistic regression, the likelihood ratio test was used to 
compare the models with and without allelic haplotype frequency changing over time. 
Thereafter further multivariate logistic analyses were performed on the dhps GE, GK and 
AK allelic haplotypes using an interaction term, which multiplied the effect of time (study 
year) and region as in equation five.  For these models the Southeast region was 
consistently used as the reference region because it had the best coverage of data points 
for each haplotype over the 20 year period (Tables 4.4 and 4.5). The Island populations 
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were excluded in these analyses because it had the least amount of data points and these 
were generally conducted after 2002.  
 
Equation 4: log(p/1-p) or xβ =  β1x1 + β2x2  
Equation 5: log(p/1-p) or xβ =  β1x1 + β2x2 + β3x3 
where  
p = probability of allelic haplotype being present 
1-p = probability of allelic haplotype being absent 
x1   = study year 
x2 = region 
x3 = region x study year 
 
 
Post estimation 
 
The Wald test was used to assess the strength of evidence for differences in frequencies 
of allelic haplotypes among the regions from the model with interactions. This test tests the 
null hypothesis that the frequency is the same in all regions, given the variation in 
sampling. The goodness of fit of each model was estimated using AIC (see post estimation 
in chapter 3). Estimating the linear combinations of the odd ratios sequentially for each 
region quantified how time (study year) affected the frequency among the regions. The 
Southeast region was used as the reference against which the other regions were 
compared (equation six) 
Equation 6: log(p/1-p) or xβ =  β1x1 + β2 nx2 + β3x3 
Where n = each region 
After running the model, graphs were constructed in Stata using the model estimates of 
the predicted probabilities of positivity (Y=1) in each region.   
 
4.3.2 Assumptions and missing data 
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Assumptions were made as described in chapter 3. For the plots of allelic haplotypes 
exclusion criteria were surveys that did not have study years and surveys that did not 
report haplotypes. 
The results for each allelic haplotype are presented sequentially in section 4.4. 
 
4.4 Results 
 
4.4.1 Frequency maps of mutations and allelic haplotypes 
 
A series of five maps are presented, illustrating the frequency of each allelic haplotype, as 
well as five sets of graphs showing the regional frequency with 95% confidence intervals. 
Tables 4.4 and 4.5 outlines the data represented in the five maps which shows that there 
were in excess of 195 surveys available for dhfr IRN and dhfr NCS in 34 countries and 152 
surveys for dhps GE/GK/AK in 37 countries. A breakdown of sample sizes by region is 
given in Tables 4.4 and 4.5. The results for dhfr NCS and IRN are presented first, followed 
by the results for dhps GE, GK and AK. The references used for each haplotype are 
provided in appendices nine through 11.
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Table 4.4 Summary of surveys available for dhfr NCS and IRN allelic haplotypes  
 
 
Regions Southeast Northeast West Southwest Central Islands All Regions 
Surveys of 
dhfr NCS 
97 11 35 13 28 11 195 
Samples 
tested for dhfr 
NCS  
8022 1022 3466 805 2661 2397 18373 
Samples 
positive for 
dhfr  NCS 
1204 179 1170 83 658 782 4076 
Unique sites 
with dhfr  
NCS 
52 10 20 12 20 8 122 
Countries with 
dhfr NCS 
11 3 11 4 2 3 34 
Study year 
range 
1987- 
2007 
1996- 
2004 
1990-
2006 
1995- 
2007 
1994-    
2004 
2002-
2008 
1987- 
2008 
Surveys of 
dhfr IRN 
106 8 31 12 29 11 197 
Samples 
tested for dhfr 
IRN 
9682 853 3404 745 2828 1757 19269 
Samples 
positive for 
dhfr IRN 
5739 146 1351 319 1774 573 9902 
Unique sites 
with dhps IRN 
54 8 20 11 21 8 120 
Countries with 
dhfr IRN 
11 3 11 4 2 3 34 
Study year 
range 
1988- 
2007 
1996- 
2004 
1993-
2006 
1995- 
2007 
1994- 
2004 
2002-
2008 
1988- 
2008 
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Table 4.5 Summary of surveys available for dhps GE double mutant, GK single mutant 
and AK fully sensitive allelic haplotypes  
 
Figure 4.1 shows that high frequencies of dhfr NCS are found in East and West Africa. 
However, closer inspection of the longitudinal studies conducted at specific sites within this 
data set shows a gradual decline in frequencies over time. For example in Kilifi, Kenya dhfr 
NCS was 100% (n=5) in 1987 and by 2006 it was 2.6% (n=26) (Certain et al., 2008). In 
Kilombero and Ulanga in Tanzania dhfr NCS frequencies were measured at 51.3% 
(n=376) in 2000, it was 47.5% in 2001 (n = 238) and 27.8% (n=489) in 2002 with similar 
declining trends observed in Rufigi (Malisa et al., 2010). In Dielmo, Senegal dhfr NCS was 
100% in 1990 (n=10) and by 1999 it was 57.1% (n=14) (Noranate et al., 2007). NCS was 
found to be absent in 43 sites and this will be discussed further in the next section.  
Regions Southeast Northeast West Southwest Central Islands All Regions 
Surveys of 
dhps 
GE/GK/AK 
80 11 24 16 13 8 152 
Unique sites  52 10 21 14 8 7 112 
Countries  10 3 14 5 2 3 37 
Study year 
range 
1993- 
2008 
1996- 
2004 
1995-
2006 
1995- 
2007 
1994-
2004 
2002-
2007 
1993- 
2008 
Samples 
tested   
12102 884 1980 1386 1554 1201 19107 
Samples 
positive for 
dhps GE 
4829 464 13 30 4 24 5364 
Samples 
positive for 
dhps GK 
198 30 1224 1037 845 504 3838 
Samples 
positive for 
dhps AK 
7075 390 743 319 705 673 9905 
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Figure 4.1 Frequency of dhfr NCS haplotype 
                       Namibia and Nigeria data obtained from C. Roper pers comm 
In the Southeast region, apart from the survey done in the late 1980s in Kilifi, Kenya all 
frequencies were 51% or less since 1988 (Figure 4.2). In Shabunda, South Kivu Province 
which is the mid-eastern part of the DRC, dhfr NCS was 7.6% (n=158) in 2004 (Swarthout 
et al., 2006) whilst in Rutshuru it was 50% in 2002 (n=2) (Wilson et al., 2005). In Matola, 
15km north of Maputo, dhfr NCS was 20% (n=89) in 2000 (Alifangis et al., 2003) and in 
Maputo itself it was 3% (n=72) in 2004 (Fernandes, Cravo and Do Rosario, 2007). 
 
In the Northeast region, all eleven surveys were done in Ethiopia, North and South Sudan 
between 1996 and 2004 (Table 4.4, Figure 4.2). In Lankien, Upper Nile District in South 
Sudan dhfr NCS was 81.8% (n=44) in 2001 (van Den Broek et al., (2003) and 60% (n=78) 
in 2002 in Akuem, Yargot Payam district Bahr El Gazal (Anderson et al., 2003). All seven 
sites in North Sudan was less than 20%  when surveyed either in 1996 or in 2003 (Al-Saai 
et al., 2009; A-Elbasit et al., 2007; Khalil et al., 2005; Khalil et al., 2003; Khalil et al., 2005, 
Hamour et al., 2005, Yusuf, Omar and Ngure, 2010). In Dilla, Southern Ethiopia (n=69) 
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(Schunk et al., 2006) and Jimma, Southwest Ethiopia (n=124) (Gebru-Woldearagai et al., 
2005) NCS was absent in 2004. 
 
In the Western region frequencies below 50% were reported since 1998 in 19 sites. There 
were a few exceptions where NCS was reported at frequencies above 50% recently 
(Figure 4.2). These were Yopounon and Adjame districts in the Ivory Coast where 73% 
(n=144) NCS was found in 2006 (Djaman et al., 2010) whilst Roper (pers. comm) found 
70% (n=20) NCS in Abuja, Nigeria in 2005. In the Southwestern region seven out of 13 
surveys had a NCS frequency below 50% between 1995 and 2006 (Kun et al., 1999; 
Mawili-Mboumba et al., 2001; Aubuoy et al., 2003; Ndounga et al., 2007; Menegon et al., 
2009; Mita et al., 2009, Roper pers. comm). This allelic haplotype was found to be absent 
from six sites (Figure 4.2), all from Angola and surveyed in 2007 (Gama et al., 2011; 
Fortes et al., 2011).  
 
In the Central region NCS was below 50% in 19 sites between 1994 and 2004 (Figure 4.2) 
(Basco et al., 1998; Basco et al., 2000, Basco et al., 2002; Menard et al., 2006; Tahar and 
Basco, 2006; McCollum et al., 2008; Mbacham et al., 2010). It was found to be above 50% 
only in Cameroon in seven sites surveyed between 2000 and 2003 (Tahar and Basco, 
2006; Mbacham et al., 2009) (Figures 4.2 and 4.3). Also dhfr NCS was found to be absent 
in Douala and Manjo, Cameroon in 1999 (Basco et al., 2002) and 2002 (Tahar and Basco, 
2006). Generally there was no overall change over time in the Central region (Figure 4.3) 
which was influenced by these large variations in frequency. 
 
There were 10 surveys from the Island region between 2002 and 2008 (Table 4.4, Figure 
4.2) with frequencies in Madagascar ranging from 1.0% (n=114) surveyed at various sites 
in 2006 (Menard et al., 2008) to 69% (n=292) surveyed at 12 sites also in 2006 
(Andriantsoanirina et al., 2009). In Sao Tome/Principe island dhfr NCS was 4.8% (n=42) in 
2002 (Tahar et al., 2007) but it was absent in Rua dos Trabalhadores in 2004 (n=6) 
(Salgueiro et al., 2010).  
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Figure 4.2 Surveys of dhfr NCS allelic haplotype frequency (with 95% confidence intervals) 
conducted during 1988-2008 and displayed according to their geographic region 
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Multivariable logistic regression analyses for dhfr NCS 
 
The logistic model predicted that for every year, the likelihood of a person having a dhfr 
NCS haplotype was 0.9 times lower providing evidence to suggest that there was a decline 
in the NCS haplotype frequencies over time (CI 0.9-0.9, p<0.001) (Table 4.6, Figure 4.3). 
The overall frequency of dhfr NCS was 22.2% (Table 4.6). The likelihood of dhfr NCS 
occurring in the Southwest was lower than it was for the Southeast region over time, with 
strong evidence for this (p=0.019) (Table 4.6). There was strong evidence for higher 
likelihoods of dhfr NCS over time in the other four regions relative to the Southeast region 
(p<0.001). The model with regions only as a predictor of dhfr NCS haplotype frequency 
produced similar likelihood estimates. The likelihood ratio test to compare the models with 
and without the effect of time provided strong evidence to suggest that the regional 
frequency of dhfr NCS was affected by time (p< 0.001).  
 
    Table 4.6 Model for dhfr NCS 
 
 
 
 
 
Model to estimate effect of time and region on frequency of 
dhfr  NCS 
Model to estimate 
effect of region on  
frequency of  dhfr  
NCS 
Covariate Proportion (%) 
of  samples 
positive [95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P value Odds 
ratio [95% 
confidenc
e interval] 
P value 
Time (per study year)  22.2[21.6-22.8] 0.9 [0.9-
0.9] 
<0.001  
Region Southeast 15.0[14.2-15.8] 1  1  
Northeast 17.5[15.2-20.0] 1.3[1.1-1.5] <0.001 1.2        
[1.0-1.4] 
0.036 
West 33.8[32.2-35.4] 2.6[2.4-2.9] <0.001 2.9          
[2.6-3.2] 
<0.001 
Southwest 10.3[8.3-12.6] 0.8[0.6-1.0] 0.019 0.7        
[0.5-0.8] 
<0.001 
Central 24.7[23.1-26.4] 1.9[1.7-2.1] <0.001 1.8        
[1.7-2.1] 
<0.001 
Island 32.6[30.7-34.5] 5.6[4.9-6.4] <0.001 2.7       
[2.5-3.0] 
<0.001 
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Figure 4.3 Estimated changes in dhfr NCS allelic haplotype frequency over time 
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The results for the dhfr IRN triple mutant will be discussed next. The dhfr IRN haplotype 
was found in 34 countries (Table 4.4, Figure 4.4). High frequencies, in excess of 80% were 
observed in 51 sites across sub-Saharan Africa from 1995 onwards (Figure 4.4).   
 
From 106 surveys in the Southeast region, 67 presented with IRN frequencies in excess of 
50% (Figure 4.5). Among the remaining 39 sites the frequencies ranged from 2.8% (n=72) 
in Rukungiri, Tanzania in 2005 (Lynch et al., 2008) to 46.7% in both Kariba, Zimbabwe 
(n=45) in 2003 (Mlambo et al., 2007) and in Rufigi, Tanzania (n=420) in 2001 (Malisa et 
al., 2010). There were fewer surveys (n=8) in the Northeast region compared with the 
Southeast region, and they spanned from 1996 to 2004 with the highest frequency of 87% 
(n=64) occurring in Dilla, Southern Ethiopia in 2004 (Schunk et al., 2006). The other seven 
sites were below 54% (Figure 4.5). 
 
In the Western region, dhfr IRN frequencies in excess of 50% occurred in 13 sites between 
2000 and 2006 (Figure 4.5). The highest IRN frequency was 85.1% (n=148) reported by 
Bonnet et al., (2007) in 2004 in a survey conducted in Laine, Liberia which borders with 
the Ivory Coast. Among the remaining 19 sites, IRN frequencies were between 12% 
(n=453) in 2002 in Ziniare and Bousse, situated north of Ouagadougou in Burkina Faso 
(Diallo et al., 2007) to 40% (n=15) in 2003 in Thies, Senegal (Ndiaye et al., 2005). 
 
In the Southwest region, all eight studies from Angola, Gabon and Namibia recorded IRN 
frequencies of less than 48% between 1995 and 2007 (Figure 4.5) (Kun et al., 1999; 
Mawili-Mboumba et al., 2001; Fortes et al., 2011; Menegon et al., 2009; Roper, pers 
comm). 
 
Similarly all nine surveys in the Central region reported less than 46% IRN from 1999 to 
2004 (Figure 4.5). In 1999 it was 43.1% (n=51) in Bertoua, Cameroon (Basco et al., 2002) 
whilst in Nkambe, situated in northwest Cameroon it was 46% (n=103) in 2003 (Mbacham 
et al., 2009). 
 
Finally, among the island populations a wide frequency range of 1.1% to 45% (n=269) was 
observed following surveys that were done at six sites in 2006 in Comoros/Mayotte 
(Andriantsoanirina et al., 2009). In Madagascar IRN frequencies ranged from 27.7% 
(n=292) in 2006 to 34.1 (n=361) in 2007 among 12 sites (Andriantsoanirina et al., 2009). 
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Figure 4.4 Frequency of dhfr IRN haplotype 
                                   Namibia and Nigeria data obtained from C. Roper pers comm 
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Figure 4.5 Surveys of dhfr IRN allelic haplotype frequency (with 95% confidence intervals) 
conducted during 1988-2008 and displayed according to their geographic region
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Multivariable logistic regression analyses for dhfr IRN 
 
The logistic model predicted an overall increase in dhfr IRN over time. For every year, the 
likelihood of a person having a dhfr IRN haplotype was 1.1 times higher and there was 
strong evidence for this (CI 1.1-1.1, p<0.001) (Table 4.7, Figure 4.6). The overall 
frequency of dhfr IRN was 51.4% (Table 4.7). Generally there was a lesser likelihood of 
dhfr IRN occurring in the Northeast, West, Southwest and Island regions compared to the 
Southeast region, with strong evidence for this reflected by p<0.001 in both models with 
and without the temporal effect (Table 4.7). The likelihood ratio test to compare the models 
with and without temporal variation provided strong evidence to suggest that the dhfr IRN 
haplotype frequency varied over time (p< 0.001). The dhfr IRN were analysed further in 
the next section. 
 
Table 4. 7 Model for dhfr IRN 
 
            
 
 
 
Model to estimate effect of time and region on frequency 
of dhfr IRN 
Model to estimate effect 
of region on  frequency  
of  dhfr IRN 
Covariate Proportion (%) 
of  samples 
positive [95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
51.4[50.7-52.1] 1.1[1.1-1.1] <0.001  
Region Southeast 59.3[58.3-60.3] 1  1  
Northeast 17.1[14.6-19.8] 0.1[0.1-0.2] <0.001 0.1[0.1-0.2] <0.001 
West 39.7[38.0-.41.4] 0.5[0.5-0.5] <0.001 0.5[0.4-0.5] <0.001 
Southwest 42.8[39.2-46.5] 0.4[0.4-0.5] <0.001 0.5[0.4-0.6] <0.001 
Central 62.7[60.9-64.5] 1.2[1.1-1.3] <0.001 1.2[1.1-1.3] <0.001 
Island 32.6[30.4-34.9] 0.2[0.2-0.2] <0.001 0.3[0.3-0.4] <0.001 
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Figure 4.6 Predicted probabilities of dhfr IRN over time 
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4.4.2 Further Analyses of dhfr IRN triple mutant 
 
Given the observed effects in the previous model, further multivariable analysis of the dhfr 
IRN triple mutant haplotype was conducted, factoring in clustering by country and 
excluding the Island populations. The results of the multivariable regression model 
showing the effect of time (study year, 1988-2008) and region on frequency are listed in 
Table 4.8. The overall frequency of dhfr IRN was 53.3% (n= 19269; Tables 4.4 and 4.8). 
The model predicted that for every year, the odds of a person having the dhfr IRN allelic 
haplotype  was 1.1 times higher  (CI 1.0-1.3, p=0.005) suggesting a general increasing 
trend in its frequency over time, although there was now weaker evidence (p=0.005) for 
this compared to the model shown in Table 4.7 (Table 4.6, Figure 4.8). 
Table 4.8 Model for dhfr IRN triple mutant using study year and region as 
covariates 
 
 
 
 
 
 
 
Covariate Proportion of samples 
positive [95% 
confidence interval] 
Odds ratio [95 % 
confidence 
interval] 
P value 
study year (1988-2008) per 
year 
53.3[52.5-54.0] 1.1[1.0-1.2] 0.005 
Region Southeast               59.3[58.3-60.3] 1  
Northeast  17.1[14.6-19.8] 0.1[0.0-1.1] 0.048 
West  39.7[38.0-.41.4] 0.5[0.2-1.1] 0.076 
Southwest  42.8[39.2-46.5] 0.4[0.1-1.4] 0.166 
 Central  62.7[60.9-64.5] 1.2[0.6-2.2] 0.627 
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Compared with the Southeast region, only the Central region had a greater likelihood of 
dhfr IRN occurring (OR 1.2, CI 0.6-2.2)(Table 4.7) whilst the other regions had a lesser 
likelihood of it occurring there, as all their odds ratios were less than one. These odds 
ratios were consistent with those reported in the previous logistic model. However, the 
observed relatively high p values in this model indicate that the strength of the evidence for 
these effects is weak (Table 4.8). The results of the Wald test also provided weak 
evidence of an overall regional effect in the frequency of dhfr IRN (p=0.0569). Given these 
findings, no further modelling was done on dhfr IRN in this chapter. 
 
An important consideration is that the regional distribution of dhfr NCS does not mirror that 
of dhfr IRN. There were some sites where both low NCS and IRN were reported in the 
same survey. For example in Kilifi, Kenya NCS was 27.8% (n=36) whilst IRN was 30.6% 
(n=36) in 1997 (Nzila et al., 2000a). Similarly in Khartoum, North Sudan during 1996 NCS 
was 15.9% (n=44) and IRN 11.4% (n=44) (Khalil et al., 2005). In these studies the 
proportion of NCS and IRN were similar rather than reciprocal. 
 
In Daraweesh and Kajara, which are approximately 15km from Gedaref in the eastern part 
of North Sudan, NCS was 2.6% (n=153) and IRN was 0.7% (n=153) in 2003 (A-elbasit et 
al., 2007). In Thies, Senegal NCS was 33% (n=15) whilst IRN was 40% (n=15) in 2003 
(Ndiaye et al., 2005). On the other hand, generally the distributions of the dhps haplotypes 
complement one other and these results are presented next. 
 
The coverage of dhps GE/GK/AK data extended to 37 countries, of which 23 countries had 
dhps GE (Figure 4.7) which will be discussed first. High frequencies of ≥50 % dhps GE 
were found predominately in East Africa where 26 sites had frequencies ranging between 
80-100%. On the other hand, the dhps GE double mutant allele is largely absent in parts of 
West Africa (Figure 4.7). 
162 
 
  
Figure 4.7 Frequency of dhps GE double mutant haplotype 
 
Evidence of the high dhps GE frequencies in East Africa is shown in Figures 4.8 and 4.9 
where the regional frequencies are plotted against time. The Southeast region had the 
largest subset of data compared with the other regions and the majority of surveys in this 
region were carried out between 1997 and 2008 (Table 4.5, Figure 4.8).  
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Figure 4.8 Surveys of dhps GE double mutant allelic haplotype frequency (with 95% 
confidence intervals) conducted during 1988-2008 and displayed according to their 
geographic region 
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Frequencies in excess of 80% were observed since 1997 and 100% dhps GE was found 
during 2005 in Malawi where both Mzimba in the North (n=46) and Dedza (n=48) had high 
fixed GE frequencies (Nkhoma et al., 2007). A study done in 2005 in Kabale, Uganda also 
reported dhps GE fixation at 100% (n=58) (Lynch et al., 2008). In the Northeast region, 
frequencies of 97%-100% were found in Ethiopia in 2004 at three sites namely Dilla, 
Humera and Jimma (Gebru-woldearegai et al., 2005; Schunk et al., 2006; Pearce et al., 
2009) and the frequencies increased over time at these sites (Figure 4.8). In the 
Southwest, West, Central and Island regions, the frequencies never exceeded 20% 
(Figure 4.8).  
 
The logistic model predicted an overall increase in dhps GE over time. The likelihood of a 
dhps GE haplotype occurring was 1.417 times higher per year and there was strong 
evidence for this (CI 1.393-1.441, p<0.001) (Table 4.9, Figure 4.9). The overall frequency 
of dhps GE was 28.1% (Table 4.9).  
 
Generally there was a greater likelihood of dhps GE occurring in the Northeast compared 
to the Southeast region, with strong evidence for this (Table 4.9) in both models with and 
without the temporal effect (Table 4.7). Given the low frequency of dhps GE in the other 
five regions as described above, the model predicted small odds ratios for these regions.  
 
The likelihood ratio test to compare the models with and without temporal variation 
provided strong evidence to suggest that the dhps GE haplotype frequency was affected 
by time (p< 0.001). Further multivariable analyses of dhps GE is presented in section 
4.4.3. 
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        Table 4.9 Model for dhps GE 
 
 
 
 
 
 
 
 
 
Model to estimate effect of time and region on  frequency 
of dhps GE 
Model to estimate effect 
of region on  frequency  
of dhps GE 
Covariate Proportion 
(%) of  
samples 
positive 
[95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
28.1       
[27.4-28.7] 
1.417               
[1.393-1.441] 
0.001  
Region Southeast 39.9      
[39.0-40.8] 
1  1  
Northeast 52.5           
[49.1-55.8] 
2.276       
[1.958-2.646] 
<0.001 1.664        
[1.451-1.908] 
<0.001 
West 0.7[0.4-1.1] 0.009         
[0.005-0.016] 
<0.001 0.010     
[0.006-0.017] 
<0.001 
Southwest 2.2[1.5-3.1] 0.016       
[0.011-0.023] 
<0.001 0.033     
[0.023-0.048] 
<0.001 
Central 0.3[0.1-0.7] 0.005        
[0.002-0.012] 
<0.001 0.004      
[0.001-0.010] 
<0.001 
Island 2.0[1.3-3.0] 0.010        
[0.007-0.015] 
<0.001 0.031       
[0.021-0.046] 
<0.001 
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Figure 4.9 Predicted probabilities of dhps GE over time 
The distribution of dhps GK allelic haplotype differs from that observed with dhps GE, in 
relation to the differential frequencies observed in East and West Africa. High frequencies 
≥50% dhps GK were found predominately in West Africa and 18 sites had frequencies 
ranging between 80-100% (Figure 4.10). The dhps GK allelic haplotype is absent in more 
sites in East Africa compared with West Africa where it was absent only in Zindarou and 
Banizoumba, Niger between 2003-2006 (n=12) (Ibrahim et al., 2009).     
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Figure 4.10 Frequency of dhps GK single mutant haplotype 
 
In the Southeast region 40 surveys did not observe the dhps GK single mutant allelic 
haplotype and the highest frequency was 40.3% in Kyela, Tanzania in 2000 (Mugittu et al., 
2004) (Figure 4.11). In the Northeast region, the frequency ranged from 1.1% (n=87) 
during 2004 in Humera, Ethiopia (Pearce et al., 2009) to 14.2% (n=148) in 2003 in 
Daraweesh and Kajara, North Sudan (A-Elbasit et al., 2007). The remaining seven surveys 
found no dhps GK.  
 
In the Central region a site in Mutengene, Cameroon surveyed during 2004-2006 had a 
dhps GK frequency of 86.7% (n=196) (Mbacham et al., 2010). The remaining 12 sites 
across the Central region had dhps GK below 65.1% (Figure 4.11). Among the island 
populations, four sites in Sao Tome/Principe had dhps GK above 80% since 2002 (83%, 
n=47) and the three others were 84% (n=90) in Neves, 85.7%(n=21) in Ribeira Afonso and 
87.5%(n=8) in Rua dos Trabalhadores, all were done during 2004 (Salgueiro et al., 2010).  
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In Bamako, Mali dhps GK was 100% (n=32) in 1995 (Plowe et al., 1997) and there were 
six studies in the Western region were it occurred in excess of 80%. These were three 
sites in Ghana surveyed in 2001 (93.4%, n=76), 2003 (88%, n=75) in the Bodomase, 
Ashanti region (Marks et al., 2005) and in 2003 in Navrongo (85%, n=99) and 2005 in 
Hoehoe (86.9%, n=99) (Pearce et al., 2009). In the Southwest region, six sites observed 
dhps GK in excess of 85%. In the Tenrikyo district of Makelekele, Brazzaville, Republic of 
Congo dhps GK was 80% (n=80) in 2003 (Ndounga et al., 2007) and the other sites 
surveyed were in Angola during in 2004 and 2007 (Menegon et al., 2009; Fortes et al., 
2011). 
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Figure 4.11 Surveys of dhps GK single mutant allelic haplotype frequency (with 95% 
confidence intervals) conducted during 1988-2008 and displayed according to their 
geographic region 
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The logistic model predicted an overall increase in dhps GK over time. The likelihood of a 
person having a dhps GK haplotype was 1.071 times per year with strong evidence for this 
(CI 1.050-1.1093, p<0.001) (Table 4.10, Figure 4.12). The overall frequency of dhps GK 
was 20.1% (Table 4.9).  
 
Generally there was a higher likelihood of dhps GK in all five regions compared to the 
Southeast region, with strong evidence for this (Table 4.10) in both models with and 
without the effect of time as a covariate (Table 4.7). The likelihood ratio test to compare 
the models with and without temporal variation provided strong evidence to suggest that 
the dhps GK haplotype frequency was affected by time (p< 0.001). Further multivariable 
analyses of dhps GK is presented in section 4.4. 
 
Table 4.10 Model for dhps GK 
 
Model to estimate effect of time and region on  frequency  of 
dhps GK 
Model to estimate effect 
of region on  frequency  
of dhps GK 
Covariate Proportion (%) 
of  samples 
positive [95% 
confidence 
interval]  
Odds ratio [95% 
confidence 
interval] 
P 
value 
Odds ratio 
[95% 
confidence 
interval] 
P value 
Time (per study 
year)  
20.1[19.5-20.7] 1.071           
[1.050-1.093] 
<0.001  
Region Southeast 1.6[1.4-1.9] 1  1  
Northeast 3.4[2.3-4.8] 2.232             
[1.510-3.299] 
<0.001 2.112                 
[1.430-3.120] 
<0.001 
West 61.8[59.6-64.0] 100.420                  
[84.895-118.785] 
<0.001 97.339           
[82.355-15.050] 
<0.001 
Southwest 74.8[82.4-77.1] 166.752           
[138.393-200.923]
<0.001 178.641                
[148.385-
215.070] 
<0.001 
Central 54.4[51.9-56.9] 78.140            
[65.580-93.106] 
<0.001 71.654         
[60.313-85.127] 
<0.001 
Island 42.0[39.2-44.8] 35.476         
[29.331-42.908] 
<0.001 43.474        
[36.266-52.113] 
<0.001 
171 
 
      
Figure 4.12 Predicted probabilities of dhps GK over time 
The third allelic haplotype dhps AK is fully sensitive and did not have any clear pattern of 
distribution when mapped across Africa (Figure 4.13). Unlike dhfr IRN and dhfr NCS which 
co-exist with double and single mutant allelic haplotypes, the three dhps allelic haplotypes 
GE/GK/AK add up to the total number tested for these alleles. Frequencies of ≥ 50% were 
observed in 69 sites across all six regions and the majority (61%) of these occurred in the 
Southeast region (Figure 4.14).  
 
Democratic Republic 
of Congo (east), 
Kenya, Malawi, 
Mozambique, 
Rwanda, South Africa, 
Swaziland, Tanzania, 
Uganda, Zambia 
Ethiopia, North 
Sudan, South Sudan 
 
Angola, Democratic 
Republic of Congo 
(west), Gabon, 
Namibia, Republic of 
Congo 
Cameroon, Central 
African Republic 
Comoros, 
Madagascar,             
Sao Tome/Principe 
Benin, Burkina Faso, 
Ivory Coast, Equatorial 
Guinea, Gambia, 
Ghana, Guinea, 
Guinea-Bissau, Liberia, 
Mali, Mauritania, Niger, 
Nigeria, Senegal 
P
re
di
ct
ed
 p
ro
ba
bi
lit
y 
of
 d
hp
s 
G
K 
172 
 
 
  
   
Figure 4.13 Frequency of dhps AK fully sensitive haplotype 
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Figure 4.14 Surveys of dhps AK allelic haplotype frequency (with 95% confidence 
intervals) conducted during 1988-2008 and displayed according to their 
geographic region 
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The logistic model predicted a lower likelihood of dhps AK over time. The likelihood of a 
person having a dhps AK haplotype was 0.8 times lower per year with strong evidence for 
this (CI 0.8-0.8, p<0.001) (Table 4.11, Figure 4.15). The overall frequency of dhps AK was 
51.8% (Table 4.11).  
 
Generally there was a lower likelihood of dhps AK occurring in four regions except the 
Island region, compared to the Southeast region and there was strong evidence for this 
(Table 4.11). However this effect was only observed in the model including time. In the 
model excluding the effect of time, dhps AK had a lower likelihood in all five regions 
compared with the Southeast region (Table 4.11). However the strength of the evidence 
for this was weak in the Island region (p=0.104). The likelihood ratio test to compare the 
models with and without temporal variation provided strong evidence to suggest that the 
dhps AK haplotype frequency was affected by time (p< 0.001). Further multivariable 
analyses of dhps AK is presented in section 4.4.5. 
 
Table 4.11 Model for dhps AK 
 
 
 
Model to estimate effect of time and region on  frequency  of  
dhps AK 
Model to estimate 
effect of region on  
frequency of  dhps AK 
Covariate Proportion (%) 
of  samples 
positive [95% 
confidence 
interval]  
Odds ratio 
[95% 
confidence 
interval] 
P value Odds ratio 
[95% 
confidence 
interval] 
P 
value 
Time (per study 
year)  
51.8[53.2-58.9] 0.8[0.8-0.8] <0.001  
Region Southeast 58.5[57.6-59.3] 1  1  
Northeast 44.1[40.8-47.5] 0.4[0.4-0.5] <0.001 0.6[0.5-0.6] <0.001 
West 37.5[35.4-39.7] 0.4[0.3-0.4] <0.001 0.4[0.4-0.5] <0.001 
Southwest 23.0[20.8-25.3] 0.3[0.2-0.3] <0.001 0.2[0.2-0.2] <0.001 
Central 45.4[42.9-47.9] 0.4[0.4-0.5] <0.001 0.6[0.5-0.7] <0.001 
Island 56.0[53.2-58.9] 2.0[1.8-2.3] <0.001 0.9[0.8-1.0] 0.104 
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Figure 4.15 Predicted probabilities of dhps AK over time 
 
The relative proportions of samples tested positive for dhps GE/GK/AK allelic haplotypes 
are illustrated in Figure 4.16. The map of pie charts reflects the relative proportions of 
samples which tested positive for dhps GE/GK/AK allelic haplotypes together (Figure 4.16) 
and shows a clear pattern of high GE frequencies in East Africa and high GK frequencies 
in West Africa, whilst there is no clear pattern of AK due to its scattered distribution. 
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Figure 4.16 Samples tested positive for dhps GE, GK and AK haplotypes 
 
The comparison of the logistic models constructed above provided evidence to show that 
there were regional trends in allelic haplotype frequencies over time. Following these 
exploratory analyses, further multivariable analyses were performed to further explore the 
relationship between dhps GE/GK/AK and the covariates, region and time whilst 
accounting for clustering by country and excluding the Island populations. The results for 
each allelic haplotype are presented next in a sequential manner. 
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4.4.3 Further Analyses of dhps GE double mutant  
 
The results of the multivariable regression model showing the effect of time and region on 
dhps GE frequency are listed in Table 4.12. The model predicted that for every year, the 
likelihood of a dhps GE double mutant haplotype allele occurring was1.422 times higher 
(95% CI 1.151-1.758), p<0.001) (Table 4.12). This suggests that there is a higher 
likelihood of dhps GE double mutant frequency over time.  
The Wald test assessed if there were any differences in dhps GE frequencies among the 
regions. Overall the Wald test showed that there was strong evidence of between-region 
differences in the frequency of dhps GE (p<0.001).   
 
In the Central (OR 0.005, CI 0.002-0.011), Southwest (OR 0.016, CI 0.004-0.063) and 
Western (OR 0.009, CI 0.002-0.044) regions the likelihood of the dhps GE double mutant 
allele being present was lower than it was for the Southeast region, with strong evidence 
for this as p<0.001 (Table 4.12). In the Northeast region the likelihood of dhps GE being 
present was higher than it was for the Southeast region but this may be due to the effect of 
sampling variation as seen from the large width of the 95% confidence interval and weak 
strength of evidence indicated by the high p value (OR 2.282, CI 0.618-8.425, p=0.215). 
           
4.4.4 Further Analyses of dhps GK single mutant 
 
The model predicted that for every year, the likelihood of a person having dhps GK 
was1.102 times higher (CI 1.007-1.207, p=0.035) (Table 4.12). As with dhps GE described 
above, this suggests a higher likelihood of the dhps GK allele frequency per year. 
However, the strength of the evidence for this effect was weak with p=0.035. The Wald 
test provided strong evidence to suggest that the frequency of dhps GK was different 
among the regions (p<0.001).  
 
For all regions the likelihood of the dhps GK allele occurring was greater than it was for the 
Southeast region. Large odds ratios were observed in the Central, Southwest and Western 
regions, suggesting very large differences between these regions and the Southeast 
reference region. The strength of the evidence for this observation was good among the 
three regions where p< 0.001 (Table 4.12) with the exception of the Northeast region.  
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4.4.5 Further Analyses of dhps AK fully sensitive allele 
 
The model predicted that the likelihood of the dhps AK sensitive haplotype allele was 
0.758 times lower per year (95% CI 0.662-0.862) and there was strong evidence for this 
downward trend in frequency (p<0.001).  
 
The Wald test indicated there was evidence for regional variation in the frequencies of 
dhps AK (p=0.0242). The likelihood of the dhps AK allele occurring in the Central, 
Northeast, Southwest and Western regions was less than the likelihood of it occurring in 
the Southeast region although the strength of evidence for this was good for the 
Southwest region only where p<0.001 (Table 4.12). 
 
Overall, the multivariable analyses for dhps GE, GK and AK showed evidence of trends 
over time and the likelihood of their occurrence differed among the regions which justified 
inclusion of the regional categorisation in the models. Given these observations, an 
interaction term between time (study year) and location (region) was factored into the 
logistic models to assess whether or not the relationship between the dhps GE/GK/AK 
frequencies, differed among the five regions with time. This test would indicate if any 
particular region’s influence over these frequencies was significant over time or not. 
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Table 4.12 Multivariable analyses of dhps GE, dhps GK and dhps AK 
 
 
 
 
 
 
 
 
 
Covariate Proportion (%) of 
samples positive 
[95% confidence 
interval] 
Odds ratio [95 % 
confidence interval] 
P value 
Model for dhps GE  
study year (1988-2008) per 
year 
29.8[29.2-30.5] 1.422                   
[1.151-1.758] 
<0.001 
Region Southeast       39.9[39.0-40.8] 1  
Northeast  52.5[49.1-55.8] 2.282[0.618-8.425] 0.215 
West  0.7[0.4-1.1] 0.009[0.002-0.044] <0.001 
Southwest  2.2[1.5-3.1] 0.016[0.004-0.063] <0.001 
Central  0.3[0.1-0.7] 0.005[0.002-0.011] <0.001 
Model for dhps GK  
study year (1988-2008)  per 
year 
18.7[18.1-19.2] 1.102[1.007-1.207] 0.035 
Region   Southeast       1.6[1.4-1.9] 1  
Northeast  3.4[2.3-1.9] 2.284                  
[0.584-8.934] 
0.235 
West  61.8[59.6-64.0] 102.734            
[45.112-233.955] 
<0.001 
Southwest  74.8[72.4-77.1] 164.125               
[73.854-364.734] 
<0.001 
Central  54.4[51.9-56.9] 81.720            
[42.708-156.70] 
<0.001 
Model for dhps AK 
study year (1988-2008)  per year 51.6[50.8-52.3] 0.758[0.662-0.862] <0.001 
Region   Southeast 58.5[57.6-59.3] 1  
Northeast  44.1[40.8-59.3] 0.428[0.120-1.533] 0.193 
West   37.5[35.4-39.7] 0.373[0.148-0.935] 0.036 
Southwest  23.0[20.8-25.3] 0.259[0.114-0.587] 0.001 
Central    45.4[42.9-47.9] 0.425[0.206-0.879] 0.021 
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4.4.6 Interaction between region and time 
 
Table 4.13 shows the extent to which the odds ratios for time (study year) and each 
regional group, differs from those in the reference Southeast region. The results for each 
dhps allelic haplotype are discussed below. 
 
Model for dhps GE double mutant 
 
The odds ratios differed among regional strata for dhps GE, providing evidence to suggest 
that there was an interaction between time (study year) and region and the likelihood of 
dhps GE occurring. Hence the increasing temporal trend in dhps GE frequency differed 
depending on the regional categorisation and there was strong evidence for this (p <0.001, 
based on chi2 and 4 degrees of freedom) (Table 4.13)(Figure 4.17).  
 
As mentioned in chapter 3 section 3.3.2, the lower of the two AIC values indicate the better 
fitted model. The AIC for the model without interaction was 0.894 whilst the model with 
interaction had a lower AIC of 0.876 providing some support for the model with interaction 
between region and time. The Southwest region did not show any association between the 
frequency of dhps GE and the interaction term (OR 1.0, CI 0.7-1.4), although there was 
weak evidence for this with p=0.952. The two models for dhps GE (with and without the 
interaction) showed increasing trends of dhps GE frequency in the Southeast and 
Northeast regions only. 
 
Model for dhps GK single mutant 
 
The odds ratios also differed among regional strata for dhps GK suggesting that the 
increasing temporal trend in frequency differed depending on the regional categorisation 
and there was strong evidence for this (p <0.001, based on chi2 and 4 degrees of freedom) 
(Table 4.13)(Figure 4.18). The AIC for the model without interaction was 0.478 whilst the 
model with interaction had an AIC of 0.471 indicating that the latter interaction model had a 
better fit. Both models (with and without the interaction term) showed increasing trends of 
dhps GK frequency in the Central, Southwest and Western regions, although this evidence 
was strong only in the Southwest region where p<0.001 (Table 4.13). 
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Model for dhps AK fully sensitive allele 
 
There was a decreasing likelihood of dhps AK among all five regions with strong evidence 
for this (p <0.030, based on chi2 and 4 degrees of freedom) (Table 4.13)(Figure 4.19). The 
likelihood of the dhps AK occurring in the Central, Southwest and Western regions was 
marginally better than it was for the Southeast region. The strength of the evidence for this 
was better in the Southwest region where p<0.001 compared with the other regions (Table 
4.13). The AIC for the model without interaction was 1.232 whilst the model with 
interaction had an AIC of 1.213 providing some evidence of a better fit for the latter model.  
 
Table 4.13 Model for dhps GE,GK and AK with interaction between time and region 
 
 
 
 
Covariate Difference in slope 
(per year) for each 
region 
Multivariable analysis 
using allelic haplotype 
frequency with interaction  
for study year x region 
Odds ratio 
[95 % 
confidence 
interval] 
P 
value 
Odds ratio [95 % 
confidence 
interval] 
P 
value 
dhps GE  
Region Southeast   1.4[1.1-1.7] 0.001 1  
Central  2.0[1.6-2.6] <0.001 1.5[1.1-2.0] 0.010 
Northeast  26.2[14.0- 
49.2]  
<0.001 18.9[9.8-36.5] <0.001 
Southwest 1.4[1.1-1.8] 0.011  1.0[0.7-1.4] 0.952 
West  1.3[0.9-2.0] 0.180 0.9[0.6-1.5] 0.811 
dhps GK 
Region Southeast   0.9[0.8-1.0] 0.020 1  
 Central  1.1[1.0- 
1.2] 
0.064  1.3[ 1.1-1.5] 0.003 
 Northeast 0.9[0.8- 
1.2] 
0.560  1.1[0.9-1.4] 0.505 
 Southwest 1.3[1.2-1.4] <0.001  1.5[1.3-1.7 <0.001 
 West  1.2[0.9-1.4] 0.202    1.3[1.0-1.7] 0.025 
dhps AK  
Region Southeast   0.7[ 0.6-
0.9] 
0.002 1  
 Central  0.9[0.8-1.0] 0.051 1.2[1.0-1.5] 0.038 
 Northeast  0.2[ 0.0-
2.0] 
0.184 0.3[0.0-2.7] 0.297 
 Southwest 0.8[0.7-0.8] <0.001 1.0[0.8-1.3] 0.851 
 West  0.9[0.7-1.1] 0.188 1.2[0.9-1.6] 0.315 
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Figure 4.17 Predicted probabilities of regional dhps GE allelic haplotype frequencies with 
interaction between region and time 
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Figure 4.18 Predicted probabilities of regional dhps GK allelic haplotype frequencies with 
interaction between region and time 
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Figure 4.19 Predicted probabilities of regional dhps AK allelic haplotype frequencies with 
interaction between region and time 
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4.5 Discussion 
 
The main finding of the ecological analyses of dhfr IRN, dhfr NCS and dhps GE/GK/AK 
allelic haplotype frequencies presented in this chapter is that their distributions are 
different within sub-Saharan Africa, suggesting that SP efficacy also varies across the 
continent. These differences are described below first for the dhfr IRN triple mutant and 
dhfr NCS fully sensitive allelic haplotype and then for the three dhps allelic haplotypes. 
Limitations and recommendations emanating from the work presented in this chapter are 
discussed. Generally, the frequencies of the sensitive alleles dhfr NCS and dhps AK was 
lower per year, whilst the frequencies of the mutant alleles dhfr IRN, dhps GE and dhps 
GK was higher per year.  
 
The logistic models showed that there was a lower likelihood of dhfr NCS occurring in the 
Southeast region compared to the Northeast, West, Central and Island regions. 
Conversely, there was a higher likelihood of dhfr IRN triple mutant in the Southeast region 
compared to the Northeast, West, Southwest and Island regions. It was shown that the 
dhfr NCS sensitive allelic haplotype is generally decreasing, whilst the dhfr IRN triple 
mutant has dispersed and increased over time to fixation in many sites across Africa. 
Thus, it is no longer possible to trace the stepwise dispersal pattern of dhfr IRN. As Roper 
et al., (2003) showed the triple mutant dhfr IRN haplotype was imported into Africa from 
Southeast Asia. Early reports of resistance to pyrimethamine monotherapy after its 
introduction as both malaria prophylaxis and treatment in the 1950s (Peters, 1970) are 
probably attributable to local mutations which emerged soon after the introduction of 
pyrimethamine in malaria control (Peters, 1969). The emergence of the triple mutant dhfr 
IRN haplotype coincided with the emergence of resistance much later when 
pyrimethamine was used in combination with sulphadoxine. Evidence of this comes from a 
study conducted by Certain et al., (2008) who found that the Asian dhfr IRN was present in 
Kilifi, Kenya around 1988 and there was a marked increase in dhfr IRN during 1987-2006 
after SP was used in this area.  
 
The distribution of the sensitive alleles dhfr NCS generally does not mirror that of IRN 
largely because of the occurrence of the dhfr 51I/108N or 59R/108N double mutants and 
the dhfr 108N single mutant shown in Table 4.1.   
 
The maps and multivariate regression models used data from 152 sites and 34 countries 
and showed that there are clear differences in the geographies of the dhps GE double 
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mutant, GK single mutant and AK fully sensitive allelic haplotypes. A distinct pattern of 
dispersal for these dhps allelic haplotypes can be characterised. For dhps GE, there is an 
East Africa-West Africa divide with high frequencies occurring in the Eastern countries and 
low frequencies occurring in West Africa. Conversely, there are high dhps GK frequencies 
primarily in West Africa and low dhps GK frequencies in East Africa.  
 
The results for dhps GE and dhps GK showing an East-West divide presented in this 
chapter are consistent with the work done by Pearce et al., (2009) who used a relatively 
smaller dataset of 50 sites among 27 countries and showed that the dhps GE double 
mutant was prevalent in East Africa whilst the dhps GK single mutant was prevalent in 
West Africa. Since the research in this chapter was carried out, new dhps allelic haplotype 
frequency data from the DRC were published by Taylor et al., (2013) and they showed the 
same East-West divide within the country with foci of the dhps GE double mutant occurring 
primarily in the eastern parts of the country and dominant foci of the dhps GK single 
mutant occurring in the western parts of the country.  
 
This study found a decreasing trend in dhps AK across all regions with some evidence for 
regional differences in its occurrence as the likelihood of this allele occurring in Central 
and West Africa was marginally greater than it was for East Africa when the effect of time 
and region were considered together. This finding is consistent with the observation that 
these sensitive alleles are being displaced by resistant alleles under selection by high SP 
use in East Africa especially. 
 
These differences in the geographies of the dhps GE double mutant, GK single mutant 
and AK fully sensitive allelic haplotypes can be explained by the differential SP drug 
pressure in West Africa and East Africa. There has been large-scale use of SP as first line 
monotherapy in East Africa (WHO, 2001) whilst SP use has been low in West Africa 
(Frosch et al., 2011) due to the varying malaria transmission intensities in these regions. 
As Pearce et al., (2009) noted, in Africa once dhps mutations arose independently at 
multiple times and became established, they circulated among five distinct mainland 
African regions, with strong selection in foci of high SP use.  
 
The timing of the introduction and duration of SP use is a contributory factor to the 
observed differential dhfr and dhps frequencies over time. Possible explanations for these 
observed differential gradients are as follows: (1) some regions used less SP compared to 
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others as mentioned previously, (2) SP was introduced at a later time in one region 
compared to other regions for operational reasons such as scheduling of drug policy 
changes, (3) a different allele is being selected for in that region or (4) a combination of all 
these factors.  
 
Limitations 
 
As mentioned above, patterns of SP use contribute to the differential gradients of dhfr and 
dhps frequencies over time but these were not factored into the models in this study 
because trends were examined by region. Frosch et al., (2011) correlated chloroquine use 
at a country level, with chloroquine resistance in five individual countries where data were 
available. To do a similar analysis, clear data regarding the duration of SP use as 
monotherapy and combination therapy with other drugs are needed for each sub-Saharan 
African country. There are some challenges in identifying the specific year in which drug 
policies changed to any SP therapy per country, noting that there is often a time lag 
between the actual operational use of SP and drug policy change and the sometimes slow 
uptake of artemisin combinations at sentinel sites. This information is accessible for IPT 
strategies as the WHO (2011a) has summarised the year in which IPT was adopted in 
each country. 
 
Recommendations 
 
The maps presented in section 4.4 afford the opportunity to highlight gaps in the dhps 
allelic haplotype data. Generally there was better coverage of the data in the Southeast 
regions than the other regions. Further monitoring of dhps allelic haplotypes across Africa 
is crucial and up-scaled surveillance using longitudinal studies which are repeated at the 
same sentinel sites over different time periods, specifically in Central and West Africa are 
important in the context of IPT strategies for malaria control.  
 
Whilst it is clear that SP efficacy varies across sub-Saharan Africa, the observed regional 
patterns in the frequency of allelic haplotypes shows that neighbouring malaria control 
programmes could benefit from joint regional initiatives such as the Lubombo Spatial 
Development Initiative (LSDI) (Sharp et al., 2007). 
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As mentioned in this chapter, frequency data are useful when comparing SP resistance 
across populations. However, there are no standard formats for collating and reporting 
frequency versus prevalence data. The results presented in this chapter on allelic 
haplotype frequencies show the value of isolating mixed infections from analyses of SP 
resistance markers. The WWARN initiative (www.wwarn.org) which was described 
previously will assist in standardising how these data types are collated and reported.   
 
In addition, there is a need to assess the current distribution of the quintuple mutation, 
which represents fully resistant SP parasites using the more stringent measure of 
frequency rather than prevalence. Mobula et al., (2009) gathered published data on the 
prevalence of the quintuple mutant since 2000 in the following 17 countries: Burkina Faso, 
Cameroon, Republic of Congo, DRC, Ethiopia, Gabon, Ghana, Guinea, Guinea-Bissau, 
Malawi, Mozambique, Nigeria, Senegal, Sudan, Tanzania, Uganda and Zambia. These 
authors illustrated that there were foci of high quintuple mutant frequencies in East Africa 
and relatively low frequencies in West African foci.  
 
This chapter showed the large regional differences in the frequencies among of dhps 
allelic haplotypes. Further analyses linking SP in vivo treatment failures to allelic haplotype 
data will provide insight into whether or not molecular measures of SP resistance correlate 
with in vivo resistance. This is investigated in chapter 5.  
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Chapter 5 The association between dhfr and dhps haplotypes and in vivo measures 
of Sulphadoxine Pyrimethamine resistance at population level  
 
5.1 Introduction 
 
The mapping presented in previous chapters has shown that different mutations are 
common in East and West Africa, yet the implications of this for SP efficacy are unclear. 
The relationship between dhfr and dhps mutations respectively and treatment outcome 
has most commonly been examined at an individual patient level but to identify a 
significant regional effect across the continent, it may be more appropriate to explore this 
using summarised population level data rather than individual patient level data. This 
chapter explores the relationship between population level in vivo measures of SP efficacy 
and summarised dhfr and dhps molecular data which were matched using the study year 
and study location and assesses the effects of genotype frequencies occurring in East and 
West Africa.   
 
The first significant obstacle to this type of approach is the standardisation of summarised 
in vivo data.  Previous classifications of antimalarial treatment efficacy from in vivo studies 
have not been standardised which rendered it difficult to compare outcomes. This study 
uses secondary data collated from studies that assessed the in vivo response of SP and 
proposes a system of classification for these data to guide spatial and temporal analyses. 
 
As described in chapter 2, in vivo studies assess the treatment outcome of people who 
received proper doses of SP over a defined follow-up period. Initially when SP was first 
introduced after treatment failures with chloroquine, there were more treatment successes 
and adequate clinical responses compared with inadequate clinical responses and 
treatment failures. With extensive use of the drug, efficacy eventually waned and treatment 
failures occurred against a backdrop of progressive development of resistance measured 
by clinical and parasitological indicators. Currently SP is no longer recommended as 
treatment for malaria and instead ACTs are recommended in sub-Saharan Africa. 
Therefore no further in vivo studies of SP treatment efficacy are being conducted. 
However as mentioned in chapter 1, SP is being used for IPT in 37 countries in sub-
Saharan Africa (WHO, 2011a) and it is thus imperative that there is continued monitoring 
of point mutations and allelic haplotypes that are associated with resistance, to provide 
information on SP efficacy in these settings.  
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During the past 15-20 years, there have been several attempts to correlate the genotypes 
(molecular markers) with phenotypes (clinical outcomes) of SP resistance, with somewhat 
inconsistent results. Plowe et al., (1997) suggested that progressive intensification of SP 
resistance from RI, RII to RIII occur in vivo because of the progressive accumulation of 
dhfr and dhps point mutations. These authors added that the influence of factors such as 
immunity levels also have major influence on treatment outcome (Plowe et al., 1997).  As 
shown in previous chapters the molecular determinants of SP resistance, in particular 
those mutations in dhps, differ in East and West Africa. However, the effects of these 
differences have never been examined. 
 
In East Africa, evidence of a relationship between specific point mutations and treatment 
failure was shown in several studies and these have been reviewed by Abdul-Ghani, 
Farag and Allam (2013).  The first studies were reported from Tanzania where reduced 
efficacy of SP was associated with the occurrence of dhfr and dhps mutations (Curtis et 
al., 1998; Wang et al., 1997). However, in Tanzania, Jelinek et al., (1998) did not find any 
statistically significant relationship between clinical outcomes and dhfr or dhps point 
mutations in 1995 or 1996 among pre-treatment samples. In a study conducted in July 
1997 and January 1999 in Kenya, Nzila et al., (2000a) showed that the dhfr 51I/59R/108N 
triple mutant was associated with RI and RII resistance to SP when found with or without 
the dhps point mutations. Kyabayinze et al., (2003) found that the dhfr 59R and dhps 540E 
were strongly associated with SP treatment failure in Kampala, Uganda during July 2000- 
August 2001 and subsequently it was shown that dhps 540E played the primary role in this 
association (Dorsey et al., 2004b). In Blantyre, Malawi the dhfr 51I/59R/108N triple mutant 
when found together with dhps 437G/540E double mutant alleles as the quintuple mutant, 
were associated with SP treatment failure (Kublin et al., 2002).   
 
Alifrangis et al., (2003) studied dhfr and dhps at four sites with different endemicities in 
three different countries namely Hag Yousif, Sudan; Kibaha and Magoda, Tanzania and 
Matola, Mozambique and found there were generally higher frequencies of mutations in 
the SP parasitologic or clinical failure groups compared with the groups that had treatment 
success.   
 
There were similar attempts to study SP efficacy in terms of phenotype and genotype in 
West African countries. 
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In Cameroon three patients who experienced SP treatment failure also had the dhfr IRN 
triple mutant (Basco et al., 1998). In a mesoendemic area of Mali, Diourte et al., (1999) 
could not address directly whether or not dhfr and dhps point mutations were predictive of 
the low SP parasitological failure rate observed (1.1%, n=190) during a 14 day follow-up 
period. However they observed higher rates of dhfr 51I, 59R and 108N among post-
treatment samples compared to pre-treatment samples suggesting that these mutations 
were precursors for SP failure in vivo in areas of unstable malaria transmission (Diourte et 
al.,1999, Djimde et al., 2004). Other studies done in West Africa did find evidence of an 
association between dhps point mutations and in vivo treatment failure (Kun et al. 1999; 
Mockenhaupt et al. 2005; Dunyo et al. 2006; Ndounga et al., 2007).  
 
It is necessary to calibrate in vivo studies emanating from different protocols and some 
issues related to this are presented in this chapter, together with a method of standardising 
results from in vivo studies using different protocols. To examine the relationship between 
molecular markers and SP efficacy, both in vivo and molecular studies across different 
countries in sub-Saharan Africa were matched according to time and place. This unique 
dataset was then used to assess the predictive value of allelic haplotypes or phenotypic 
outcome in exploratory analyses of the relationship between these two measures of 
resistance in East and West Africa. 
 
5.2 Aim 
 
To explore the relationship between measures of in vivo SP efficacy and the frequency of 
dhfr and dhps allelic haplotypes circulating in the parasite population at the time of the 
efficacy trial. 
 
This chapter presents a simplified categorisation of summarised antimalarial in vivo 
efficacy data which enables studies carried out using different WHO protocols to be 
amalgamated and mapped across multiple sites. 
 
5.3 Objectives 
 
1. To calibrate in vivo studies according to a classification system that allows comparison 
across different protocols 
192 
 
2. To match in vivo studies with dhfr and dhps allelic haplotype studies based on 
geographic location (nearest neighbour) and study year (± two years) 
3. To investigate the influence of dhfr and dhps allelic haplotype frequencies on the 
prevalence of in vivo outcomes using logistic regression  
 
5.4 Methods 
 
Study selection 
 
Basic inclusion and exclusion criteria were described in chapter 2. A subset of studies with 
a 28 day or longer follow-up period and PCR correction were drawn from the database 
(Table 5.1). 
Table 5.1 Inclusion criteria for selection of in vivo studies 
Criteria for study selection Description 
Inclusion criteria SP monotherapy 
28 day or longer follow-up period  
PCR correction 
Unrestricted criteria all age groups 
study design – including randomised and other trials 
symptomatic or asymptomatic study participants 
malaria transmission setting 
 
Standardised in vivo treatment outcomes 
 
In this study, a classification scheme for the different outcomes measured by in vivo 
efficacy studies was adopted. It categorises outcomes into three variables: S, R1 and R2 
on the basis of a combination of parasitological and therapeutic responses (Table 5.2).  
 
Descriptions of parasitological and therapeutic responses, where provided for each SP in 
vivo efficacy study, were noted along with the WHO protocol used and any deviations 
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thereof. These notes were used to classify outcomes into the three standardised 
categories as described below. Descriptions of the study end points as per the WHO 
protocols were provided in Tables 2.1a and b in chapter 2.  
 
R1: Late treatment failure (LTF) or late clinical Failure (LCF) and late parasitological failure 
(LPF) were combined into the category R1 as it was not always clear whether or not fever 
could be a reliable indicator of treatment efficacy given confounding by antipyretics, 
concomitant illnesses and the acquired immunity of individual study participants. These 
regularly used in vivo study endpoints were grouped together with RI parasitological 
failures, which had the same definition as LPF. RI (late) responses were classified as R1 
due to the occurrence of recrudescent parasites, implying decreasing drug efficacy. 
 
R2: RII and RIII parasitological responses were grouped given the variability of microscopy 
which could limit the accuracy of the distinction between RII and RIII responses. These 
were grouped together with early treatment failures (ETFs) because they all reflect failures 
that would have occurred by seven days of follow-up. RI (early) responses were classified 
as R2 (poor response) as its definition was similar to an RII response. 
 
The combined total of R2+R1 gives the total treatment failure rate.  From a public health 
perspective, there is a substantial difference between the consequences associated with 
ETFs (R2) and LTFs (R1) and in many instances the R1 responses needed to be analysed 
independently from the R2 responses.   
 
S:  This category included adequate clinical response (ACR), adequate clinical and 
parasitological response (ACPR) and treatment cure or success. 
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Table 5.2 Classification of in vivo treatment responses used to generate resistance profiles  
 
Resistance 
profile 
Endpoint from 
WHO Protocols 
Description of treatment efficacy 
R2 RI (early), RII, 
RIII,ETF 
High grade resistance reflecting a poor 
response to SP, requiring alternative treatment 
R1 RI (late),RI, 
LTF,LCF,LPF 
Intermediate grade resistance response, 
indicates decreasing SP efficacy 
R  R1 + R2  Total failure rate 
S S,ACR,ACPR No resistance, adequate response indicating 
cure or treatment success 
 
The matrix with the resistance profile is based on a review of the descriptions and 
classifications used by each in vivo study. It offers a uniform method of classifying 
heterogeneous antimalarial efficacy study endpoints in one of three resistance categories 
for comparison purposes. 
 
Assumptions and points to consider with this approach 
 
The assumption is that all studies adhered strictly to the WHO protocol that it employed. 
For example, patients who responded favourably to SP treatment remained so after the 
last follow-up day. 
 
Some studies use both clinical (ACR/ETF/LTF) and parasitological (RI/RII/RIII) response 
which implies that the data would fit into more than one category in the matrix for the same 
resistance profile. There are two examples below from Driessen et al., (2002) and Talisuna 
et al., (2004a).  
 
In Driessen et al., (2002) the WHO (1996) therapeutic response (ACR/ETF/LTF) and the 
RI/RII/RIII response for parasitological response were used. In assessing policy change 
criteria, Driessen et al., (2002) suggested that if the level of RIII parasitological response 
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exceeds 5–10%, the clinical response should be carefully evaluated and if this shows that 
the median duration of clinical response was less than 14 days and/or the haematological 
response was suboptimal compared with an effective drug, a change in first line treatment 
ought to be considered. 
 
In the study done by Talisuna et al., (2004a) the WHO (1996) protocol and ACR/ETF/LTF 
therapeutic endpoints were used. However, these authors chose the RI/RII/RIII 
classification system after the 28th day of follow-up because less than 10% of recruited 
patients had treatment failures at day 14. Thus they did not use the ACPR/LCF/LPF/ETF 
classification at day 14 due to the low treatment failure rate. 
 
Feasibility of comparing results from different WHO protocols, as described by 
WHO 
 
WHO (1973) and WHO (1996) or WHO (2001) 
A comparison of the classification endpoints described in the 1973 and 2001 protocols 
appeared in a WHO (2005) report. Two issues concerning study variability and different 
transmission intensity settings were highlighted in this report and these are mentioned 
below: 
 (1) Application of the WHO (1973) protocol in the field was prone to variability and 
adaptation which might influence comparability among studies. Furthermore, different 
definitions of the S/RI/RII/RIII response might have been used within these studies. 
(2) In high transmission areas, the S/RI/RII/RIII endpoints measured with the WHO (1973) 
protocol are not comparable with the endpoints measured with the new protocols i.e. the 
sum of RI+RII+RIII treatment failures is not equivalent to the sum of ETF+LCF (WHO, 
2001). 
(3) In low-to-moderate transmission areas, the RI+RII+RIII endpoints measured using the 
WHO (1973) protocol are equivalent to ETF+LCF+LPF (WHO, 2001). 
WHO (1996) and WHO (2001) 
As mentioned previously, the primary difference between the WHO (1996) protocol and 
the WHO (2001) protocol was the categorisation of treatment failure into LCF and LPF and 
inclusion of parasitological response in ACPR.  In high transmission settings, the 
possibility of re-infections is high which can confound LCF and LPF endpoints. Despite 
these differences between the two protocols, WHO (2005) reported that they are still 
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comparable. The 2001 protocol took into account different malaria transmission settings 
and changes were made to the follow-up period, sampling method and classification of 
efficacy. The WHO (2001) protocol recommended 14 or possibly 28 day follow-up periods 
in high transmission settings and 28 day follow-up periods in low/moderate transmission 
settings (Table 2.1 in chapter 2). This can be summarised as follows: in low to moderate 
malaria transmission settings, the RI+RII+RIII (WHO, 1973) endpoints are equivalent to 
ETF+ LCF+LPF (WHO, 2001) or ETF + LTF (WHO, 1996) since LTF = LCF + LPF. 
 
Examples of studies that re-categorised therapeutic data 
Two studies done in Equatorial Guinea (1992-1999) and Cameroon (pre-1998) related 
therapeutic response to parasitological response and both re-categorised the response in 
a similar way to that proposed here. These two studies are discussed below. Firstly, 
Roche et al., (2003) did a study in Malabo, Equatorial Guinea using the WHO (1996) 
protocol (ACR/ETF/LTF) with a 14 day follow-up period. They reclassified the WHO 
categories as described in Table 5.3 to compare in vivo efficacy studies done pre-1996 
and post-1996. Studies done pre-1996 reported S/RI/RII/RIII responses and did not 
consider the clinical aspects of the treatment response. 
 
Table 5.3 Roche et al., (2003) reclassification of in vivo end points  
Reclassification by 
Roche et al., (2003) 
Resistance  
Profile used 
From WHO 
Protocols 
ETF = RIII R2 RI (early), RII, RIII,ETF 
LTF = RI, RII R1 S/RI (late),RI, LTF,LCF,LPF 
S = ACR S S,ACR,ACPR 
 
The primary difference between the reclassification of Roche et al., (2003) and this study’s 
proposed reclassification system is to do with the RII parasitological response. In the work 
by Roche and colleagues (2003), the RII parasitologic response was classified as LTF 
while this study proposes that RII is more similar to an RIII and ETF response than a RI 
and LTF response for the reasons described previously, which were related to the 
variability of assessing parasites under the microscope. 
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In the second study, Basco et al., (1998) used the WHO (1996) and 28 day follow-up 
period in Yaounde, Cameroon. The definition of ACR/ETF/LTF in the Roche et al., (2003) 
and Basco et al., (1998) studies were similar and fit in with the standardised matrix with 
one difference related to presence or absence of fever with ACR used by the latter 
authors. An anomaly from these two studies was that the RII parasitological response was 
classified as indicative of ETF or LTF in Basco et al., (1998) but as LTF only in Roche et 
al., (2003).   
 
Another study used the WHO (1994) protocol, although it is not a mainstream protocol. For 
example in Uganda, Kamya et al., (2001) used both WHO (1996) and WHO (1994) 
protocols. The revised WHO (1996) protocol for areas of intense transmission was used 
together with the modified criteria in WHO (1994). In this study clinical failures (ETF or 
LTF) and parasitological resistance (RI/RII/RIII) were reported separately. The authors 
considered the re-categorisation of both resistance classification schemes by introducing 
two modifications related to the RII/RIII and ETF responses. The reclassification took into 
account ETFs and their parasite densities within the first three days of follow-up. Those 
with ETF and increasing parasite densities were classified as RIII, whilst those who were 
ETF but had decreasing parasite densities were classified as RII. According to the present 
study’s proposed standardisation matrix, both categories would fall into the R2 resistance 
profile.  
 
These re-calibrated in vivo data were used for further analyses with the molecular data 
described in the next section. In total 53 in vivo studies passed quality control criteria and 
the details of these studies are listed in Appendices 12 through 16. 
 
 
Matched resistance profile from in vivo studies with dhfr and dhps haplotypes 
 
The selected in vivo studies were matched with molecular haplotype studies of dhfr IRN, 
dhfr NCS (Appendix 13) and dhps (GE/GK/AK) (Appendix 14)  according to the closest 
study period (± two  year gap) and nearest neighbour. The data were grouped broadly into 
East and West African countries as shown in the map in Figure 5.1. The Western region 
consisted of 11 countries namely Angola, Burkina Faso, Cameroon, Chad, Democratic 
Republic of Congo (West) Gabon, Ghana, Madagascar, Mali, Republic of Congo and 
Sierra Leone. The Eastern region consisted of nine countries namely Democratic Republic 
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of Congo (East) Kenya, Malawi, Mozambique, South Africa, Tanzania, Uganda, North 
Sudan and South Sudan. 
 
The frequencies of dhfr IRN and dhfr NCS haplotypes exclude a third category of ‘other’ 
haplotypes (see below). The coverage of in vivo data points are illustrated in Figure 2.3 in 
chapter 2. The different datasets were mapped using Mapinfo and Google Earth.  
For each matched survey, the allelic haplotype frequency was calculated as the number of 
samples with the allelic haplotype/total number of samples analysed, as in equation one. 
Equation 1:  
Frequency of allelic haplotype = [number of samples with the allelic haplotype/total number 
of samples tested for which an allelic haplotype could be determined] X 100 
The prevalence of in vivo efficacy was calculated as follows: 
[number of people with in vivo efficacy outcome /total number of people completing the 
survey] X 100 
 
To explore trends in the raw data, allelic haplotype frequencies were ordered from lowest 
to highest and frequencies at quarterly intervals were selected. The corresponding 
phenotype prevalence was observed at these frequencies. In the event of there being 
more than one phenotype prevalence, at a specific allele frequency, the mean prevalence 
was calculated. 
 
Logistic regression analysis of phenotypic and genotypic responses 
 
The aim was to assess whether or not there was any association between in vivo studies 
describing SP phenotypic outcome and genotypic measures of resistance. The data were 
derived by matching studies with the nearest geographic neighbour and the study year. 
The phenotypic outcome was the number of people clinically classified as having 
resistance to SP treatment (in vivo R) or clinical success (in vivo S). Two measures of in 
vivo resistance were used in this analysis namely any resistance (R) and high grade 
resistance (R2).To perform a logistic regression the phenotypic outcome was expanded to 
each individual based on the number of people that completed each survey.  Genotype 
frequencies were rescaled by 10% and the data were treated as surveys in Stata. 
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A logistic regression with robust standard errors was constructed, allowing for clustering by 
study site and stratified across the two regional strata namely East and West as illustrated 
by the map in Figure 5.1 and using equation one.   
Equation 1: log (p/1-p) = β0 + β1x1  
where  
p = probability of phenotype being present 
1-p = probability of phenotype being absent 
x1   = frequency of dhfr or dhps allelic haplotype 
β0  = constant 
Receiver operating characteristic curves (ROC) were constructed using predicted 
probabilities from the logistic regression analysis.  The predicted probabilities of any 
phenotype resistance were estimated using the results from the dhps GE and dhps GK 
models. The allelic haplotype frequencies were unadjusted. No cut-offs were used to 
generate the ROC using the phenotype response as the classification variable. The area 
under the receiver operating curve (AUC) was used to compare the models generated for 
dhps GE and dhps GK. No further interpretation of the AUC was conducted.  
 
To assess whether or not there were any regional differences in the model estimated 
above, another logistic regression with robust standard errors was constructed, allowing 
for clustering by study site and this time without stratification across regions, using Stata’s 
survey methodology. Genotype frequencies were rescaled by 10%. Region was modelled 
as a covariate with and without interaction with the dfhr IRN, dhps GE and dhps GK 
genotype. The Eastern region was used as the reference region throughout. 
 
Other dhfr alleles 
 
The database was queried for dhfr studies where haplotypes were available. Combinations 
of allelic haplotypes were extracted that were not of the dhfr 51I/59R/109N triple mutant or 
fully sensitive 51N/59C/109S allelic haplotypes. These dhfr single or double mutant allelic 
haplotypes are less common than the triple mutant or fully sensitive forms. This group was 
termed ``other” and haplotypes included in this category are listed in Table 5.4.  
 
200 
 
     Table 5.4  Less common dhfr alleles     
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Codon 50 51 59 108 140 164 
Sensitive Cys    
(C) 
Asn  
(N) 
Cys  
(C) 
Ser  
(S) 
Val  
(V) 
Ile  
(I) 
Triple 
Mutant 
 Ile 
(I) 
Arg  
(R) 
Asn  
(N) 
  
Others Ile 
(I) 
Cys  
(C) 
Asn  
(N) 
  
Ile 
(I) 
Cys  
(C) 
Asn  
(N) 
 Leu  
(L) 
Ile 
(I) 
Cys  
(C) 
Ser  
(S) 
  
Ile 
(I) 
Arg  
(R) 
Ser  
(S) 
  
Ile 
(I) 
Arg  
(R) 
Thr 
(T) 
  
Asn  
(N) 
Cys  
(C) 
Asn  
(N) 
  
Asn  
(N) 
Cys  
(C) 
Thr 
(T) 
  
Asn  
(N) 
Arg  
(R) 
Thr 
(T) 
  
Asn  
(N) 
Arg  
(R) 
Asn  
(N) 
  
Asn  
(N) 
Arg  
(R) 
Ser  
(S) 
  
Asn  
(N) 
Tyr  
(T) 
Ser  
(S) 
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The studies were categorised into East or West African sites as shown in the map 
in Figure 5.1 and a t-test with equal variances was performed to assess whether 
or not the frequencies of the less common dhfr allelic haplotypes differed between 
these two regions. The results were confirmed using the Wilcoxon Mann Whitney 
test. No further analysis was performed on these less common dhfr haplotypes.  
 
  
           
Figure 5.1 Regional classification of sub-Saharan African countries for matched in 
vivo and molecular studies  
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5.5 Results 
 
There were 53 SP in vivo studies that fulfilled the inclusion criteria and of these 42 studies 
were matched with the dhfr surveys and 26 studies matched with surveys of dhps allelic 
haplotypes. Appendices 13 and 14 list the matched studies and the publications from 
which these data were obtained are listed in appendices 12, 15 and 16. The following 
sections summarises the available data and presents the results of the logistic regression 
analyses.  
 
Matched in vivo studies with dhfr NCS fully sensitive allelic haplotype 
 
The coverage of surveys available for statistical analyses of dhfr NCS matched with SP 
phenotype is presented in Table 5.5. The study years ranged from 1996 to 2006, spanning 
32 unique sites in 17 countries. The proportion of people with any in vivo resistance was 
29.1% (n=3766) whilst 8.0% of people had high grade resistance (n=3370). The frequency 
of dhfr NCS was similar in surveys matched to in vivo studies with R and R2 phenotypic 
responses (21.6% and 23.5%).  
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Table 5.5 Prevalence of phenotypic response to SP treatment matched with frequency of 
dhfr NCS allelic haplotype 
         
*Proportion (%) with treatment outcome = number with specific treatment outcome/total 
number of people completing the survey x 100 
 
 Matched in vivo studies with dhfr IRN triple mutant allelic haplotype 
 
Table 5.6 shows the coverage of surveys for the matched dhfr IRN and SP phenotype 
data. There were 32 unique sites from 17 countries covering the period from 1996 to 2006.  
The proportion of people with any phenotype resistance was 26.6% (n=5329).These were 
matched with surveys in which 52.1% samples contained the dhfr IRN triple mutant allelic 
haplotype (n=3344). The frequency of dhfr IRN was similar for matched surveys with R 
and R2 phenotypic responses (52.1% and 55.1%). 
 
Phenotype 
Category 
Total 
number 
of people 
with 
clinical 
outcome 
across 
all sites  
[median, 
range] 
Total 
number of 
people 
included 
across all 
sites 
Proportion* 
with 
treatment 
outcome 
(%) [95% 
confidence 
interval]  
Samples 
tested 
positive for 
dhfr NCS 
haplotype 
(frequency) 
Samples 
tested for   
dhfr NCS 
haplotype 
Proportion 
with dhfr 
NCS (%) 
[95% 
confidence 
interval] 
Category 
1:  
Any 
phenotypic 
resistance 
(in vivo R) 
1097 
[18,1-89] 
3766 29.1            
[27.7-30.6] 
1011 4672 21.6           
[20.5-22.8] 
Category 
2:  
High grade 
phenotypic 
resistance 
(in vivo 
R2) 
271 
[6.5,     
0-38] 
3370 8.0 
[7.1-9.0] 
938 3994 23.5 
[22.2-24.8] 
Category 
3: 
Treatment 
success 
(in vivo S) 
2645 
[44,       
7- 345] 
3766 70.2           
[68.7-71.7] 
1011 4672 21.6        
[20.5-22.8] 
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Table 5.6 Prevalence of phenotypic response to SP treatment and frequency of dhfr IRN 
allelic haplotype in matched surveys 
 
 
 
 
 
 
 
 
 
Phenotype 
Category 
Total 
number 
of 
people 
with 
clinical 
outcome 
across 
all sites  
[median, 
range] 
Total 
number of 
people 
included 
across all 
sites 
Proportion 
with 
treatment 
outcome 
(%) [95% 
confidence 
interval]  
Samples 
tested 
positive for 
dhfr IRN 
haplotype 
(frequency) 
Samples 
tested for    
dhfr IRN 
haplotype 
Proportion 
with dhfr 
IRN (%) 
[95% 
confidence 
interval] 
Category 
1:  
Any 
phenotypic 
resistance 
(in vivo R) 
1418  
[18,     
0-89] 
5329 26.6         
[25.4-27.8] 
3344 6421 52.1         
[50.8-53.3] 
Category 
2:  
High grade 
phenotypic 
resistance 
(in vivo R2) 
346       
[5,0-38] 
4600 7.5         
[6.8-8.3] 
3063 5562 
 
55.1      
[53.8-56.4] 
Category 
3: 
Treatment 
success (in 
vivo S) 
3862     
[52,         
7-345] 
5329 72.5     
[71.3-73.7] 
3344 6421 52.1      
[50.8-53.3] 
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Tables 5.7 and 5.8 describe the observed prevalence of SP phenotype resistance at 
various dhfr and allelic haplotype frequencies. Relatively low dhfr NCS frequencies were 
observed with specific higher phenotypic resistance levels. A clear trend of generally 
increasing dhfr NCS frequencies was observed with increasing treatment success rates 
(Table 5.8).  
 
Table 5.7 Observed prevalence of SP phenotype resistance at various dhfr allelic 
haplotype frequencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
Frequency (%) of dhfr allelic 
haplotype  
Observed prevalence (%) of 
any grade resistance (in vivo 
R)  
NCS 
10.6 41.5 
25.4 40.2 
58.3 16.3 
74.0 13.8 
IRN 
11.4 16.1 
27.5 26.8 
51.0 40.2 
75 42.4 
Frequency (%) of dhfr  
allelic haplotype  
Observed prevalence (%) of 
high grade resistance (R2)  
NCS 
10.6 9.8 
25.4 2.8 
58.3 12.0 
74.0 5.7 
IRN 
11.9 5.7 
20.0 1.3 
58.4 1.5 
75 4.6 
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Increasing dhfr IRN frequencies were observed with increasing phenotypic resistance 
(Table 5.7) but this was more apparent among the matched studies of any phenotypic 
resistance (R) rather than with high grade phenotypic resistance (R2).    
Table 5.8 Observed prevalence of SP treatment success at various dhfr allelic haplotype 
frequencies 
 
 
 
 
 
    
    
    
    
    
    
    
    
    
    
           
    
Frequency (%) 
of dhfr  allelic 
haplotype 
Observed Prevalence  
(%) of treatment 
success (S) 
NCS 
10.6 58.5 
25.4 63.7 
58.3 83.7 
74.0 85.4 
IRN 
11.4 67.7 
27.5 71.4 
58.4 87.7 
75 57.6 
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Univariate logistic regression analysis of SP phenotypic outcomes with dhfr 
genotypes 
 
With every 10% increase in dhfr NCS frequencies, there was a lower likelihood of 
phenotypic resistance (R) and higher likelihood of treatment success (Table 5.9).  
 
The odds of any phenotypic resistance was lowered 0.835 (CI 0.676-1.032) times, per 
10% increase in dhfr NCS frequencies although there was weak evidence for this with 
p=0.092. Similarly, a 10% increase in dhfr NCS frequencies resulted in a lower likelihood 
of high grade phenotypic resistance (R2) (OR 0.831, CI 0.703-0.982) and the evidence for 
this was strong with p=0.031 (Table 5.9). Furthermore, the odds of treatment success 
were 1.187 times higher (CI 0.964-1.461) per 10% increase in dhfr NCS frequencies. 
However p=0.104, indicating weak evidence for this.  
 
The model for dhfr IRN triple mutant showed increasing phenotypic resistance and 
decreasing treatment success with every 10% increment in dhfr IRN frequencies (Table 
5.9). Specifically the odds of any phenotypic resistance was 1.180 (CI 1.040-1.339) times 
higher with every 10% increment in dhfr IRN frequencies and there was strong evidence 
for this with p=0.012. A 10% increase in dhfr IRN resulted in higher odds (OR 1.110, CI 
0.980-1.258) of high grade phenotypic resistance although there was weak evidence for 
this (p=0.097). Conversely, the odds of treatment success resulted in 0.858 times lower 
odds (CI 0.764-0.964) per 10% increase in dhfr IRN and the evidence for this was strong 
with p=0.011.  
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Table 5.9 Results of analysis for dhfr NCS and dhfr IRN predicting SP phenotype 
The genotype frequencies were rescaled by 10% and dhfr NCS and dhfr IRN was 
modelled individually as covariates with SP treatment outcome in different models. Two 
models were constructed for each phenotypic outcome category. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Given the abovementioned evidence that dhfr IRN was a strong predictor of phenotypic 
outcome, a logistic regression was performed using region as a covariate. Overall, there 
was strong evidence showing a higher likelihood of any SP phenotypic resistance 
occurring in the Eastern region compared to the Western region (OR 2.234, CI 1.119-
4.458, p = 0.024). 
 
In the model, the likelihood of any phenotypic resistance (R) was 1.158 times higher (CI 
1.022-1.314) per 10% dhfr IRN and there was strong evidence for this as p=0.023. There 
was strong evidence indicating that any phenotypic resistance (R) was lower in the 
Western region compared to the Eastern region (OR 0.520, CI 0.280 – 0.967, p = 0.039). 
Covariate Prevalence of 
treatment outcome 
(%) [95% confidence 
interval] 
Odds ratio of 
treatment outcome 
per 10% increase in 
allelic haplotype [95% 
confidence interval] 
P value 
Category 1: Any phenotypic resistance (in vivo R) 
Model 1: 
dhfr NCS 
29.1 [27.7-30.6]  0.835[0.676-1.032] 0.092 
Model 2: 
dhfr IRN   
26.6  [25.4-27.8] 1.180[1.040-1.339] 0.012 
Category 2: High grade phenotypic resistance (in vivo R2) 
Model 1: 
dhfr NCS  
8.0 [7.1-9.0]  
 
0.831[0.703-0.982] 0.031 
Model 2: 
dhfr IRN   
7.5 [6.8-8.3] 1.110[0.980-1.258] 0.097 
Category 3: Treatment success (in vivo S) 
Model 1: 
dhfr NCS   
70.2 [68.7-71.7] 1.187[0.964-1.461] 0.104 
Model 2: 
dhfr IRN  
72.5  [71.3-73.7] 0.858[0.764-0.964] 
 
0.011 
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However, when the interaction between dhfr IRN and region was included in the model this 
regional effect was no longer evident (OR 1.004, CI 0.826 – 1.222, p=0.961). 
                      
Matched in vivo studies with dhps allelic haplotypes  
 
Data were available for 29 unique sites in 18 countries where dhps allelic haplotypes were 
matched with SP phenotypic response. The overall rate of treatment success was 74.2% 
(Table 5.10). The total frequencies of dhps GE, GK and AK allelic haplotypes in surveys 
matched with the three SP phenotypes are listed in Table 5.11. Overall, the AK 
frequencies were highest, followed by GE frequencies and GK frequencies (Table 5.11). 
Inspection of the dhps allelic haplotype frequencies and matched prevalence of resistance 
was used to look for trends in variability at specific phenotypic responses (Tables 5.12, 
5.13 and 5.14). There was an observed higher likelihood of high grade phenotypic 
response (R2) at specific increasing dhps GE frequencies only (Table 5.13). 
Table 5.10 Prevalence of phenotypic response to SP treatment among studies matched 
with dhps allelic haplotypes  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Phenotype 
Category 
Total number 
of people with 
clinical 
outcome 
across all sites 
[median, 
range] 
Total 
number of 
people 
included 
across all 
sites 
Proportion 
with 
treatment 
outcome (%) 
[95% 
confidence 
interval]  
Category 1: 
Any 
phenotypic 
resistance 
(in vivo R) 
1009            
[17.5, 0-89] 
4351 23.2  
[21.9-24.4] 
Category 2: 
High grade 
phenotypic 
resistance 
(in vivo R2) 
266[5, 0-38] 3837 6.9  
[0.61-7.8] 
Category 3: 
Treatment 
success (in 
vivo S) 
4510 [51,7-345] 3350 74.2  
[73.0-75.6] 
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Table 5.11 Frequencies of dhps GE, GK and AK allelic haplotypes in surveys matched 
with SP phenotype 
 
 
                    
  
   
 
  
  
  
   
. 
Generally, the three dhps allelic haplotypes GE/GK/AK add up to the total number tested 
for these alleles.  
 
 
 
 
 
 
 
 
 
 
 
Phenotype 
Category 
Samples 
tested 
positive for 
dhps GE        
[% positive]    
Samples tested 
positive for 
dhps GK [% 
positive]      
Samples 
tested 
positive for 
dhps AK     
[% positive]    
Samples 
tested for    
dhps allelic 
haplotype 
Category 1: 
Any 
phenotypic 
resistance 
(in vivo R) 
1551 [22.1]      1410 [20.1]           4027 [57.5]      7006 
Category 2: 
High grade 
phenotypic 
resistance 
(in vivo R2) 
1572 [25.8]      1349 [22.2]           3143 [51.6]      6090 
Category 3: 
Treatment 
success (in 
vivo S) 
1813 [24.7]  1426 [19.4] 4067 [55.5] 7334 
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Table 5.12 Observed prevalence of any grade resistance (in vivo R) at various dhps allelic 
haplotype frequencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency dhps 
haplotype (%) 
Observed prevalence 
(%) of any grade 
resistance (in vivo R) 
dhps GE  
9.8 10.1 
30.6 42.4 
45.2 22.9 
98.6 58.2 
dhps GK 
10.2 42.2 
25.0 7.0 
46.2 4.4 
98.3 13.8 
dhps AK 
9.2 41.5 
25.0 18.5 
51.2 4.4 
100.0 69.9 
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Table 5.13 Observed prevalence of high grade phenotypic  resistance at various dhps 
allelic haplotype frequencies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency dhps 
haplotype (%) 
Observed prevalence (%) 
of high grade resistance 
(R2) 
dhps GE  
9.8 1.3 
30.6 4.5 
45.2 16.7 
98.6 24.8 
dhps GK 
10.2 4.5 
25.0 2.0 
46.2 1.1 
98.3 5.7 
dhps AK 
9.2 9.8 
25.0 4.4 
51.2 1.1 
100.0 5.8 
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Table 5.14 Observed prevalence of SP treatment success at various dhfr allelic haplotype 
frequencies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Frequency dhps 
haplotype (%) 
Observed prevalence  (%) 
of treatment success (S) 
dhps GE  
9.8 93.2 
30.6 57.6 
45.2 77.1 
98.6 41.8 
dhps GK 
10.2 57.6 
25.0 93.0 
46.2 95.6 
98.3 85.4 
dhps AK 
9.2 58.5 
25.0 80.8 
51.2 95.6 
100.0 30.1 
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Univariate logistic regression analysis of SP phenotypic and dhps genotypic 
responses 
 
The results of the logistic regression analysis for dhps GE, dhps GK and dhps AK 
individually predicting in vivo outcome are shown in Table 5.15. A fourth logistic regression 
analysis assessed the combined effect of the dhps GE double mutant together with the 
dhps GK single mutant on phenotypic outcome. The results are discussed sequentially for 
each of the three phenotypic outcomes.  Category one describing any phenotype 
resistance is discussed first below. 
Table 5.15 Results of dhps GE, GK, GE+GK and AK individually predicting in vivo 
outcome 
The genotype frequencies were rescaled by 10% and each covariate was modelled 
individually with phenotype outcome. Four models were constructed for each phenotypic 
outcome category. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Category 1: Any phenotypic resistance (in vivo R) 
The model predicted a higher likelihood of phenotypic resistance with an increase of 10% 
dhps GE and dhps GE+ dhps GK.  The odds of any phenotypic resistance was 1.164 
times higher (CI 1.059-1.280) when dhps GE increased by 10% and there was strong 
evidence for this as indicated by p=0.002 (Table 5.15). The relationship of dhps GK with 
any phenotypic resistance (R) was weak (p=0.602) and the likelihood of any phenotypic 
Covariate Frequency of 
allelic 
haplotype (%) 
[95% 
confidence 
interval] 
Odds ratio of 
treatment outcome  
per 10% increase in 
genotype  
[95% confidence 
interval] 
P 
value 
Category 1: Any phenotypic resistance (in vivo R)  
Model 1: GE   22.1 [21.2-23.1] 1.164[1.059-1.280] 0.002 
Model 2: GK   20.1 [19.2-21.1] 0.969[0.858-1.094] 0.602 
Model 3: AK   57.5 [56.3-58.6] 0.851[0.742-0.977] 0.023 
Model 4: GE+AK  42.3 [41.1-43.4] 1.178[1.025-1.354] 0.022 
Category 2: High grade phenotypic resistance   (in vivo R2)  
Model 1: GE   25.8 [24.7-26.9] 1.148[1.048-1.257] 0.004 
Model 2: GK   22.2 [21.1-23.2] 0.951[0.832-1.087] 0.449 
Model 3: AK    51.6 [51.6-52.8] 0.847[0.761-0.942] 0.003 
Model 4: GE+GK  48.0 [46.7-49.2] 1.182[1.060-1.318] 0.004 
Category 3: Treatment success (in vivo S) 
Model 1:GE   24.7[23.7-25.7] 0.856[0.787-0.931] 0.001 
Model 2:GK  19.4[18.5-20.4] 1.069[0.947-1.205] 0.272   
Model 3:AK 55.5[54.3-56.6] 1.152[1.024-1.295] 0.020 
Model 4:GE+GK   44.2[43.0-45.3] 0.867[0.769-0.977] 0.021 
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resistance was actually lower with every 10% increase in dhps GK (OR 0.969, CI 0.858-
1.094).  
 
When estimating the combined effect of dhps GE+ dhps GK, the odds of any phenotypic 
resistance was 1.178 times higher (CI 1.025-1.354) per 10% increase in these allelic 
haplotypes and there was strong evidence for this as indicated by p=0.022. As expected 
the odds of any phenotypic resistance (R) was reduced (OR 0.969, CI 0.858-1.094) with a 
10% increase in dhps AK frequency. There was strong evidence for this (p = 0.23) (Table 
5.15).  
 
Category 2: High grade phenotypic resistance (in vivo R2) 
The likelihood of high grade phenotypic resistance (R2) was higher with every 10% 
increment in dhps GE, (OR 1.148, CI 1.048-1.25) and there was strong evidence for this 
as indicated by the low p value of p=0.004 (Table 5.15). Conversely the likelihood of high 
grade phenotypic resistance was lowered with each 10% increment in dhps AK frequency 
(OR 0.951, CI 0.832-1.087). There was strong evidence for this (p = 0.003).  Interestingly, 
as with R,  the odds of high grade phenotypic resistance (R2) was reduced 0.951 times 
per 10% increase in dhps GK, though the strength of the evidence for this was weak with 
p=0.449. When the combined effect of dhps GE+ dhps GK was assessed, the odds of high 
grade phenotypic resistance was 1.182 times higher (CI 1.060-1.318) with p=0.004.  
 
Category 3: Treatment success (in vivo S) 
There was a reduction in treatment success (OR 0.856, 0.787-0.931) as dhps GE 
frequency increased by 10%. There was strong evidence for this (p = 0.001). Similarly the 
odds of treatment success was lowered (OR 0.867, CI 0.769-0.977) as the combined 
effect of dhps GE+ dhps GK increased by 10% and the evidence for this was strong (p = 
0.021) (Table 5.15). For every 10% increase in dhps GK alone, however there was a 
higher likelihood of treatment success (OR 1.069, CI 0.947-1.205), although there was 
weak evidence for this effect (p= 0.272). The odds of treatment success were higher with 
every 10% increase in dhps AK (OR 1.152, CI 1.024-1.295) and there was strong 
evidence for this as p=0.020. 
 
To summarise the models presented in Table 5.15, there was strong evidence of 
decreasing high grade phenotype resistance and any phenotype resistance with 
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increasing frequencies of the dhps AK sensitive allelic haplotype. While there was strong 
evidence of increasing high grade phenotype resistance and any phenotype resistance 
with increasing dhps GE frequencies, surprisingly there was little evidence of a relationship 
between dhps GK frequencies and phenotypic resistance. 
Following these results, ROC curves were constructed to compare the sensitivity and 
specificity of the individual models for dhps GE and dhps GK.  
 
Sensitivity and specificity of dhps GE and dhps GK models 
 
Using the results presented for category one in Table 5.15 receiver operator curves were 
constructed. The area under the curve was 0.627 (95% CI 0.606-0.648) for dhps GE and 
0.515 (95% CI 0.495-0.534) (Figure 5.2). The model for dhps GE was better in 
discriminating between phenotypic resistance versus no phenotypic resistance (p<0.001) 
compared to the dhps GK model. 
 
  
Figure 5.2 Sensitivity and specificity of dhps GE and dhps GK incremented by 10% 
frequencies, in predicting any phenotypic resistance  
The two dhps GE and GK allelic haplotypes were then included in the model as covariates 
and these results are described next.  
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Multivariable logistic regression analyses of SP phenotypic and dhps genotypic 
responses 
 
The results of the logistic regression analysis using dhps GE, dhps GK as covariates 
predicting in vivo outcome are shown in Table 5.16. The results are discussed separately 
for each of the three phenotypic outcomes.   
 
Table 5.16 Multivariable logistic regression analysis using both GE and GK as covariates 
for predicting in vivo outcome 
The genotype frequencies were rescaled by 10% and the two covariates dhps GE and 
dhps GK were modelled together with each SP phenotype outcome. Therefore three 
models were constructed for each phenotypic outcome category using the two covariates.  
 
 
 
 
 
 
 
 
 
 
 *Odds ratio with dhps GE adjusted for dhps GK and vice versa 
 
Category 1: Any phenotype resistance:  
The odds of any phenotypic resistance was higher (Adjusted OR 1.211, CI 1.060-1.384) 
with every 10% increment in dhps GE frequencies, after adjusting for dhps GK frequencies 
and the evidence for this was strong with p=0.006 (Table 5.16.) Similarly, the likelihood of 
any phenotypic resistance was higher (Adjusted OR 1.096, CI 0.949-1.266) with every 
10% increase in dhps GK frequencies after adjusting for dhps GE, but the evidence for this 
was weak with p=0.206.  
dhps 
Covariate 
Frequency of allelic 
haplotype (%) [95% 
confidence interval] 
Adjusted* Odds 
ratio of treatment 
outcome per 10% 
increase in 
genotype  
[95% confidence 
interval] 
P 
value 
Category 1: Any phenotypic resistance (in vivo R)  
GE  22.1 [21.2-23.1] 1.211[1.060-1.384] 0.006 
GK  20.1 [19.2-21.1] 1.096[0.949-1.266] 0.206 
Category 2: High grade phenotypic resistance  (in vivo R2)  
GE  25.8 [24.7-26.9] 1.197[1.087-1.319] 0.001 
GK  22.2 [21.1-23.2] 1.096[0.995-1.206] 0.062 
Category 3: Treatment success (in vivo S) 
GE  24.7[23.7-25.7] 0.839[0.747-0.941] 0.004 
GK  19.4[18.5-20.4] 0.952[0.835-1.085] 0.453 
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Category 2: High grade phenotypic resistance (in vivo R2) 
After adjusting for dhps GK the odds of high grade phenotypic resistance was 1.197 times 
higher (CI 1.087-1.319) per 10% increase in dhps GE frequencies and the evidence for 
this was strong with p=0.001 (Table 5.16.).  After adjusting for dhps GE, the odds of any 
phenotypic resistance was 1.096 times higher (CI 0.995-1.206) per 10% increase in dhps 
GK frequencies but the evidence for this was weak with p=0.062 (Table 5.16.).  
 
Category 3: Treatment success (in vivo S) 
The odds of treatment success was lowered with every 10% increase in both dhps GE and 
dhps GK frequencies, OR 0.839 (CI 0.747-0.941) and OR 0.952 (CI 0.835-1.085) 
respectively. There was strong evidence for this effect but only for the dhps GE 
frequencies with p=0.004.  
 
Comparing the models in Tables 5.15 and 5.16, there is evidence that the effect of dhps 
GK to increase any phenotypic resistance is not as strong as the effect of dhps GE on any 
phenotypic resistance. 
 
The model in Table 5.16 assessed the effect of dhps GE and dhps GK as covariates on 
phenotypic outcome and found that both genotypes increased the likelihood of phenotypic 
resistance and decreased the likelihood of treatment success. However, it must be noted 
that the evidence for this was weak when assessing dhps GK as a covariate in this model.  
With increasing dhps GE frequencies there was a higher likelihood of phenotypic 
resistance and lower likelihood of treatment success (Table 5.15). The same trend was 
observed when dhps GE frequencies were added together with dhps GK frequencies in a 
logistic model. 
 
In a subsequent analysis all three dhps allelic haplotypes namely dhps GE, dhps GK and 
dhps AK were used as covariates predicting in vivo outcome. However, the results were 
inconsistent with the previous two models and the high p values (p>0.263) indicate weak 
evidence to support this model. 
 
Given the observed effect of dhps GE on phenotypic resistance as described in Tables 
5.15 and 5.16 and the observation that dhps GE is predominant in East Africa, region was 
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introduced into the model as an explanatory variable to test whether or not the effect was 
due to region or to dhps GE itself. The results are presented in Table 5.17.  
 
Effect of dhps GE and dhps GK and region on any phenotypic resistance  
 
Firstly, the model tested whether or not there were any regional differences in the 
prevalence of any resistance (Table 5.17). The odds of any resistance was lower in the 
Western region (OR 0.605, 0.252-1.452) compared to the Eastern region but the high p 
value of 0.252 indicated weak evidence for this.              
Table 5.17 Regional variation in phenotypic outcome 
 
 
 
 
 
           
     
Thereafter, the effect of dhps GE and dhps GK on any phenotypic resistance (category 
one) was modelled to assess whether or not they were modified by regional differences 
(Table 5.18).  
Table 5.18 Multivariate logistic regression analysis of SP phenotypic outcome with 
genotype and region as covariates in one model 
*Odds ratio with dhps allelic haplotype adjusted for region  
 
Covariate Prevalence of 
treatment outcome 
(%) [95% confidence 
interval] 
Odds ratio  
[95% confidence 
interval] 
P 
value 
Model 1: Any phenotypic resistance (in vivo R) 
East 69.3[66.3-72.1] 1  
West 30.7[27.9-33.7] 0.605[0.252-1.452] 0.252 
Covariate Prevalence of 
treatment outcome 
(%) [95% 
confidence interval] 
Adjusted* Odds ratio  
[95% confidence 
interval] 
P value 
Model 1: Any phenotypic resistance (in vivo R) with dhps GE and region 
dhps GE  23.2 [21.9-24.4] 
 
1.195[1.032-1.384] per 
10% increase 
0.019 
Region East 69.3[66.3-72.1] 1  
West 30.7[27.9-33.7] 1.440[0.443-4.681] 0.535 
Model 2: Any phenotypic resistance (in vivo R) with dhps GK and region 
dhps GK  23.2 [21.9-24.4] 
 
1.229[1.003-1.507] per 
10% increase 
0.047 
Region East 69.3[66.3-72.1] 1  
West 30.7[27.9-33.7] 0.166[0.0367-0.750] 0.021 
220 
 
The likelihood of any phenotypic resistance per 10% increase in dhps GE was higher after 
adjusting for regional differences (OR 1.195, CI 1.032-1.384) and there was strong 
evidence for this with p=0.019 (Table 5.18). The higher likelihood of any phenotypic 
resistance per 10% increase in dhps GE was consistent with the previous models 
presented earlier. Although the likelihood of any phenotypic resistance was higher in the 
Western region compared to the Eastern region (OR 1.440, CI 0.443-4.681) after adjusting 
for differences in dhps GE frequencies, the evidence for this difference was weak 
(p=0.535) (Table 5.18).  
 
After adjusting for the confounding effect of region, there was borderline evidence for a 
higher likelihood of SP phenotypic resistance associated with increasing GK (Adjusted OR 
1.229, 0.047). This suggests some evidence of an independent association between SP 
phenotypic resistance and dhps GK frequencies. 
 
After adjusting for differences in the frequency of dhps GK, the likelihood of any 
phenotypic resistance was lower (OR 0.166, CI 0.0367- 0.750) in the West compared to 
the East and there was strong evidence for this with p=0.021 (Table 5.18). To assess the 
regional effect of dhps GE and dhps GK on SP phenotypic resistance, an interaction term 
was introduced. 
 
Again, there was a higher likelihood of any phenotypic resistance per 10% increase in 
dhps GE (OR 1.193, CI 1.030-1.382) with p=0.020, indicating strong evidence for this. The 
likelihood of any phenotypic resistance was higher when the regional effect was assessed 
together with dhps GE frequency as an interaction term (OR 1.572, CI 0.712-3.472] 
although there was weak evidence for this as p=0.255.  
 
There was a higher likelihood of any phenotypic resistance per 10% increase in dhps GK 
(OR 1.739, CI 0.0534-5.665) but there was weak evidence for this as p=0.348. There was 
also a lower likelihood of any phenotypic resistance when the regional effect was 
assessed together with dhps GK frequency as an interaction term (OR 0.696, CI 0.210-
2.304), with weak evidence for this as p=0.543.  
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Other dhfr alleles 
 
The t-test showed that there is a statistically significant difference between the mean 
frequency of the less common dhfr allelic haplotypes among the East and West African 
countries (t = -3.4128, p=0.0008). The East African countries have a significantly higher 
mean frequency (45.5%) of the `other’ dhfr allelic haplotypes than the West African 
countries (29.9%) (Table 5.19).  
 
Table 5.19 Surveys with less common dhfr allelic haplotypes categorised by region 
 
 
 
   
   
   
  
5.6 Discussion 
 
There are other factors which affect in vivo response to SP treatment in addition to the 
influence of dhfr and dhps allelic haplotypes explored here. Not all treatment failures can 
be attributed to drug resistance as mentioned in chapter 2. A major factor is immunity. 
Among patients surveyed in Nagongera Health Centre, Tororo District in Eastern Uganda 
which is found along the Kenyan border, Talisuna et al., (2004b) found that patients with P. 
falciparum infections responded favourably to SP treatment despite detecting relatively 
high prevalence of dhfr and dhps point mutations. Acquired immunity allows people to 
clear parasites even when point mutations are present (Khalil et al., 2002). Against the 
backdrop of these highly variable patient-specific effects, the ecological analyses 
described here assessed the effect of dhfr and dhps allelic haplotypes on SP phenotypic 
outcome.  
 
As expected the sensitive dhfr NCS allelic haplotype was associated with a lower 
likelihood of SP phenotypic resistance and higher likelihood of treatment success although 
the evidence for the latter effect was weak.  There was increasing SP in vivo resistance 
and decreasing SP treatment success associated with increasing dhfr IRN triple mutant 
Region Number 
of 
Surveys 
Mean (%) 
frequency of other 
dhfr allelic 
haplotypes  
West 88 29.9[23.4-36.5] 
East 153 45.5[39.8-51.2] 
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frequencies. In the model with dhps IRN and region as covariates there was strong 
evidence to suggest that any SP phenotypic resistance was lower in the Western region 
compared to the Eastern region. This finding is not explained by differences in dhfr IRN 
frequencies and might be due to differences in dhps allelic haplotype frequencies or to 
more sites with high levels of acquired immunity in West Africa. 
 
Notably the population frequency of the fully sensitive 51N/59C/108S allelic haplotype is 
not a mirror image of the dhfr 51I/59R/108N triple mutant frequency as mentioned in 
section 4.5, chapter 4. This is influenced by the dhfr double mutant haplotypes 51I/108N 
and 59R/108N which displaced the 51N/59C/108S sensitive allelic haplotype in many 
populations prior to the appearance of the dhfr 51I/59R/108N triple mutant. The ‘other’ dhfr 
alleles i.e. neither 51N/59C/108S nor 51I/59R/108N but which are partially resistant alleles 
constitute a considerable proportion of the total number tested. The observation of weak 
evidence for increasing SP treatment efficacy along with higher dhfr NCS frequencies 
might perhaps be explained by the presence of intermediate resistance alleles and/or to 
the additional factor which lies with dhps and its sulphadoxine sensitivity. There are few 
minor dhps alleles and the frequency of dhps GE/GK/AK generally sums up to the total 
number tested. Thus these dhps frequencies are more likely to reciprocate each other. 
 
The dhps sensitive AK allelic haplotype was associated with a lower likelihood of high 
grade SP phenotype resistance and any phenotype resistance.  Furthermore there was 
strong evidence of a higher likelihood of high grade phenotype resistance and any 
phenotype resistance corresponding with increasing dhps GE frequencies throughout the 
analyses. Coinciding with this observation, there was strong evidence of a lower likelihood 
of treatment success with increasing dhps GE frequencies.  
 
There was borderline evidence for a higher likelihood of SP phenotypic resistance 
associated with increasing dhps GK frequencies only after adjusting for regional effects. 
This suggests some evidence of a positive association between SP phenotypic resistance 
and dhps GK frequencies. Furthermore, after adjusting for differences in dhps GK 
frequencies, there was evidence of regional differences in SP phenotypic resistance 
between East and West Africa. There was a lower likelihood of SP phenotypic resistance 
in the West compared to the East, which might be explained by differential drug pressure 
in this region. 
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The work presented in chapter 4 showed that different dhps haplotypes prevail in East 
Africa and in West Africa. High dhps GE frequencies occur in East Africa and low 
frequencies occur in West Africa. The dhps GK allelic haplotype predominates among 
West African sites. However, evidence of any association between the dhps 437G point 
mutation and SP treatment efficacy has been inconsistent. Previous work in four West 
African countries found the dhps 437G point mutation to be associated with in vivo 
treatment failure namely Lambarene, Gabon (1995-1996)(Kun et al. 1999), Tamale, 
Ghana (2002) (Mockenhaupt et al. 2005), Farefenni, Gambia (2001) (Dunyo et al. 2006), 
Brazzaville, Republic of Congo (2003-2004) (Ndounga et al. 2007). However, Marks et al. 
(2005) found no association between the dhps 437G point mutation and in vivo outcomes 
in the hyperendemic malaria area of Bodomase, Ashanti Region, Ghana when surveyed in 
2001 and 2003. As mentioned in chapter 4 there are differences in the use of SP in East 
and West Africa, with large-scale use of SP as first line monotherapy in East Africa and 
relatively low SP use in West Africa ((WHO, 2001, Frosch et al., 2011) due to the different 
malaria transmission intensities among these regions.  
 
Predicted in vivo failure rates based on dhps allelic haplotypes 
 
The matched dhps allelic haplotype frequencies and in vivo prevalence showed that dhps 
GE raised the likelihood of phenotypic resistance and lowered the likelihood of treatment 
success. The same trend was observed when dhps GE frequencies were added together 
with dhps GK frequencies as well as after adjusting for dhps GK and the evidence for this 
was strong. The higher likelihood of phenotypic resistance with increasing dhps GE was 
consistent after adjusting for region.  Using the univariate logistic regression results for 
dhps GE from Table 5.15, the predicted in vivo resistance rates were extrapolated using 
the model’s regression coefficients (Table 5.20) as in the equation: 
Predicted in vivo R = (exp(-1.687951+(0.0152146 x dhps GE 
frequency)))/(1+exp( -1.687951+(0.015214 x dhps GE frequency))) 
The dhps GE frequencies were unadjusted in these estimates. At 50% dhps GE, the 
predicted phenotypic resistance was 28.3% and at 100% dhps GE the predicted 
phenotypic resistance was 45.8%. In chapter 6, these predicted in vivo prevalence 
measures were mapped and linked to the WHO (2005) defined categories for assessing 
clinical failures leading to a recommendation for drug policy change in high transmission 
areas. In areas saturated with dhps GE, the phenotypic resistance is also likely to be 
influenced by other factors which impact on treatment failure. This analysis represents the 
first approximation of the relationship between dhps GE and any SP in vivo resistance. 
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Table 5.20 Predicted probability of any phenotype resistance based on varying dhps GE 
frequencies  
 
 
 
 
 
 
 
 
 
The re-calibration of the in vivo studies enabled comparison with the dhfr and dhps allelic 
haplotypes in an ecological analysis and the results correlating these two phenotypic and 
genotypic measures of resistance suggests that there is value in such a categorisation. 
This study illustrates that population measures of molecular markers can be used to 
predict in vivo efficacy at a population level.  
 
Limitations 
 
The in vivo efficacy data are summarized estimates rather than individual patient level 
estimates and limitations relating to such data, mentioned previously in chapter 2, also 
apply here. Furthermore, the complete dataset was reduced after matching the allelic 
haplotypes with SP in vivo efficacy based on nearest neighbour and study year. The two 
regional groupings used in this analysis cover 19 countries including an Island, with 
different malaria transmission intensities and these differences might have been too large 
to allow distinct regional patterns to emerge.  
 
Being young of age is a risk factor for SP treatment failure. This study used any age group 
due to the paucity of suitable in vivo studies available to match with the molecular studies. 
Age group seems to be less important once all five dhfr and dhps mutations occur together 
and in this scenario the risk of treatment failure is the same regardless of age group 
Frequency dhps 
GE haplotype 
(%) 
Predicted prevalence (%) 
of any grade phenotypic 
resistance (in vivo R) with 
95% confidence intervals 
0% 15.6 [8.5-22.7] 
10% 17.7 [10.8-24.6] 
25% 21.3 [14.5-28.0] 
50% 28.3 [20.7-36.0] 
75% 36.7 [25.6-47.7] 
100% 45.8 [29.9-61.8]  
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(Talisuna et al., 2004b). This study did not take into account the immunity status of study 
participants and transmission intensity in the sites studied, which are important 
confounders and could be factored into future models.  
 
Recommendation 
 
Here the first attempt to quantify the differential effects of alternative dhps GE and dhps 
GK resistance alleles on SP phenotypic outcome is described. This study shows strong 
evidence that the dhps GE double mutant is consistently associated with a higher 
likelihood of SP phenotypic resistance. In addition there was some evidence of a positive 
association between SP phenotypic resistance and dhps GK frequencies. The threshold of 
50% prevalence of dhps 540E is already being used as a cut-off for SP in IPTi (WHO, 
2009a). These findings support the use of GE as a marker for SP resistance and indicate 
that continued monitoring of dhps GE and dhps GK in Africa should be informative for use 
of SP for IPT in specific regions.  
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Chapter 6 Summary and Discussion 
 
The research conducted in this thesis aimed to summarise the pan-African geography of 
SP resistance using aggregate data and to apply analytical methods to characterise its 
emergence and rate of spread. This concluding chapter contains a summary and 
discussion of the major findings. It highlights the main recommendations and limitations of 
this work, considers possibilities for future work and outlines its implications for the broader 
context of artemisinin resistance containment.  
 
Overview of major findings 
 
After outlining the history of antimalarial drug use in Africa and exploring the various 
factors known to influence the emergence and spread of resistance, the scope of the 
research project was outlined in chapter 1. The goal of the project was to gather molecular 
and in vivo SP resistance data from the published literature to create a georeferenced and 
standardised database of SP resistance measures. These data could then be analysed to 
explore spatial and temporal patterns across sub-Saharan Africa. 
 
The scale and coverage of the georeferenced measures of resistance which were 
abstracted from the literature were described in chapter 2. The mapped distributions of SP 
in vivo efficacy studies and molecular surveys for a range of different point mutations and 
allelic haplotypes related to SP resistance were shown. The WHO (1973) and WHO (1996) 
protocols were used most frequently to assess SP in vivo efficacy. The most commonly 
used method to assess the prevalence of resistance markers was PCR-RFLP followed by 
sequencing and dot blotting. Consistent gaps in data coverage for both in vivo and 
molecular measures of SP resistance were identified in seven countries namely Botswana, 
Burundi, Cape Verde, Eritrea, Somalia, Togo and Mauritius. 
 
The mapped sub-Saharan distribution of seven individual point mutations and their 
prevalence in every suitable molecular survey were examined in chapter 3.  Exploratory 
analyses were performed on prevalence data for each point mutation. To assess whether 
or not there were any observable trends in prevalence over time, surveys were grouped 
into specific geographic regions. These regions had been previously defined according to 
whether or not P. falciparum parasites from those countries shared drug resistance 
mutations with a common origin. The observations made from the mapping and regional 
analysis of temporal changes were used to categorise point mutations into three broad 
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categories reflecting the pattern in which they occur: (1) scarce and/or not associated with 
foci of SP resistance (e.g. dhps 436A and dhps 613S), (2) emerging mutations (e.g. dhfr 
164L and dhps 581G) which are comparatively rare but increasing in specific geographical 
foci of resistance (3) major resistance mutations such as dhps 540E and dhps 437G which 
are widespread. 
 
The first group describes point mutations that scarce or rare. The dhps 436A mutation 
occurred in 32 countries and 107 unique sites covering all six regions. There was a lower 
likelihood of dhps 436A occurring over time. The minimal prevalence of dhps 436A in the 
Southeast suggests that it may be an ancestral variant. The likelihood of dhps 436A 
occurring in the West, Southwest and Central regions were higher than that of the 
Southeast. 
 
Also in this group is the dhps 613S point mutation. It was found in 10 countries but was 
absent in the Southwest region, suggesting that its distribution is sporadic in the other 
regions. The cumulative prevalence of dhps 613T in Africa was the lowest of all mutations 
at 0.1% (11/10152) between 1988 and 2008 and it was present in three countries (in the 
Southeast, West and Island regions) and was absent in 21 countries. Generally, there was 
a lower likelihood of dhps 613S/T occurring over time, with the highest likelihoods in the 
West.   
 
The second group consists of point mutations with emerging foci of resistance, dhfr 164L 
and dhps 581G. The dhfr 164L point mutation was absent in 21 countries, occurring only in 
the Southeast, Central and Island regions and being absent in the Northeast, West and 
Southwest regions. Its cumulative continental prevalence was 0.7% (130/19923) between 
1998 and 2008. Thus dhfr 164L is still relatively rare in sub-Saharan Africa. Notably there 
was a higher likelihood of dhfr 164L occurring over time with the highest likelihoods among 
the Island populations.  
 
The dhps 581G point mutation is emerging sporadically and was found in 13 countries, 
was absent in 15 countries between 1988 and 2008 with a cumulative prevalence of only 
5.1% (14526/15398) between 1993 and 2008. Generally the prevalence of dhps 581G was 
low across sub-Saharan Africa with emerging foci in Mali and Tanzania. Generally, there 
was a higher likelihood of dhps 581G occurring over time, with the highest likelihoods in 
the Southeast and Northeast regions. 
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The third group includes the widespread dhps 437G and 540E point mutations which 
confer major resistance where they occur together as the dhps GE double mutant. The 
prevalence of the dhps 437G and 540E point mutations increased over time but there were 
noteworthy regional differences in their prevalence. High prevalence of dhps 437G 
occurred in all 37 countries and 152 unique sites surveyed. 
 
The dhps K540E had the best data coverage of all the point mutations studied and it 
occurred in 27 countries and was absent in 10 countries. Generally high dhps K540E 
prevalence was observed in East Africa with the highest prevalence recorded in the 
Southeast and Northeast regions, where it was ≥50% at 74 sites. The prevalence was 
consistently low (<50%) in the West, Southwest, Central and Island regions over time.  
 
The results of the logistic regression models for dhps 540E and dhps 437G suggested that 
there was a steady increase in the prevalence of both point mutations over time but that 
there were regional differences in prevalence. These point mutations were found 
predominantly in the Southeast regions and were less prevalent in the Western regions, 
where a declining prevalence trend was predicted. The predicted probabilities of dhps 
437G and 540E in the Western and Southwestern regions were generally less than that 
found in the Southeast region. For dhps 437G the Southern African countries were similar 
to each other and different from the Western, Central and Northeast regions. The dhps 
437G point mutation generally occurred together with dhps 540E in the Southeast and 
Northeast region.  
 
Summarised frequency distributions of the dhfr sensitive allelic haplotype (51N/59C/108S), 
dhfr triple mutant allelic haplotype (51I/59R/108N) and the three dhps haplotype alleles 
437G/540E (GE), 437G/540K (GK) and 437A/540K (AK) were presented graphically and 
mapped in chapter 4.  
 
High frequencies of the dhfr NCS sensitive haplotype were found scattered across East 
and West Africa but cumulatively there was a gradual decline in its frequency over time in 
all regions. The dhfr IRN allelic haplotype generally increased over time with strong 
evidence for this. However, there was only weak evidence of an overall regional effect in 
the frequency of dhfr IRN. As dhfr IRN has evidently dispersed and reached fixation in 
many sites throughout Africa, regional differences are less apparent. The regional 
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distribution of dhfr NCS does not mirror that of dhfr IRN and this is because of the 
occurrence of the dhfr 51I/108N or 59R/108N double mutants.  
 
There were regional differences in the African distribution of the dhps haplotypes. The 
maps and regression models showed clear differences in the distribution of the dhps GE 
double mutant, GK single mutant and AK fully sensitive allelic haplotypes with some 
distinct regional patterns discernible. For dhps GE, there appears to be an East Africa-
West Africa divide and high frequencies occur in the Eastern countries and low 
frequencies occur in West Africa. The distribution of dhps GK mirrors that of dhps GE with 
a West-East divide. High dhps GK frequencies occur primarily in West Africa and low 
frequencies occur in East Africa. Generally, there were higher likelihoods of dhps GE and 
dhps GK and correspondingly lower likelihoods of dhps AK per year. 
 
In chapter 5 the relationship between these molecular markers and in vivo efficacy was 
explored at a population level using a standardised categorisation of summarised 
antimalarial in vivo efficacy data and matching molecular surveys from similar times and 
places. The SP in vivo studies selected for inclusion were matched with dhfr and dhps 
allelic haplotype studies based on nearest geographic location and study year and an 
assessment of their association was conducted. The influence of East African and West 
African genotypes on clinical outcome could then be explored.  
 
Given the broad distribution of dhfr IRN it is expected that it should be a good predictor of 
in vivo resistance. Where the frequency of dhfr IRN is high, treatment failures and 
resistance rates should be high, whilst the treatment success rates should be low. This 
was consistent with what was observed in this study as there was a higher likelihood of SP 
in vivo resistance as the dhfr IRN triple mutant frequencies increased. This finding 
supports the results obtained by Picot et al., (2009) who conducted a meta-analysis and 
found that the presence of the dhfr IRN triple mutant increased the risk of SP treatment 
failure. Whilst there was a higher likelihood of any phenotypic resistance in the East 
compared to the West, this was not consistent when the interaction between region and 
the dhfr IRN triple mutant was factored in the model. It is also expected that dhfr NCS 
would be a good predictor of in vivo efficacy, where its frequency is high the treatment 
success rate should also be high. Generally, there was a lower likelihood of phenotypic 
resistance and higher likelihood of treatment success with increasing dhfr NCS 
frequencies but the evidence for this was inconsistent. This inconsistency may be due to 
the observed high frequencies of dhfr double mutant allelic haplotypes in East Africa. 
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For dhps AK to be a good predictor of in vivo efficacy, its frequencies should be positively 
correlated with treatment success and negatively correlated with resistance rates. Indeed 
the likelihood of any in vivo resistance was lower as dhps AK frequencies increased. 
Similarly the likelihood of treatment success was higher with increasing dhps AK 
frequencies. 
 
Since dhps GE and GK are resistance mutants it is expected that their frequency in 
populations would be good predictors of in vivo efficacy. Their frequencies are expected to 
be negatively correlated with treatment success and positively correlated with resistance 
rates. There was strong evidence for this with dhps GE but weak evidence for this with 
dhps GK when these genotypes were modelled together as covariates in a logistic 
regression analysis. The evidence for any regional differences upon phenotypic outcome 
was weak after adjusting for dhps GE. There was a lower likelihood of any phenotypic 
resistance in the West compared to the East when region was modelled with dhps GK, but 
this was not consistent when the interaction between region and dhps GK was factored in 
the model. The likelihood of any SP in vivo resistance on its own was higher in the East 
compared to the West, but there was weak evidence for this, suggesting there were no 
regional differences in phenotypic outcome. 
 
Discussion of major findings and recommendations 
 
Since the first protocols for measuring antimalarial drug resistance were developed, new 
tools such as in vitro tests and molecular methods have been developed. The WHO 
definition of antimalarial drug resistance described in chapter 1 can be simplified as an 
infection that survives, multiplies and gets carried over to the next host despite being 
treated (Sibley and Price, 2012). This definition is based on clinical responses of the 
patient and does not consider other measures of resistance. A combination of the results 
of clinical, molecular, pharmacological and in vitro tests to characterise the definition of 
resistance to SP would be useful (Sibley and Price, 2012). As Basco and Ringwald (2000) 
stated, the original definition of antimalarial resistance is inadequate and ought to factor in 
treatment failures, 50% inhibitory concentration of the drug as well as mutations 
associated with resistance. A revised definition of drug resistance would be timely in the 
context of SP being used for IPT strategies and artemisinin resistance containment. 
 
 As the use of molecular methods to detect resistance gains momentum and the WHO 
recommendations now include a molecular prevalence threshold for the decision on IPTi 
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implementation, there is a need for a standardised framework for measuring and equally 
importantly, reporting of molecular data in a systematic manner. This thesis described the 
geographic and temporal changes using measures of the prevalence of single point 
mutations and the frequency of allelic haplotypes. Among the genotyping studies gathered 
in this study, prevalence was the more commonly reported measure compared to 
frequencies. To carry out an analysis on the combinations of point mutations called ’allelic 
haplotypes,’ reporting of mutation data needs to be carried out in such a way that 
haplotypes can be identified and mixed infections should be documented and clearly 
reported so that these can be handled in a standardised way.    
 
Ideally patient level data would be reported but it is not always practical to do so and 
wherever longitudinal studies are carried out there should be adherence to standardised 
study designs, data collection methods, data analyses and reporting standards. With 
online infrastructure becoming increasingly available, data sharing is far more practical 
now than it was a few decades ago.  
 
Recognising the need for support structures to collect and standardised data the WWARN 
partnership offers support for designing protocols and has set up regional centres for data 
collection, providing tools for partners to collect, clean and analyse their data and then 
standardise the data according to a predefined data management and statistical analysis 
plan. These tools are available online for easy access at 
http://www.wwarn.org/partnerships/study-groups/asaqal-molecular-marker-study-group.  
To date WWARN has obtained SP clinical resistance data from Angola, Chad, DRC, Mali, 
Mozambique, Sierra Leone, Uganda and South Africa but again efficacy rates are 
available in summarised estimates at http://www.wwarn.org/resistance/explorer. The data 
gathered in this thesis have been made available online at www.drugresistancemaps.org 
where the reference for each study is provided together with the study year, number of 
samples tested for a particular point mutation and number of samples tested positive. This 
website of African surveillance data originated a global online database 
(http://www.wwarn.org/resistance/surveyors/molecular) where these African data are 
combined with georeferenced molecular data from sites across the globe. 
 
The data gaps identified in the surveillance coverage of in vivo and molecular markers of 
SP resistance in this study, point to a shortage in the West African countries of Chad, 
Sierra Leone and Togo as well as Somalia in the horn of Africa and Burundi in East Africa. 
As stated previously, these gaps could represent a genuine absence of data or simply 
232 
 
point to a lack of availability of such data in the public domain. Where SP is no longer used 
as first line treatment, molecular methods are the only practical means of quantifying 
resistance. Systematic surveillance for establishing molecular levels of SP resistance 
using longitudinal studies is especially relevant where these gaps exist, as IPT 
programmes are rolled out. Surveillance should include symptomatic and asymptomatic 
infections. Asymptomatic infections act as a reservoir and active surveillance of 
asymptomatic infection is more likely to reflect the true biomass of circulating parasites in 
the community (Malisa et al., 2010). Sampling only at health facilities where participants 
are symptomatic is likely to overestimate resistance levels since patients may have had 
prior treatment, which would have selected for resistant parasites (Malisa et al., 2010). 
Alker et al., (2008) suggested the collection of some clinical data to support the use of 
molecular markers when monitoring drug resistance. These clinical measures could 
include parasite density among study participants who test positive for P. falciparum.  
 
The results presented in this thesis provided evidence for important differences in the 
genetic basis of SP resistance between West Africa and East Africa. High dhps GE 
frequencies occur in East Africa and not in West Africa. However, there was no evidence 
of regional differences associated with phenotypic outcome after adjusting for dhps GE 
using matched studies for each of these measures. There was consistent evidence that 
dhps GE was negatively correlated with treatment success and positively correlated with 
SP resistance. 
 
To examine the implications of this for SP efficacy and monitoring dhps GE in the present 
day a subset of surveys carried out since 2004 were selected to extrapolate SP phenotypic 
outcome from dhps GE. The predicted in vivo efficacy for each survey site was calculated 
using the equation described in section 5.6 of chapter 5. These were used to explore the 
contemporary in vivo treatment failure rates in all sites where recent measures of dhps GE 
had been recorded.  
 
As indicated in chapter 5 the WHO (2005) defined four milestones for clinical failures 
leading to a change in drug policy in high transmission areas: 0 to 4% treatment failures 
indicated a grace period, 5 to14% failures indicated an alert period, 15 to 24% treatment 
failures indicated the action period and any treatment failures ≥25% required a change in 
the drug policy. The predicted failure rates are mapped in Figure 6.1, showing sites that 
had dhps GE frequencies between 15%-24% and 25%-100%. Notably no sites fell into the 
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0-4% and 5%-14% treatment failure categories, which indicate the grace and alert periods 
respectively, for monitoring SP efficacy (WHO, 2005). 
 
 
Figure 6.1 Map of predicted SP failure rates (%) between 2004 and 2008 according to 
recent measures of dhps GE frequencies. The brown circles indicate the action phase and 
red circles indicate the need for a treatment policy change based on WHO (2005) 
recommendations.  
 
Twenty two countries had predicted in vivo treatment failures between 15%-24% which 
were defined as the action period for monitoring efficacy (WHO, 2005).  These were the 
Southwest (Angola, Democratic Republic of Congo (west), Gabon, Namibia, Republic of 
Congo), West (Benin, Burkina Faso, Gambia, Ghana, Guinea, Ivory Coast, Niger, Nigeria, 
Senegal) Central (Cameroon, Central African Republic), Southeast (Mozambique, 
Swaziland, Tanzania) and the Islands (Comoros, Madagascar, Sao Tome/Principe).  
 
Higher SP failure rates of ≥25% were predicted by dhps GE in nine East African countries 
only. These were Democratic Republic of Congo (east), Ethiopia, Kenya, Malawi, 
234 
 
Mozambique, Rwanda, Tanzania, Uganda and Zambia (Figure 6.1). These sites would 
require a change in treatment policy (WHO, 2005). Based on the WHO (2005) grading 
system and predicted in vivo treatment failures using the dhps GE double mutant, more 
sites in East Africa required a change in drug policy from SP to ACTs.  
 
A  clear theme in this work is that there is regional variability in the pattern of dhps 
genotypes in sub-Saharan Africa which provides evidence to support the view that there 
should be different drug policies for different regions, which would be driven by the local 
malaria epidemiology as described by WHO (2012) and illustrated in Figure 1.1. The WHO 
guidelines should specify methods for measuring molecular markers of resistance as these 
markers become available, to confirm treatment failures in its guidelines for monitoring 
drug efficacy. These should be used to guide global malaria control efforts and should also 
advocate for malaria control based on regional groupings of countries with similar malaria 
epidemiology. Talisuna et al., (2012) drew attention to the lack of systematic surveillance 
of antimalarial drug resistance in Africa since ACTs were adopted in Africa. The authors 
advocated for regional malaria surveillance activities in Africa and recommended that they 
be coordinated by a central body with a regional institutional centre so that regional 
ownership is maintained (Talisuna et al., 2012). These activities would include a strong 
emphasis on data quality and data standardisation.  
 
While it is uncertain whether or not the pattern of spread of artemisinin resistance will 
follow that of chloroquine and SP resistance, the global plan for artemisinin resistance 
containment advocates customising the monitoring guidelines to regional requirements 
(WHO, 2011b). It then becomes necessary to define these regional groupings and there is 
utility in categorising malaria endemic countries in sub-Saharan Africa not only according 
to similar malaria transmission intensities but also according to antimalarial drug 
resistance profiles. Interestingly there is a link between the malaria surveillance networks 
in Africa and migration and antimalarial resistance dispersal patterns (Talisuna et al., 
2012). Malaria migration as described in Tatem et al., (2010) and dispersal of drug 
resistance as described in Pearce et al., (2003) have similar regional patterns which are 
also reflected in the regional malaria surveillance networks. For example the participating 
countries in the East African Network for Monitoring Antimalarial Treatment (EANMAT) 
were Burundi, Kenya, Rwanda, Tanzania and Uganda. Pearce et al., (2003) found that the 
dhps SGE1 haplotype was distinct to Tanzania, Kenya and Uganda whilst Tatem et al., 
(2010) showed that these five countries represent common migration communities.  
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Limitations  
 
The scope of this thesis required a comprehensive dataset with maximal geographic 
coverage which could only be sourced from summarised estimates of molecular markers 
and SP in vivo efficacy studies in published studies. Thus this is an ecological study which 
uses aggregate measures to make inferences about groups of people rather than 
individuals (Morgenstern, 1995). The sourcing of data from primarily published studies 
introduces the risk of publication bias towards positive results as mentioned in Picot et al., 
2009. However, the SP resistance data collected in this thesis did cover a 20 year period 
which provided sufficient evidence to draw conclusions about its historical distribution over 
time and space.  
 
Although Basco and Ringwald (2000) recommended that standardised methods be applied 
when monitoring antimalarial drug resistance, this thesis demonstrated a wide variation in 
the application of WHO protocols for SP in vivo efficacy studies. This confirms that 
investigators often deviate from the prescribed inclusion and exclusion criteria based on 
their study rationale (Sibley and Price, 2012). Furthermore, as mentioned in chapter 2 it is 
likely that investigators will continue to use varying study designs (Price et al., 2007) and 
any attempts at consolidating the results of these studies in a pooled analyses will always 
have this limitation.  
 
Given the variation in adherence to WHO protocols for in vivo efficacy testing as well as 
the issues related to reporting prevalence or frequencies of molecular markers, strict 
inclusion criteria for studies that used standardised follow-up periods, similar outcome 
measures and study populations would have limited the number of studies available for 
analyses in this thesis. Shah et al., (2011) also used summary estimates of in vivo 
chloroquine resistance and opted not to use a meta-analysis framework, choosing instead 
a systematic review process to select studies that would describe overall trends for 
chloroquine resistance dispersal in India. The criteria applied in the meta-analysis 
conducted by Picot et al., (2009) gathered studies over a 10 year period to correlate 
molecular markers and treatment efficacy but this effectively restricted their analyses over 
time and space. Sridaran et al., (2010) noted the challenge in comparing different 
molecular studies for dhfr and dhps in the absence of standardised methods for measuring 
and reporting different mutants and very few studies became eligible for inclusion in their 
meta-analysis. As discussed in chapter 2, a balance has to be sought between adhering to 
the criteria for systematic reviews and collating sufficient data that will allow meaningful 
analyses to answer specific research questions, in the absence of individual patient data.  
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In this study SP in vivo efficacy data were matched with molecular measures of resistance 
to assess if there was any correlation between these two measures or not. The method for 
matching these studies was based on nearest neighbours and closest study year. Ideally 
the treatment outcome of each patient together with individual patient molecular data 
should be directly measured at the time of sampling, alleviating the need to develop a 
method for matching them at a later stage. Picot et al., (2009) provided a checklist for the 
design of future studies on molecular markers and advised that clinical and molecular 
measures be linked to each study participant. 
 
Thus, with secondary data collection data quality and availability are important 
considerations which dictate the analytical plan. There are several reasons for the 
analytical approach used in this thesis: (1) the variation in in vivo efficacy study protocols 
and outcomes, (2) the variations related to prevalence and frequency of molecular markers 
and accounting for mixed infections (3) availability of point mutation data versus allelic 
haplotype data and (4) the data gap analysis showing countries where no resistance data 
were found, represents a result itself but these data gaps also presents challenges when 
making inferences about these data as they represent missing data. In addition to these 
data gaps some studies had to be excluded on the basis of insufficient details. For 
instance an important variable such as missing study years despite efforts to obtain them 
rendered some studies unusable. 
 
The variability in the data available for each country is another limitation. Some countries 
such as those grouped together in the Southeast region had good coverage of data across 
the 20 year study period whereas other countries had limited data with gaps in the 
temporal sequence (see Tables 3.4a, 3.4b, 4.4 and 4.5). This variability of data among 
countries leads to confounding, which was mitigated by identifying each country as a 
cluster in the multivariable analysis.  Ideally both ecologic studies and individual patient 
data would be used to develop models of SP resistance over space and time. Within these 
data constraints and with the aim of providing insights that would be useful for decision 
makers, a conservative analysis plan was developed using multivariable regression.  
 
The basic elements of epidemiology are person, place, time (Moore and Carpenter, 1999) 
and this thesis mapped SP resistance rates but did not attempt to develop spatially explicit 
models predicting its distribution where no data exist nor did it forecast future trends over 
time. The ecological analyses are useful for generating new hypothesis for further work, 
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possibly using sophisticated statistical methods such as Bayesian analysis. These and 
other ideas for future work are discussed next. 
 
Future work 
 
Particular attention should be paid to monitor and gather data on emerging resistance 
markers such as dhfr 164L and dhps 581G. Monitoring the emergence of dhfr 164L in new 
hotspots and tracking its spread across foci are important due to its association with 
pyrimethamine resistance when found together with the dhfr triple mutant.  When dhps 
581G is found with the dhps GE double mutant and the dhfr triple mutant, it is an important 
resistance marker. Although there is good coverage of dhps 437G and 540E, additional 
longitudinal studies of these together with the quintuple mutant are required, given their 
predictive value for SP efficacy.  
 
The spatial predictions using methods such as Bayesian models mentioned above would 
have resulted in smooth mapped outputs where every data gap would be filled. These 
spatial models would need to be structured to account for spatial uncertainties in the data 
such as autocorrelation and be validated using appropriate methodologies, as outlined by 
Brooker (2007). Furthermore uncertainties in the data and the models generated from 
them require careful consideration if the goal is to develop spatially explicit models that 
have practical significance for malaria control activities (Brooker, 2007).  
 
In this study the primary goal was to compile the large literature of in vivo and molecular 
measures of SP resistance in sub-Saharan Africa in a geographical and temporal 
framework. The duration of follow-up and use of PCR genotyping were used as selection 
criteria for extracting SPR phenotype studies which were then matched with genotype 
studies. Thus, phenotype and genotype data were not linked and needed to be matched 
using their nearest geographic location and study year. Two covariates representing time 
and geography were factored into the models to track SPR emergence and spread. Other 
data were also collected such as patient’s age, malaria endemicity, malaria seasonality 
and country drug policy. These additional data were collected with the possibility of using 
these as covariates for future work outside the scope of this thesis, once their coverage 
and consistency are assessed. 
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Selected factors contributing to the development of antimalarial drug resistance were 
discussed in chapter 1 and advanced models could incorporate the following covariates:  
 
(1) population density in sub-Saharan Africa (2) drug use data as described by Frosch et 
al., (2011) who assessed the level of chloroquine use and chloroquine resistance. The 
question that could be posed is whether or not drug use accounts for the regional 
differences among dhps GE and GK allelic haplotypes, (3) age as a surrogate for acquired 
immunity and a risk factor for treatment failure, (4) transmission intensity reflecting the 
parasite biomass in communities, (5) treatment failures attributed to HIV infection rather 
than antimalarial drug resistance and the use of trimethoprim sulphamethoxazole which 
has a similar mode of action to SP (Laufer and Plowe, 2004) and (6) migration 
communities that are linked by high levels of malaria infection movements e.g. Nigeria 
which represent a problem for containing the spread of resistance (Tatem and Smith, 
2010; Lynch and Roper, 2011).  
 
In Chapter 2, the different WHO protocols for collecting clinical data were described and 
children under five years of age were highlighted as a vulnerable group for unsatisfactory 
treatment response, even in areas with acquired immunity (WHO, 2002). Whilst young age 
is a risk factor for SP phenotypic failure, age seems to be less important in areas of high 
genotypic resistance for example where the five dhfr and dhps mutations occur together 
(Talisuna et al., 2004b, Staedke et al., 2004). Against this high genotypic resistance 
backdrop the phenotypic failure risk is the same regardless of age group (Talisuna et al., 
2004b) and a possible explanation for this observation is that with increasing parasite 
resistance, the relative role of host immunity becomes less significant. Furthermore, few 
studies have directly accounted for age in genotyping studies (Staedke et al., 2004). 
Complete data linking phenotypic outcome with genotypic outcome, stratified by age would 
be valuable in assessing age as an explanatory variable for the spread of antimalarial drug 
resistance in future models. Age could be accounted for using an age structured 
population based model as in Pongtavornpinyo et al., (2008).   
 
Similarly transmission intensity as discussed in chapter 1, could be factored in as a 
covariate using the transmission intensity model described in Gething et al., (2011). Other 
workers have modelled different severities of P. falciparum phenotypic malaria outcomes 
across all transmission intensities in sub-Saharan Africa (Carneiro et al., 2010). Carneiro 
et al., (2010) found that younger age groups were associated higher malaria burdens in 
areas of increasing transmission intensity.   
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The link between human movement and transport of antimalarial resistance warrants 
some discussion here as it was mentioned previously in chapters 1, 3 and 4.  
 
Migration plays a central role in the regional dispersal of drug resistant malaria. Circulating 
SP drug resistant lineages reflects communities that are connected by high levels of 
migration (Lynch and Roper, 2011). As shown in this thesis, resistance alleles circulate 
regionally and the qualitative characteristics of resistance are regionally similar whilst 
quantitative variability in resistance levels can occur, presumably because of variable drug 
pressure within each region. Some patterns are evident when migration communities are 
mapped together with resistance markers (Figure 6.2). 
 
The distribution of the dhps GE double mutant indicates significant migration among 
countries in Southeast Africa including Malawi, Tanzania, Mozambique Swaziland and 
South Africa and separately among the Southwestern countries of Namibia and Angola 
(Figure 6.2). The path of resistance dispersal as reflected by migration communities has 
significant implications for the dispersal of artemisinin resistance and the tiered approach 
recommended for different regions (continental) by WHO for resistance containment 
(WHO, 2011b). There is a need to establish guidelines for best practices for malaria 
control along border areas in migrant populations (Lynch and Roper, 2011) as is the case 
in Asia (Shah et al., 2011).  
 
The influence of human migration on the transport of antimalarial drug resistance between 
island populations and the mainland is worth investigating. Notably the island populations 
are different with different drug resistance markers occurring there. These differences are 
apparent even among islands that are situated in close proximity to each other (Menard et 
al., 2007). In Madagascar the dhfr 164L point mutation was found among a unique 
combination of point mutations that have not been reported in mainland Africa to date 
(Andriantsoanirina et al., 2009, Naidoo and Roper, 2011). The dhfr IRN triple mutant 
decreased among the island populations, although it was observed to have reached 
fixation in mainland Africa. The dhps point mutations have evolved independently among 
the Island regions. The presence of dhfr and dhps point mutations among the islands 
albeit at low prevalence, illustrates the role that migration must play in resistance dispersal 
rather than mosquito mediated dispersal. The latter is unlikely given the distance a 
mosquito would need to travel between the islands and the mainlands (Salgueiro et al., 
2010). Furthermore migration of people between the islands and mainlands is less 
frequent than the movement among the regions and resistance dispersal is consequently 
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stochastic (Naidoo and Roper, 2011). Further work is required to assess the contribution of 
migration to the regional dispersal of drug resistance lineages. 
 
 
 
Figure 6.2 Migration communities in sub-Saharan Africa with dhps allelic haplotypes. The 
migration communities are taken from Tatem and Smith (2010).  
 
Surveillance of SP for IPT should be carried out routinely and these data assessed to see 
if there are any shifts in the regional patterns observed in this thesis, particularly where 
there are gaps in the data and in regions where there is no clear trend in the prevalence of 
resistance. According to Cairns et al., (2012) the high levels of SP resistance in Southern 
and Eastern Africa as demonstrated in Naidoo and Roper (2012) provided evidence that a 
replacement for the SP plus amodiaquine combination is needed for SMC in these 
regions. The SP plus amodiaquine combination remains suitable for SMC in West Africa 
but requires close monitoring. Molecular markers such the dhps GE double mutant and 
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dhps GK single mutant could be useful indicators of waning SP efficacy for IPT, but the 
thresholds of these allelic haplotypes related to IPT efficacy needs to be assessed.  
As Sibley and Price (2012) point out, once resistance foci are identified the main questions 
are whether or not it has arisen or spread to other hotspots or foci and what the routes of 
resistance dispersal are. Talisuna et al., (2012) also stated that empirical analyses of risk 
factors associated with the spatial emergence of resistance to chloroquine and SP would 
be useful.  
 
This thesis attempted to answer these questions for SP resistance using retrospective 
data and several issues bear reference when reflecting on artemisinin resistance 
containment.  
 
Efforts to collate artemisinin efficacy data from individual patients to pool them for analyses 
at different geographic scales should be supported by national malaria control 
programmes. Myint et al., (2004) observed an improvement in the quality of antimalarial 
drug trials in recent years which gave rise to better data on the newer artemisinin derivates 
compared to the data available for established drugs such as SP. Adherence to 
standardised methods of measuring tolerance/resistance as well as reporting results 
should continue to be encouraged through platforms like the WWARN initiative. Good 
quality spatially referenced antimalarial efficacy data are crucial especially if they are to be 
used to establish baseline levels of artemisinin resistance to inform decisions at small 
scales such as village or district levels, to identify hot spots and foci of resistance and to 
delineate buffer zones for artemisinin resistance containment especially at border posts 
and at the fringes of endemic malaria areas. These data can also be used to track the 
emergence and spread of artemisinin resistance over time across both small (village and 
district level) and large (country, regional) geographic scales. Such data can then be used 
to establish if there are any distinct regional patterns related to SP resistance and to 
support the recommended regional efforts to contain resistance dispersal. 
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Appendix 1 Proforma 
 
SECTION 1: DATA REFERENCE 
ADMINISTRATIVE INFORMATION 
Date data transcribed (dd/mm/yyyy)   -   -     
  
Data transcribed  
 
Data checked at co-ordinating centre
 
DATA REFERENCE 
Category of document                                                     
Journal  MOH report  
Book  Other report  
Thesis  Personal communication  
        
Language  
 
Reference source 
Authors  
 
 
 
Title  
 
Origin / 
J l
 
 
Journal Non-journal 
Volume  Issue no.  Total pages from  to  
Pages from  to  Specific 
pages 
from  to  
 
  
Report number    -     
Year of publication  
How many data points are there in this 
report? 
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SECTION 2: SURVEY LOCATION  Number 
2.1 Geographic location of survey 
 Name Code 
Country         
First level administrative unit (e.g. 
province) 
        
Second level administrative unit 
(e.g.district) 
        
Third level (e.g. area, division)         
Fourth level (e.g. location)         
Nearest large town         
Community level name (village, 
settlement) 
        
  
2.2 Survey location georeference 
N.B.  Latitude refers to North (+) or South (-) 
 Longitude refers to East (+) or West (-) 
Decimal degrees: 
Point Point name Latitude  
Degrees
+/- 
N/S
Longitude 
Degrees
+/- 
E/W
1  .  .  
2  .    
3  .    
4  .    
   or, 
Degrees and decimal minutes: 
Point Point name Latitude Longitude 
Deg Minutes +/-
N/S 
Deg Minutes +/-
E/W
1   .   .  
2   .   .  
3   .   .  
4   .   .  
     or, 
 Report number    -     
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Degrees, minutes and seconds: 
Point Point name Latitude Longitude 
Deg Min Sec +/-
N/S
Deg Min Sec +/-
E/W
1          
2          
3          
4          
 
Comments:  2.3 Is the survey location a: 
Is the survey location a:  
Point  Polygon  Multiple points (with pooled 
results) 
 Administrative unit  
 
2.4 How did you georeference? 
 
Africa Data Sampler  Scanned topographic map  
Africa Data Sampler  Topographic map, manually  
Census  MARA Prevalence  
Geoname  Google Earth  
Geonet  GPS  
Health Map  Encarta  
Other digital map  Other (specify):   
Co-ordinates given in report  
 
2.5 Climatological and geographical data 
Is a graph, map or table available (of area, rainfall, temperature, disease 
profile, seasonal abundance of infection or vectors, etc.)? 
Yes No 
 
 
 
 
 
If a topographic map was used, indicate its scale (e.g. 1: 5 000)  
270 
 
 
 
2.6 General information on the survey area:  
Is malaria transmission in the area : Yes No Not stated 
    Epidemic/unstable/highland    
    Endemic/stable    
    Seasonal    
Are the population studied refugees or displaced 
persons? 
   
Is rice grown in the area?    
Is there an irrigation scheme?    
Is there a swamp/wetlands/dam etc. close by?    
 
Is the area : Urban  Peri-urban  Rural  Not stated  
 
Information on country drug policy or drug 
resistance 
 
 
 
     Comments: 
  
Estimated contemporary  
entomological inoculation 
rate 
EIR Year 
estimated
EIR Comments     
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ANTIMALARIAL DRUG RESISTANCE 
 
5.1 INSTITUTION RESPONSIBLE FOR REPORT: 
 
Ministry of Health  Non-government 
organization (NGO) 
 
Government Med 
Research Inst 
 WHO  
Other  University  
                If other, specify: 
 
 
 
STUDY METHODOLOGY: 
  
 Type of Report and Study Design: 
   
Study Design 
Data point number    -     -      
Case report of treatment failure  Case report of prophylaxis failure  
Case series of treatment failure  Case series of prophylaxis failure  
Field trial of prophylaxis  In vitro efficacy study  
In vivo efficacy study  Other 
Intermittent preventive treatment 
(IPT) in pregnant women 
 
Case series  Randomised   
Comparative  Randomised  controlled trial open label  
Cross-sectional  Randomised controlled trial  
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Drugs studied in this report:   
Drug name Dosage (mg/kg) Drug name Dosage 
(mg/kg) 
Chloroquine  Quinine  
Sulphadoxine/Pyrimethamine  Mefloquine  
Amodiaquine  Halofantrine  
Artesunate    
Other drug or Drug 
Combination or Dosage 
(specify name(s) and 
dosage) 
 
If dosage by age group or weight, specify age range or weight and dose: 
 
Copy of report on file? Yes  No  
Study Methodology described? Yes  No  
Study Protocol provided? Yes  No  
 
Follow-up days (check all days patients were to be seen - Day 0 = initial day of enrolment): 
 
    Day   Day   Day Day Day Day 
0            
1  8  15  22      
2  9  16  23      
3  10  17  24      
4  11  18  25      
5  12  19  26      
Case-control  Randomised controlled trial double blind  
Other  
All doses observed or given by study staff? Yes  No  Not stated  
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6  13  20  27      
7  14  21  28      
If specific days for any week of follow-up not provided, mark below 
Week1  Week 2  Week 3  Week 4  Week 5  Week 6  
Definitions of treatment success and failure used: 
 WHO Protocol  
Tick if Standard 
WHO Protocol 
(stated in report)  
 
 WHO 
(1973
) 
  
 
WHO 
(199
6) 
  
WHO 
(200
1) 
 Specify if other 
protocol stated 
in report 
 
 
Definition of Parasitologic Response: 
Standard (S)/RI/RII/RIII Yes  No  
RI (late) Yes  No  
If yes, RI (late) defined as:  
 
 
 
 
RI (early) Yes  No  
If yes, RI (early) defined as: 
 
 
 
 
 
Other definitions used for parasite response (specify): 
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Describe any deviations from the WHO standard protocol for parasitological response: 
 
 
 
 
 
 
Definitions of Therapeutic Response:  
Standard WHO (1996) ETF/LTF/ACR Yes  No  
Standard WHO (2001) 
ETF/LCF/LPF/ACPR 
Yes  No  
Other definitions for clinical response (specify): 
 
 
 
Describe any deviations from the WHO protocol for therapeutic response: 
 
 
Adverse event outcomes 
recorded 
Yes  No  
If yes, describe adverse event 
outcomes  
 
 
 
 
 
 INCLUSION CRITERIA: 
Age Ranges 
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Under 5 years  All ages  
School Aged  Not specified  
Adults  Other age range  
Pregnant women    
Specific age range given 
(specify months or years) 
 
Min  Max  
Parasite Information Species   
       
 
 
 
Method used to determine parasite count 
 
Expressed as asexual parasites/μL  Yes  No  
Minimum parasite count  
Maximum parasite count  
     
Expressed as + system  Yes  No  
1-10 parasites per 100 thick film fields  +  
11-100 parasites per 100 thick film fields ++  
1-10 parasites per single thick film field +++  
> 10 parasites per single thick film field  ++++  
 
Describe if other method 
used: 
 
Minimum parasite count  
Maximum parasite count  
P.falciparum  P.ovale  P.vivax  
Mixed  P.malariae  
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Specify frequency of 
parasite smears 
 
 
 
 
 
History of fever? Yes  No  Not stated  
Measured fever? (°C) Min  
 
Max  Not stated  
Haemoglobin (g/dl) Min  
 
Max  Not stated 
Not used 
 
Haematocrit (%) Min  
 
Max  Not stated 
Not used 
 
Other inclusion criteria? Specify:  
 
 
EXCLUSION CRITERIA 
Previous treatment 
excluded? 
Yes  No  Not  
stated 
 Specify 
drug tested 
for  
 
Method of urinalysis, if 
used 
 
 
Pregnancy excluded? Yes  No  Not stated  
Not applicable  
Severe malaria 
excluded? 
Yes  No  Not stated  
Concurrent illness 
excluded? 
Yes  No  Not stated  
Hospitalised excluded? Yes  No  Not stated  
Anaemia excluded? Yes  No  Not stated  
Gametocyte response 
reported?  
Yes  No  
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 If yes, below what 
level? 
 
 
Other exclusion 
criteria? Specify: 
 
 
 
 
 
STUDY RESULTS 
A.  Study population characteristics: 
Beginning date (dd/mm/yyyy)   -   -     
Ending date (dd/mm/yyyy)   -   -     
 
 
Data point 
number 
   -     -      
Reported malaria 
transmission/ 
season 
Dry  Short 
Rains 
 
Rains  Long 
Rains 
 
Name of drug(s) tested  
Number enrolled  
Number completing 
study/evaluated at end of 
study? 
                 Follow-up 
days 
 
Age ranged of 
enrolled?(specify years or 
months) 
Min  Max  Not stated  
Mean age of enrolled(specify 
years or months) 
 SD  Not stated  
Mean weight (kg)  SD    
Gender (%) M  F  Not stated  
278 
 
Parasite density 
at enrolment? 
Geometric 
mean 
 SD  Range  Not 
stated 
 
Haemoglobin 
(g/dl) at 
enrolment  
Mean  SD  Range  Not 
stated 
 
Haematocrit 
(%)at enrolment 
Mean  SD  Range  Not  
stated 
 
Gametocytaemia 
(μL) at enrolment 
Mean   SD  Range  Not 
stated 
 
 
Parasite clearance time (specify days or 
hours) 
 Mean  SD  
Fever clearance time (specify days or 
hours) 
 Mean  SD  
Parasite reduction ratio at 48 hours  Mean  SD  
Describe haematologic results: 
 
 
 
 
Type of analyses 
 
 
 
 
 
 
 
 
 
 
Intention to treat  
Per protocol   
Survival analysis Kaplan-Meier  
Other 
Were results corrected by PCR genotyping? Yes  No  
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PCR Genotyping:  
Markers used 
  msp 
1 
msp 2 msp 1 and msp 
2  
msp 1, msp 2 & 
glurp 
msp 1, msp 2 & 
others 
Not 
reported 
      
Definition of recrudescence: 
Interpretation of mixed results: 
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Parasitologic Results: 
Standard WHO categories (as reported) –  specify if other combined results reported 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Response Follow-up days Number % Resistance  
Profile 
Sensitive 
 
    
    
RI      
    
RII 
 
    
    
RIII  
 
    
    
RI + RII 
 
    
    
RII + RIII 
 
    
    
RI + RII + RIII 
 
    
    
If other definitions used, specify results: 
 
 
281 
 
Therapeutic Response:  
Standard WHO categories (as reported): 
 
 
 
 
 
 
 
 
Respons
e 
Follow
-up  
days 
Response Recrudescenc
e 
 
New 
Infection 
Unresolve
d 
 
95% 
CI 
 
Resistanc
e  
Profile No. % No.    % No. % No. % 
ETF            
           
LTF             
           
LCF             
           
LPF             
           
ACR:             
           
ACPR:             
           
Cure            
Total/Glo
bal 
failure 
rate  
           
Describe results for adverse events: 
Describe if other definitions used: 
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MOLECULAR MARKERS 
ADMINISTRATIVE INFORMATION: 
 Country: 
Country  
Beginning date (mm/yyyy)   -     
Ending date (mm/yyyy)   -     
Comments if author(s) contacted  
 
 Survey Site:  
Survey Site Name  
Beginning date (mm/yyyy)   -     
Ending date (mm/yyyy)   -     
Comments if author(s) contacted  
 
 
 
 
 
 
 
 
 
 
 
 
Data point 
number 
   -     -      
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DHFR                                                                                                                                                
Method by which mutations looked for 
 
 
 
 
 
 
 
                                      Method    Reference 
A Sequencing (looks for everything)  
B Dot blotting  
Pearce et al., AAC 2003 
Abdel-Muhsin et al., AJTMH 2002 
Alifrangis et al., AJTMH 2005 
( all same probe seqs) 
 
C PCR-RFLP  
Duraisingh et al., Exp. Parasitol. 1998  
 
D PCR Specific Amplification  
Plowe et al., AJTMH 1995 
Doumbo et al., JID 2000 
 (this method assumes seq for wt codon 50 in their primer 
for 51) 
 
E Mass Spectrometry  
Marks et al., AAC  2004 
 
F SNP Typing by Primer Extension  
Nair et al., Int J. Parasitol 2002 
Marks et al., AAC 2005 
 
G Other  
H Indicate if more than one method used  
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HAPLOTYPE COUNT (TOTAL N):  
 
 
 
 
 
 
Codon 
w/t 
16A 50C 51N 59C 108S 140V 164I Other 
Mutati
ons/  
Notes 
Looke
d at?  
(Tick 
yes 
/no) 
YES  YE
S 
 YE
S 
 YES  YES  YE
S 
 YE
S 
 YE
S 
 
NO  NO  NO  NO  NO  NO  NO  NO  
What 
was  
found
? 
A(GCA) C(TGT) N(AAT) C(TGT) S(AGC) V(GTT) I(ATA)  
S(TCA) R(CGT) N(AAC) R(CGT) N(AAC) L(CTT) L(TTA)  
V(GTA)  I(ATT) Y (TAT) T(ACC)    
 
Preval
ence 
 N N 
Tot 
 N N  
Tot 
 N N 
Tot 
 N N 
Tot 
 N N 
Tot 
 N N  
Tot 
 N N 
Tot 
Other 
A   C   N   C   S   V   I    
S   R   N   R   N   L   L    
V    I    T      
Can haplotypes be deduced? :     YES            NO  
Haplotypes Identified 
Count  16 50 51 59 108 140 164 Other  
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 DHPS: 
Method by which mutations looked for: 
 
 
 
 
 
 
 
 
 
 
                                      
                                            Method 
 
  
         Reference 
 
A Sequencing (looks for everything)  
B Dot blotting Pearce et al., AAC 2003 
Alifrangis et al., AJTMH 2005 
 
C PCR-RFLP  
Duraisingh et al., Exp. Parasitol. 1998 
 
D PCR Specific Amplification  
Plowe et al., JID 1997 
 
E Mass Spectrometry  
Marks et al., AAC  2004 
 
F SNP Typing by Primer SNP typing by primer 
extension 
Nair et al., Int J. Parasitol 2002 
Marks et al., AAC 2005 
 
G Other  
H Indicate if more than one method used  
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Codon 
w/t 
436S 437A 540K 581A 613A Other 
Mutations/   
Notes 
Looked at?  
(Tick yes /no) 
YES  YES  YES  YE
S  
 YE
S 
 YES  
NO  NO  NO  NO  NO  NO  
What was 
found? 
S(TCT) A(GCT) K(AAA) A(GCG) A(GCC)  
F(TTT) G(GGT) E(GAA) G(GGG) S(TCC)  
A(GCT)    T(ACC)  
C(TGT)      
 
Can haplotypes be deduced? :    YES            NO  
Haplotypes Identified 
Count  436S 437A 540K 581A 613A Other   
       
       
 
HAPLOTYPE COUNT (TOTAL N):       
 
 
 
 
 
 
 
 
Prevalence 
 N N 
Tot 
 N N 
Tot 
 N N 
Tot 
 N N 
Tot 
 N N  
Tot 
Other 
S   A   K   A   A    
F   G   E   G   S    
A        T    
C            
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Appendix 12 Suitable and matched in vivo studies 
 
There were 53 suitable in vivo studies and of these 38 were matched with molecular 
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East   
Country in vivo site 
Study period 
Reference 
Longitud
e 
Latitude Demographic 
information 
Follow -
up days 
dhfr IRN site 
study period  
Reference 
dhfr NCS site 
study period  
Reference 
Democratic  
Republic  
of  
Congo 
Kabalo 
2004  
Bonnet et 
al.,2009 
 
26.91708 -6.05011 8 months-96 
months 
28 Shabunda, 330 km 
north of Kabalo 
2004 
Swarthout et al., 2006 
 
Shabunda, 330 km 
north of Kabalo 
2004 
Swarthout et al., 2006 
 
Kenya Mbita 
2003-2004  
Bousema et 
al.,2006  
 
34.23986 -0.0004 2 years – 5.3 
years 
28 
 
Kakamega, 35 km east 
of Mbita; Kombewa, 28 
km east of 
2005 
Zhong et al., 2008 
Kombewa, 28 km east 
of 
2005 
Zhong et al., 2008 
Kenya Siaya 
2002-2004  
Shah et al.,2006  
 
34.286 0.06 Adults -  
median 31 
years 
28 Kisumu, 51 km east of 
Siaya 
2002  
Hamel et al.,2008 
Two villages in Kisii 
District 
1998 
Mita et al., 2009 
Malawi Chileka 
2003-2005  
Bell et al., 2008 
 
34.43509 -
15.97416 
12 months – 
60 months 
42 Blantyre, 57.5 km north 
east of Chileka 
2005 
Nkhoma et al.,2007 
 
Salima District, 220 km 
north of Chileka 
2000 
Bwijo et al.,2003 
 
Mozambique  Maputo 
Province 
(Catuane, 
Namaache, 
Boane, Magude) 
2003-2005  
Allen et al., 
2009 
32.58916
6 
-
25.96527
7 
5 years – 22 
years 
42 Maputo 
2003 
Raman et al., 2008 
Maputo 
2004 
Fernandes et al., 2007 
Appendix 13 Matched studies: SP in vivo studies with dhfr IRN and NCS 
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North Sudan New Halfa 
(Elhara Elrula) 
2001-2002  
Adam et al., 
2004 
 
35.583 15.333 1 year – 14 
years 
28 Daraweesh and Kajara 
,130 km south of New 
Halfa 
2003 
A-elbasit et al. ,2007 
Daraweesh and Kajara 
,130 km south of New 
Halfa 
2003 
A-elbasit et al. ,2007 
North Sudan New Halfa 
(Alhara Aloula) 
2004  
Adam et al., 
2005 
 
35.583 15.3333 Mean 12.8 
years 
28 Ngorban country, 610 
km southwest of New 
Halfa 
2003 
Hamour et al.,2005; 
Yusuf et al.,2010 
Ngorban country, 610 
km southwest of New 
Halfa 
2003 
Hamour et al.,2005; 
Yusuf et al.,2010 
North Sudan Daraweesh and 
Kajara 
2003  
A-elbasit et al., 
2008 
 
35.37 14.0 Not stated 28 Daraweesh and Kajara 
Eastern Sudan 
2003 
A-elbasit et al. ,2007 
Daraweesh and Kajara 
Eastern Sudan, 
 2003 
A-elbasit et al. ,2007 
South Africa  Mosvold 
Hospital 
1996 
Freese et al., 
1996 
 
32.00527 -
27.13678 
23.8 years 28 Ingwavuma (Mosvold 
and Ndumu) 
1996 
Roper et al., 2003 
Ingwavuma (Mosvold 
and Ndumu) 
1996 
Roper et al., 2003 
South Africa Mangweni Clinic 
2002  
Mabuza et al., 
2005 
 
31.82 -25.74 2 years and 
above 
42 Mpumalanga 
2000, 2002 
Barnes et al.,2008 
 
No match 
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South Africa Naas 
1998, 
2000, 
2002  
Barnes et al., 
2008 
 
31.86 -25.67 9 years - 28 
years; 10 
years – 23 
years; 11 
years – 28 
years 
42 Naas and Mangweni 
2000,2002 
Barnes et al.,2008 
 
No match 
South Sudan Kajo Keji 
2001-2002  
Stivanello et 
al.,2004 
 
31.667 3.883 6 months – 59 
months 
28 Akuem, Yargot Payam 
district Bahr El Gazal.  
Akuem is 710  
km northwest of Kajo 
Keji 
2002 
Anderson et al.,2003 
Akuem, Yargot Payam 
district Bahr El Gazal.  
Akuem is 710  
km northwest of Kajo 
Keji 
2002 
Anderson et al.,2003 
Tanzania Ipinda 
2003  
Mugittu et al., 
2005 
 
33.76491 -9.05015 6 months – 59 
months 
28 Mkokola and 
Kwamasimba, 670 km 
north east of Ipinda 
2003 
Alifrangis et al.,2009 
 
Masasi is 33 km  
northeast of Ipinda 
1997 
Mugittu et al.,2004 
Mkokola and 
Kwamasimba, 670 km 
north east of Ipinda 
2003 
Alifrangis et al.,2009 
 
Masasi is 33 km  
northeast of Ipinda 
1997 
Mugittu et al.,2004 
Tanzania Eukayosi, 
Bagamoyo 
2004 
Martensson et 
al., 2007 
 
38.81434
1 
-
6.107977 
6 months 42 Korogwe, 123 km north 
of Eukayosi 
2004 
Alifrangis et al.,2009 
 
Kibaha is 69 km south 
of Eukayosi 
1998  
Alifrangis et al.,2003 
Korogwe, 123 km north 
of Eukayosi 
2004 
Alifrangis et al.,2009 
 
Kibaha is 69 km south 
of Eukayosi 
1998  
Alifrangis et al.,2003 
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Tanzania Tindiga(Kilosa) 
2004  
Eriksen et al., 
2008 
 
37.002 -6.00258 6 months – 60 
months 
28 Chamwino, 120 km 
west of Tindiga 
2005 
Enevold et al.,2007 
Chamwino, 120 km 
west of Tindiga 
2005 
Enevold et al.,2007 
Tanzania Tanga  
2006  
Gesase et al., 
2009 
 
38.6 -5.283 Mean 31.1 
months 
28 Hale (Tanga Region) 32 
km north of Muheza  
2006 
Gesase et al., 2009 
 
Hale (Tanga Region) 32 
km north of Muheza  
2006 
Gesase et al., 2009 
 
Uganda Mbarara 
1999-2000  
Priotto et al., 
2003 
 
30.65 -0.62 6 months – 59 
months 
28 Mbarara, 79km 
southeast from 
Rukungiri 
2005-2008 
Lynch et al.,2008 
Mbarara, 79km 
southeast from 
Rukungiri 
2005-2008 
Lynch et al.,2008 
Uganda Bundi Bugyo 
2002  
Checci et al., 
2004 
 
30.07 0.7 6 months – 59 
months 
28 Rukingiri, 150 km south 
of Bundi bugyo 
2005 
Lynch et al.,2008 
 
Kampala,  279 km east 
of Bundi bugyo 
2000 
Kyabayinze et al.,2003 
Sendagire et al.,2005 
 
 
No match 
Uganda Mulago 
1999-2001  
Dorsey et al., 
2004 
 
32.58 0.35 6 months – 10 
years 
28 Kampala, 3 km south of 
Mulago 
2000 
Kyabayinze et al.,2003 
Sendagire et al.,2005 
Kampala, 3 km south of 
Mulago 
2000 
Kyabayinze et al.,2003 
Sendagire et al.,2005 
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Uganda Nagongera 
2001-2002  
Talisuna et al., 
2004 
 
34.02 0.77 6 months – 59 
months 
28 
 
 
Tororo 
Nagongera is 20km 
northeast from Tororo 
2003-2006 
Malamba et al.,2010 
No match 
Uganda Tororo 
2001-2002  
Talisuna et al., 
2004 
 
34.186 0.695 6 months – 59 
months 
28 Tororo 
2003-2006 
Malamba et al.,2010 
No match 
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West  
Country Site 
Study period 
Reference 
Longitud
e 
Latitude Demographic 
information 
Follow- up 
days 
dhfr IRN  
site 
study period  
Reference 
dhfr NCS 
Angola  Caala 
2002  
Guthmann et 
al.,2005    
15.558 -12.85 Mean age 26.4 
months 
28 Uige,  630 km 
north of Caala 
2004 
Menegon et al., 
2009 
Uige,  630 km 
north of Caala 
2004 
Menegon et al., 
2009 
Burkina Faso 
 
Ouagadougou 
2003  
Gansane et al., 
2009 
 
-1.01939 12.35886 6 months – 59 
months 
28 Nanoro, 85km 
from 
Ouagadougou 
2003 
Tinto et al., 2007 
 
Ziniare and  
Bousse are 19 km 
north of 
Ouagadougou 
2002 
Diallo et al., 2007 
 
Nanoro, 85km 
from 
Ouagadougou 
2003 
Tinto et al., 2007 
 
Ziniare and  
Bousse are 19 km 
north of 
Ouagadougou 
2002 
Diallo et al., 2007 
 
Cameroon  Mutengene 
(between  
Limbe and Tiko) 
2004-2006  
Mbacham et al. 
2010 
 
 
9.13403 4.00179 6 months – 59 
months 
28 Mutengene 
2004-2006 
Mbacham et al. 
2010 
 
 
Mutengene 
2004-2006 
Mbacham et al. 
2010 
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Chad 
 
Bongor 
2002  
Grandesso et 
al.,2006  
 
15.3711
6 
10.27591 6 months – 59 
months 
28 Maroua,  120km 
north west of 
Bongo 
2000 
Tahar and Basco 
2006 
Maroua,  120km 
north west of 
Bongo 
2000 
Tahar and Basco 
2006 
Democratic 
Republic of 
Congo 
 
Boende 
2003-2004  
Bonnet et 
al.,2009 
 
 
21.1310
2 
 
0.10117 6 months-59 
months 
28 Boende  
2003-2004 
Cohuet et al., 
2006 
 
Boende  
2003-2004 
Cohuet et al., 
2006 
 
Gabon Bakoumba 
2000  
Aubouy et al., 
2003  
 
12.3 -1.55 Mean 3.8 years 
Maximum 10 
years 
28 Bakoumba, Haut 
Ogooue Province 
Gabon 
2000 
Aubouy et 
al.,2003 
Bakoumba, Haut 
Ogooue Province 
Gabon 
2000 
Aubouy et 
al.,2003 
Gabon Lambarene 
2005-2006 
Oyakhirome et 
al., 2007    
10.212 -0.707 3 years- 14 
years 
28 Lambarene 
2005-2007 
Mombo-Ngoma et 
al., 2011 
 
Lambarene 
2005-2007 
Mombo-Ngoma et 
al., 2011 
 
Gabon Oyem 
2005  
Nsimba et al., 
2008 
 
11.5638 1.0183 6 months-59 
months 
28 Lambarene 
140km southwest 
of Oyem 
2005-2007 
Mombo-Ngoma et 
al., 2011 
 
Lambarene 
140km southwest 
of Oyem 
2005-2007 
Mombo-Ngoma et 
al., 2011 
 
Ghana Tamale 
2002  
Mockenhaupt et 
-0.834 9.4 6 months-59 
months 
28 Tamale 
2002 
Muehlen al.,2004 
Tamale 
2002 
Muehlen et al., 
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al., 2005   Mockenhaupt et 
al., 2005   
2004  
Mockenhaupt et 
al., 2005   
Ghana Navrongo 
2003  
Koram et al., 
2005  
-1.1 10.9 8 months-56 
months 
28 Tamale 150 km 
south of Navrongo 
2002 
Muehlen al.,2004 
Mockenhaupt et 
al., 2005   
Tamale 150 km 
south of Navrongo 
2002 
Muehlen al.,2004 
al.,2004 
Mockenhaupt et 
al., 2005   
Ghana Nkoranza 
2003-2004  
Tagbor et al., 
2007 
 
-1.03517 7.05108 Children under 5 
years 
28 Kintampo, Brong 
Ahafo Region,  < 
1 km south of 
Nkoranza 
2003  
Owusu-agyei et 
al.,2009 
Ashanti region, 
Bodomase 
2003  
Marks et al., 2005 
 
Madagascar Moramanga and 
Saharevo 
2006  
Menard et al., 
2007   
47.7779
1 
-
20.35941
5 
6 months – 12 
months 
28 12 sites 
2006 
Andriantsoanirina 
et al., 2009 
 
12 sites 
2006 
Andriantsoanirina 
et al., 2009 
 
Madagascar Ejeda 
2006-2007  
Menard et al., 
2008 
 
44.517 -24.35 6 months – 15 
years 
28 various sites 
2006 
Mernard et 
al.,2008 
various sites 
2006 
Mernard et 
al.,2008 
Mali Koumanto 
2003-2004  
de Radigues et 
al.,2006 
 
-
6.83333
3 
11.41666
6 
1 year – 3 years 28 Kolle, 160 km east 
of Koumanto 
2003 
Tekete et al.,2009 
 
Bougoula-
No match  
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Hameau, 200 km 
west of Koumanto 
2002 
Djimde et al., 
2008 
 
Mali Kolle 
2002 - 2003  
Tekete et al., 
2009 
 
-5.281 11.314 6 months – 59 
months 
28 Kolle 
2002 - 2003 
Tekete et al.,2009 
No match  
Republic of 
Congo 
Brazzaville 
(Bacongo) 
2003-2004  
Ndounga et al., 
2007 
 
15.224 -4.296 6 months – 67 
months 
28 Brazzaville(urban 
health centre of 
Tenrikyo in district 
of Makelekele) 
2003-2004 
Ndounga et 
al.,2007 
 
Brazzaville(urban 
health centre of 
Tenrikyo in district 
of Makelekele) 
2003-2004 
Ndounga et 
al.,2007 
 
Republic of 
Congo 
Makelekele  
2003-2004  
Ndounga et al., 
2007 
 
14.016 -3.09 6 months – 67 
months 
28 Brazzaville(urban 
health centre of 
Tenrikyo in district 
of Makelekele). 
Brazzaville is 180 
km southwest of 
Makelekele 
2003-2004 
Ndounga et 
al.,2007 
Brazzaville(urban 
health centre of 
Tenrikyo in district 
of Makelekele). 
Brazzaville is 180 
km southwest of 
Makelekele 
2006 
Mita et al.,2009 
Republic of 
Congo 
Mfilou and 
Makelekele 
health districts 
2003-2004  
11.88 -4.25 6 months – 67 
months 
28 Pointe Noire, 
Brazzaville and 
Gambona.  Pointe 
Noire is 170 km 
Pointe Noire, 
Brazzaville and 
Gambona.  Pointe 
Noire is 170 km 
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Ndounga et al., 
2007  
 
north east of 
Makelekele 
2006 
Mita et al.,2009 
north east of 
Makelekele 
2006 
Mita et al.,2009 
Sierra Leone Freetown 
2002-2003  
Checci et al., 
2005 
-13.25 8.5 6 months – 59 
months  
28 No match  No match  
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East  
Country in vivo site 
Study period 
Reference 
Longitud
e 
Latitude Demographic 
information 
Follow- 
up days 
dhps GE/GK/AK site 
study period  
Reference 
Democratic  
Republic  
of  
Congo 
Kabalo 
2004  
Bonnet et 
al.,2009 
 
26.91708 -6.05011 8 months-96 
months 
28 Shabunda, 330 km 
north of Kabalo 
2004 
Swarthout et al., 2006 
 
Kenya Mbita 
2003-2004  
Bousema et 
al.,2006  
 
34.23986 -0.0004 2 years – 5.3 
years 
28 
 
Kombewa, 28 km east 
of 
2005 
Zhong et al., 2008 
Kenya Siaya 
2002-2004  
Shah et al.,2006  
 
34.286 0.06 Adults -  
median 31 
years 
28 Kakamega, 32 km east 
of Siaya 
2005 
Zhong et al., 2008 
Malawi Chileka 
2003-2005  
Bell et al., 2008 
 
34.43509 -
15.97416 
12 months – 
60 months 
42 Blantyre, 57.5 km north 
east of Chileka 
2005 
Nkhoma et al.,2007 
Mozambique  Maputo 
Province 
(Catuane, 
Namaache, 
Boane, Magude) 
2003-2005  
Allen et al., 
2009 
 
32.58916
6 
-
25.96527
7 
5 years – 22 
years 
42 Maputo 
2003,2004 
Raman et al., 2008 
 
Maputo 
2004,2005 
Raman et al., 2010 
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North Sudan New Halfa 
(Elhara Elrula) 
2001-2002  
Adam et al., 
2004 
 
35.583 15.333 1 year – 14 
years 
28 Khartoum,  20km north 
of New Halfa 
1996-1997 
Khalil et al., 2005 
North Sudan New Halfa 
(Alhara Aloula) 
2004  
Adam et al., 
2005 
 
35.583 15.3333 Mean 12.8 
years 
28 Khartoum,  20km north 
of New Halfa 
1996-1997 
Khalil et al., 2005 
North Sudan Daraweesh and 
Kajara 
2003  
A-elbasit et al., 
2008 
 
35.37 14.0 Not stated 28 Daraweesh and Kajara  
2003 
A-elbasit et al. ,2007 
South Africa  Mosvold 
Hospital 
1996 
Freese et al., 
1996 
 
32.00527 -
27.13678 
23.8 years 28 Ingwavuma  
1995-1996 
Roper et al., 2003 
South Africa Mangweni Clinic 
2002  
Mabuza et al., 
2005 
 
31.82 -25.74 2 years and 
above 
42 Komatipoort 
2000 
Pearce et al., 2009 
 
South Africa Naas 
1998, 
2000, 
2002  
31.86 -25.67 9 years - 28 
years; 10 
years – 23 
years; 11 
42 Komatipoort 
2000 
Pearce et al., 2009 
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Barnes et al., 
2008 
 
years – 28 
years 
South Sudan Kajo Keji 
2001-2002  
Stivanello et 
al.,2004 
 
31.667 3.883 6 months – 59 
months 
28 Lankien, 500km north 
east of Kajo Keiji 
2001 
van den Broek et al., 
2003 
Tanzania Ipinda 
2003  
Mugittu et al., 
2005 
 
33.76491 -9.05015 6 months – 59 
months 
28 Masasi is 33 km  
northeast of Ipinda 
2000 
Mugittu et al.,2004 
Tanzania Eukayosi, 
Bagamoyo 
2004 
Martensson et 
al., 2007 
 
38.81434
1 
-
6.107977 
6 months 42 Korogwe, 123 km north 
of Eukayosi 
2004 
Alifrangis et al.,2009 
 
 
Tanzania Tindiga(Kilosa) 
2004  
Eriksen et al., 
2008 
 
37.002 -6.00258 6 months – 60 
months 
28 Chamwino, 120 km 
west of Tindiga 
2005 
Enevold et al.,2007 
Tanzania Tanga  
2006  
Gesase et al., 
2009 
 
38.6 -5.283 Mean 31.1 
months 
28 Korogwe, 33km 
northwest of Tanga 
2006 
Alifrangis et al.,2009 
 
Uganda Mbarara 
1999-2000  
Priotto et al., 
2003 
30.65 -0.62 6 months – 59 
months 
28 Mbarara, 79km 
southeast from 
Rukungiri 
2005-2008 
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 Lynch et al.,2008 
Uganda Bundi Bugyo 
2002  
Checci et al., 
2004 
 
30.07 0.7 6 months – 59 
months 
28 Kampala,  279 km east 
of Bundi bugyo 
2000-2001 
Kyabayinze et al.,2003 
Uganda Mulago 
1999-2001  
Dorsey et al., 
2004 
 
32.58 0.35 6 months – 10 
years 
28 Kampala, 3 km south of 
Mulago 
2000 
Sendagire et al.,2005 
 
Uganda Nagongera 
2001-2002  
Talisuna et al., 
2004 
 
34.02 0.77 6 months – 59 
months 
28 
 
 
Kampala, 160 km east 
of Nagongera 
2000-2001 
Kyabayinze et al.,2003 
Uganda Tororo 
2001-2002  
Talisuna et al., 
2004 
 
34.186 0.695 6 months – 59 
months 
28 Kampala, 175km west 
of Tororo  
2000-2001 
Kyabayinze et al.,2003 
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West 
Country Site 
Study period 
Reference 
Longitud
e 
Latitude Demographic 
information 
Follow- up 
days 
dhps GE/GK/AK 
site 
study period  
Reference 
Angola  Caala 
2002  
Guthmann et 
al.,2005    
15.558 -12.85 Mean age 26.4 
months 
28 Huambo is 16km 
north east of 
Caala 
2007 
Fortes et al., 2011 
Burkina Faso 
 
Ouagadougou 
2003  
Gansane et al., 
2009 
 
-1.01939 12.35886 6 months – 59 
months 
28 Nanoro, 85km 
from 
Ouagadougou 
2003 
Tinto et al., 2007 
Cameroon  Mutengene 
(between  
Limbe and Tiko) 
2004-2006  
Mbacham et al. 
2010 
 
 
9.13403 4.00179 6 months – 59 
months 
28 Mutengene 
2004-2006 
Mbacham et al. 
2010 
 
 
Chad 
 
Bongor 
2002  
15.3711
6 
10.27591 6 months – 59 
months 
28 Garoua,  210 
north west of 
403 
 
Grandesso et 
al.,2006  
 
Bongor; 
2004-2006 
Mbacham et al., 
2010 
Democratic 
Republic of 
Congo 
 
Boende 
2003-2004  
Bonnet et 
al.,2009 
 
 
21.1310
2 
 
0.10117 6 months-59 
months 
28 Boende  
2003-2004 
Cohuet et al., 
2006 
 
Gabon Bakoumba 
2000  
Aubouy et al., 
2003  
 
12.3 -1.55 Mean 3.8 years 
Maximum 10 
years 
28 Franceville, Haut-
Ogooue district in 
south east Gabon 
1998, 120km east 
of Bakoumba 
Mawili-mboumba 
et al., 2001 
Gabon Lambarene 
2005-2006 
Oyakhirome et 
al., 2007    
10.212 -0.707 3 years- 14 
years 
28 Lambarene 
2007 
Pearce et al., 
2009 
 
Gabon Oyem 
2005  
Nsimba et al., 
2008 
 
11.5638 1.0183 6 months-59 
months 
28 Lambarene, 
230km northwest  
from Oyem 
2007 
Pearce et al., 
2009 
 
Ghana Tamale 
2002  
Mockenhaupt et 
al., 2005   
-0.834 9.4 6 months-59 
months 
28 Navrongo,  150km 
south of Tamale  
2003 
Pearce et al., 
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2009 
Ghana Navrongo 
2003  
Koram et al., 
2005  
-1.1 10.9 8 months-56 
months 
28 Navrongo,  2003 
Pearce et al., 
2009 
Ghana Nkoranza 
2003-2004  
Tagbor et al., 
2007 
 
-1.03517 7.05108 Children under 5 
years 
28 Ashanti region, 
Bodomase 
2003  
Marks et al., 2005 
 
Madagascar Moramanga and 
Saharevo 
2006  
Menard et al., 
2007   
47.7779
1 
-
20.35941
5 
6 months – 12 
months 
28 12 sites 
2006 
Andriantsoanirina 
et al., 2009 
Madagascar Ejeda 
2006-2007  
Menard et al., 
2008 
 
44.517 -24.35 6 months – 15 
years 
28 12 sites 
2007 
Andriantsoanirina 
et al., 2009 
Mali Koumanto 
2003-2004  
de Radigues et 
al.,2006 
 
-
6.83333
3 
11.41666
6 
1 year – 3 years 28 Sotuba ,190 km 
north west of 
Koumanto 
1995 
Diourte et al., 
1999 
Mali Kolle 
2002 - 2003  
Tekete et al., 
2009 
 
-5.281 11.314 6 months – 59 
months 
28 Bobo-Dioulasso 
2004 
Dokomajilar et al., 
2006 
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Republic of 
Congo 
Brazzaville 
(Bacongo) 
2003-2004  
Ndounga et al., 
2007 
 
15.224 -4.296 6 months – 67 
months 
28 Brazzaville(urban 
health centre of 
Tenrikyo in district 
of Makelekele) 
2003-2004 
Ndounga et 
al.,2007 
 
Kindamba, 18km 
west of 
Brazzaville 
2004 
Pearce et al., 
2009 
 
 
Republic of 
Congo 
Makelekele  
2003-2004  
Ndounga et al., 
2007 
 
14.016 -3.09 6 months – 67 
months 
28 Brazzaville(urban 
health centre of 
Tenrikyo in district 
of Makelekele). 
Brazzaville is 180 
km southwest of 
Makelekele 
2003-2004 
Ndounga et 
al.,2007 
Republic of 
Congo 
Mfilou and 
Makelekele 
health districts 
2003-2004  
Ndounga et al., 
2007  
 
11.88 -4.25 6 months – 67 
months 
28 Pointe Noire, 
Brazzaville and 
Gambona.  Pointe 
Noire is 170 km 
north east of 
Makelekele 
2006 
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Mita et al.,2009 
Sierra Leone Freetown 
2002-2003  
Checci et al., 
2005 
-13.25 8.5 6 months – 59 
months  
28 No match  
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